BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. [PMID: 29405329 DOI: 10.1002/hep.29800] [Cited by in Crossref: 1129] [Cited by in F6Publishing: 901] [Article Influence: 376.3] [Reference Citation Analysis]
Number Citing Articles
1 Kardani K, Basimi P, Fekri M, Bolhassani A. Antiviral therapy for the sexually transmitted viruses: recent updates on vaccine development. Expert Rev Clin Pharmacol 2020;13:1001-46. [PMID: 32838584 DOI: 10.1080/17512433.2020.1814743] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut 2021;70:1782-94. [PMID: 34103404 DOI: 10.1136/gutjnl-2020-323888] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Sarkar M, Brady CW, Fleckenstein J, Forde KA, Khungar V, Molleston JP, Afshar Y, Terrault NA. Reproductive Health and Liver Disease: Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;73:318-65. [PMID: 32946672 DOI: 10.1002/hep.31559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Moretto F, Catherine FX, Esteve C, Blot M, Piroth L. Isolated Anti-HBc: Significance and Management. J Clin Med. 2020;9. [PMID: 31940817 DOI: 10.3390/jcm9010202] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
5 Gao X, Duan X, Cai H, Hu Y, Liu M, Kang K, Zhou M, Fu D, Yi W. Pregnancy outcomes for pregnant women with chronic hepatitis B exposing to entecavir or adefovir dipivoxil therapy before or in early pregnancy. J Matern Fetal Neonatal Med 2020;:1-5. [PMID: 32019360 DOI: 10.1080/14767058.2020.1723540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Liu HH, Fang Y, Wang JW, Yuan XD, Fan YC, Gao S, Han LY, Wang K. Hypomethylation of the cyclin D1 promoter in hepatitis B virus-associated hepatocellular carcinoma. Medicine (Baltimore) 2020;99:e20326. [PMID: 32443384 DOI: 10.1097/MD.0000000000020326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Li Q, Wang J, Islam H, Kirschning C, Lu H, Hoffmann D, Dittmer U, Lu M. Hepatitis B virus particles activate B cells through the TLR2-MyD88-mTOR axis. Cell Death Dis 2021;12:34. [PMID: 33414473 DOI: 10.1038/s41419-020-03284-1] [Reference Citation Analysis]
8 Tsai YF, Hsu CM, Hsiao HH. Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment. J Pers Med 2021;11:267. [PMID: 33918206 DOI: 10.3390/jpm11040267] [Reference Citation Analysis]
9 Li J, Qu L, Sun X, Liu Y, Gong Q, Yu D, Zhang D, Jiang J, Chen J, Wei D, Han Y, Gao Y, Zhang Q, She W, Chen L, Zhang J, Zhang X. Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naïve patients. J Viral Hepat 2021. [PMID: 34228855 DOI: 10.1111/jvh.13571] [Reference Citation Analysis]
10 Song DS, Kim W, Ahn SH, Yim HJ, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Yang JM, Kim KH, Han KH, Um SH. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial. Clin Mol Hepatol 2021;27:346-59. [PMID: 33493393 DOI: 10.3350/cmh.2020.0307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Gerasi M, Frakolaki E, Papadakis G, Chalari A, Lougiakis N, Marakos P, Pouli N, Vassilaki N. Design, synthesis and anti-HBV activity evaluation of new substituted imidazo[4,5-b]pyridines. Bioorganic Chemistry 2020;98:103580. [DOI: 10.1016/j.bioorg.2020.103580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
12 Yin Y, Xue M, Shi L, Qiu T, Xia D, Fu G, Peng Z. A Noninvasive Prediction Model for Hepatitis B Virus Disease in Patients with HIV: Based on the Population of Jiangsu, China. Biomed Res Int 2021;2021:6696041. [PMID: 33860053 DOI: 10.1155/2021/6696041] [Reference Citation Analysis]
13 Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020;370:m2200. [PMID: 32873599 DOI: 10.1136/bmj.m2200] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
14 Lee J, Park JY, Yang SJ, Lee JY, Kim DG, Joo DJ, Kim MS, Kim SI, Lee JG. Renal safety of tenofovir disoproxil fumarate and entecavir with hepatitis B immunoglobulin in liver transplant patients. J Viral Hepat 2020;27:818-25. [PMID: 32302037 DOI: 10.1111/jvh.13291] [Reference Citation Analysis]
15 Jones JM, Gurbaxani BM, Asher A, Sansom S, Annambhotla P, Moorman AC, Kamili S, Brooks JT, Basavaraju SV. Quantifying the risk of undetected HIV, hepatitis B virus, or hepatitis C virus infection in Public Health Service increased risk donors. Am J Transplant 2019;19:2583-93. [PMID: 30980600 DOI: 10.1111/ajt.15393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Rajasekaran A, Franco RA, Overton ET, McGuire BM, Towns GC, Locke JE, Sawinski DL, Bell EK. Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population. Kidney Int Rep 2021;6:1788-98. [PMID: 34307975 DOI: 10.1016/j.ekir.2021.04.015] [Reference Citation Analysis]
17 Zou X, Fang M, Li S, Wu L, Gao B, Gao H, Ran X, Bian Y, Li R, ShanshanYu, Ling J, Li D, Tian D, Huang J. Characteristics of Liver Function in Patients With SARS-CoV-2 and Chronic HBV Coinfection. Clin Gastroenterol Hepatol. 2021;19:597-603. [PMID: 32553907 DOI: 10.1016/j.cgh.2020.06.017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 20.0] [Reference Citation Analysis]
18 Lau KCK, Burak KW, Coffin CS. Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphotropism in Antiviral Treatment and Oncogenesis. Microorganisms 2020;8:E1470. [PMID: 32987867 DOI: 10.3390/microorganisms8101470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
20 Roade L, Riveiro-Barciela M, Esteban R, Buti M. Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B. Ther Adv Infect Dis 2021;8:2049936120985954. [PMID: 33614029 DOI: 10.1177/2049936120985954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Cheng HR, Yang HC, Lin SR, Yang TY, Lin YY, Su TH, Tseng TC, Liu CJ, Kao JH. Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients. Hepatol Int 2021;15:582-92. [PMID: 33886088 DOI: 10.1007/s12072-021-10186-7] [Reference Citation Analysis]
22 Wang J, Huang H, Liu Y, Chen R, Yan Y, Shi S, Xi J, Zou J, Yu G, Feng X, Lu F. HBV Genome and Life Cycle. Adv Exp Med Biol 2020;1179:17-37. [PMID: 31741332 DOI: 10.1007/978-981-13-9151-4_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
23 Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Rep 2021;3:100290. [PMID: 34041470 DOI: 10.1016/j.jhepr.2021.100290] [Reference Citation Analysis]
24 Kwon JH. The Role of Serum HBV-RNA Levels as a Marker of Intrahepatic Viral and Histologic Activity. Korean J Gastroenterol 2018;71:297-9. [PMID: 29791991 DOI: 10.4166/kjg.2018.71.5.297] [Reference Citation Analysis]
25 Miao J, Yang X, Shang X, Gao Z, Li Q, Hong Y, Wu J, Meng T, Yuan H, Hu F. Hepatocyte-targeting and microenvironmentally responsive glycolipid-like polymer micelles for gene therapy of hepatitis B. Mol Ther Nucleic Acids 2021;24:127-39. [PMID: 33738144 DOI: 10.1016/j.omtn.2021.02.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Huang BY, Tsai MR, Hsu JK, Lin CY, Lin CL, Hu JT, Huang YW, Liu CJ, Wu WJ, Wu CF, Sung FY, Chen PJ, Liang HJ, Lin SM, Yu MW. Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma. Mol Carcinog 2020;59:1269-79. [PMID: 32914490 DOI: 10.1002/mc.23255] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Hsu YC, Chen CY, Chang IW, Chang CY, Wu CY, Lee TY, Wu MS, Bair MJ, Chen JJ, Chen CC, Tseng CH, Tai CM, Huang YT, Ku WH, Mo LR, Lin JT. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. Lancet Infect Dis 2021;21:823-33. [PMID: 33524314 DOI: 10.1016/S1473-3099(20)30692-7] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Evon DM, Lin HS, Khalili M, Fontana RJ, Yim C, Wahed AS, Fried MW, Hoofnagle JH; Hepatitis B Research Network (HBRN). Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. Aliment Pharmacol Ther 2020;51:457-68. [PMID: 31943262 DOI: 10.1111/apt.15618] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
29 Pei SN, Liu YF, Kuo CY, Wang MC, Ma MC, Liao CK, Ng HY, Chen CH. Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab. Leuk Lymphoma 2021;:1-8. [PMID: 34323157 DOI: 10.1080/10428194.2021.1948034] [Reference Citation Analysis]
30 Navarroza AMC, Wong SN. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease. Indian J Gastroenterol 2021. [PMID: 34213749 DOI: 10.1007/s12664-021-01184-6] [Reference Citation Analysis]
31 Chen R, Pei S, Chen Y, Tan L, Xue Y, Liu S, Huang Y, Fan X. Suboptimal Response to Tenofovir Alafenamide in Two Patients With HBeAg-Positive Hepatitis B: A Case Report. Front Med (Lausanne) 2021;8:701061. [PMID: 34307428 DOI: 10.3389/fmed.2021.701061] [Reference Citation Analysis]
32 Tsou HH, Yang HC, Hsiao CF, Hsiung CA, Liu TW, Chuang MH, Wu HY, Hsu YT, Tsui CW, Chen PJ, Cheng AL, Hsu C; Taiwan Cooperative Oncology Group. Cost-effectiveness of preventing hepatitis B virus reactivation in patients with lymphoma and resolved HBV infection. J Formos Med Assoc 2020;119:335-44. [PMID: 31235201 DOI: 10.1016/j.jfma.2019.05.027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Chang WY, Chiu YC, Chiu FW, Hsu YC, Tseng TC, Cheng PN, Yang SS, Liu CJ, Su TH, Yang HC, Liu CH, Chen PJ, Chen DS, Kao JH. High Risk of Clinical Relapse in Patients With Chronic Hepatitis B Virus Infection After Cessation of Prophylactic Antiviral Therapy for Rituximab-Containing Chemotherapy. J Infect Dis 2020;222:1345-52. [PMID: 32396638 DOI: 10.1093/infdis/jiaa256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
34 Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021;. [PMID: 33387124 DOI: 10.1007/s10620-020-06725-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Papatheodoridi M, Papatheodoridis GV. Current status of hepatitis delta. Curr Opin Pharmacol 2021;58:62-7. [PMID: 33895531 DOI: 10.1016/j.coph.2021.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Huang DQ, Lim SG. Hepatitis B: Who to treat? A critical review of international guidelines. Liver Int 2020;40 Suppl 1:5-14. [PMID: 32077616 DOI: 10.1111/liv.14365] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
37 Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Kushner T, Chen Z, Tressler S, Kaufman H, Feinberg J, Terrault NA. Trends in Hepatitis B Infection and Immunity Among Women of Childbearing Age in the United States. Clin Infect Dis 2020;71:586-92. [PMID: 31504302 DOI: 10.1093/cid/ciz841] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
39 Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol 2020;73:1037-45. [PMID: 32553667 DOI: 10.1016/j.jhep.2020.06.011] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
40 Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, Bulterys M, Chan PL, El-Sayed MH, Giaquinto C, Jonas MM, Meyers T, Walsh N, Wirth S, Penazzato M. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4:466-476. [PMID: 30982722 DOI: 10.1016/s2468-1253(19)30042-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 18] [Article Influence: 21.5] [Reference Citation Analysis]
41 Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients. Clin Liver Dis 2019;23:493-509. [PMID: 31266623 DOI: 10.1016/j.cld.2019.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Gantner P, Cotte L, Allavena C, Bani-Sadr F, Huleux T, Duvivier C, Valantin MA, Jacomet C, Joly V, Chéret A, Pugliese P, Delobel P, Cabié A, Rey D; Dat’AIDS Study Group. Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV/HIV co-infection. PLoS One 2019;14:e0215464. [PMID: 30998789 DOI: 10.1371/journal.pone.0215464] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
43 Lee HW, Chan HL. Unresolved issues of immune tolerance in chronic hepatitis B. J Gastroenterol 2020;55:383-9. [PMID: 32016713 DOI: 10.1007/s00535-020-01665-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
44 Stellbrink HJ, Lazzarin A, Woolley I, Llibre JM. The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV. HIV Med 2020;21 Suppl 1:3-16. [PMID: 32017355 DOI: 10.1111/hiv.12833] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
45 Canzoni M, Marignani M, Sorgi ML, Begini P, Biondo MI, Caporuscio S, Colonna V, Casa FD, Conigliaro P, Marrese C, Celletti E, Modesto I, Peragallo MS, Laganà B, Picchianti-Diamanti A, Rosa RD, Ferlito C, Salemi S, D'Amelio R, Stroffolini T. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. Microorganisms 2020;8:E1792. [PMID: 33207663 DOI: 10.3390/microorganisms8111792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
46 Li L, Zou H, Xu M, Li S, Zhu Y, Zheng S, Duan Z, Chen Y. Risk factors related to postpartum hepatic inflammation in pregnant women with chronic hepatitis B. J Int Med Res 2020;48:300060520966439. [PMID: 33208011 DOI: 10.1177/0300060520966439] [Reference Citation Analysis]
47 Dong XQ, Wu Z, Zhao H, Wang GQ; China HepB-Related Fibrosis Assessment Research Group. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients. J Viral Hepat 2019;26:297-307. [PMID: 30380170 DOI: 10.1111/jvh.13031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
48 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Kiruthika S, Bhat R, Dash R, Rathore AS, Vivekanandan P, Jayaram B. A novel piperazine derivative that targets hepatitis B surface antigen effectively inhibits tenofovir resistant hepatitis B virus. Sci Rep 2021;11:11723. [PMID: 34083665 DOI: 10.1038/s41598-021-91196-1] [Reference Citation Analysis]
50 Han Z, Zhang Y, Hou H. Response to the comment on “Mother‐to‐child transmission of hepatitis B virus after amniocentesis: A retrospective matched cohort study”. Prenatal Diagnosis 2019;39:1300-1. [DOI: 10.1002/pd.5574] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Shah P, Sundaram V, Björnsson E. Biologic and Checkpoint Inhibitor-Induced Liver Injury: A Systematic Literature Review. Hepatol Commun 2020;4:172-84. [PMID: 32025603 DOI: 10.1002/hep4.1465] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
52 Cheah JT, Faragon JJ, Marks KM. Management of hepatitis B and C infections in rheumatologic disease. Best Pract Res Clin Rheumatol 2018;32:848-68. [PMID: 31427059 DOI: 10.1016/j.berh.2019.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Zhang M, Zhang Z, Imamura M, Osawa M, Teraoka Y, Piotrowski J, Ishida Y, Sozzi V, Revill PA, Saito T, Chayama K, Liang TJ. Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models. J Hepatol 2021:S0168-8278(21)01960-7. [PMID: 34363922 DOI: 10.1016/j.jhep.2021.07.030] [Reference Citation Analysis]
54 Gao F, Zhang WT, Lin YY, Wang WM, Xu N, Bai GQ. Early Start Of Tenofovir Treatment Achieves Better Viral Suppression In Pregnant Women With A High HBV Viral Load: A Real-World Prospective Study. Infect Drug Resist 2019;12:3475-84. [PMID: 31807036 DOI: 10.2147/IDR.S228982] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Papatheodoridi M, Papatheodoridis G. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. Cells. 2020;9. [PMID: 32093411 DOI: 10.3390/cells9020493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
56 Wübbolding M, Cornberg M, Höner zu Siederdissen C. Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV. Curr Hepatology Rep 2019;18:512-21. [DOI: 10.1007/s11901-019-00502-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Sung PS, Park DJ, Kim JH, Han JW, Lee EB, Lee GW, Nam HC, Jang JW, Bae SH, Choi JY, Shin EC, Park SH, Yoon SK. Ex vivo Detection and Characterization of Hepatitis B Virus-Specific CD8+ T Cells in Patients Considered Immune Tolerant. Front Immunol 2019;10:1319. [PMID: 31244857 DOI: 10.3389/fimmu.2019.01319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
58 Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
59 Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Progression of Untreated Minimally Active Chronic HBV Infection Compared to Inactive Infection. Clin Gastroenterol Hepatol 2019;17:2808-2810.e2. [PMID: 30639778 DOI: 10.1016/j.cgh.2019.01.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
60 Park JH, Seo N, Chung YE, Kim SU, Park YN, Choi JY, Park MS, Kim MJ. Noninvasive evaluation of liver fibrosis: comparison of the stretched exponential diffusion-weighted model to other diffusion-weighted MRI models and transient elastography. Eur Radiol 2021;31:4813-23. [PMID: 33439321 DOI: 10.1007/s00330-020-07600-3] [Reference Citation Analysis]
61 Li EM, Xiao LX, Xu Z, Mo ZS, Li JQ, Mei YY, Lin CS. Factors associated with non-compliance with breastfeeding recommendation: a retrospective survey in hepatitis B virus-infected mothers who had taken Nucleos(t)ide analogs during pregnancy. BMC Pregnancy Childbirth 2021;21:551. [PMID: 34384374 DOI: 10.1186/s12884-021-04020-z] [Reference Citation Analysis]
62 Nicastro E, Norsa L, Di Giorgio A, Indolfi G, D'Antiga L. Breakthroughs and challenges in the management of pediatric viral hepatitis. World J Gastroenterol 2021;27:2474-94. [PMID: 34092970 DOI: 10.3748/wjg.v27.i20.2474] [Reference Citation Analysis]
63 Cheung CKM, Law MF, Chao DC, Wong SH, Ho R, Chao ACW, Lai JWY, Chan TYT, Tam MTK, Lau SLF, Tam THC. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis. J Dig Dis 2020;21:160-9. [PMID: 32040243 DOI: 10.1111/1751-2980.12848] [Reference Citation Analysis]
64 Wang K, Huang G, Chen Y, Wang Y. Hepatitis B Surface Antigen (HBsAg) Kinetics in Chronic Hepatitis B Patients during Peginterferon Treatment. Med Sci Monit 2020;26:e921487. [PMID: 32587233 DOI: 10.12659/MSM.921487] [Reference Citation Analysis]
65 Zhang S, Sang X, Hou D, Chen J, Gu H, Zhang Y, Li J, Yang D, Zhu H, Yang X, Wang F, Zhang C, Chen X, Zen K, Zhang C, Hong Z. Plant-derived RNAi therapeutics: A strategic inhibitor of HBsAg. Biomaterials 2019;210:83-93. [DOI: 10.1016/j.biomaterials.2019.04.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
66 Argentiero A, Solimando AG, Ungaro V, Laforgia M, Strippoli S, Pinto D, Negri A, Ferraiuolo S, Zito A, Guida M. Case Report: Lymphocytosis Associated With Fatal Hepatitis in a Thymoma Patient Treated With Anti-PD1: New Insight Into the Immune-Related Storm. Front Oncol 2020;10:583781. [PMID: 33381454 DOI: 10.3389/fonc.2020.583781] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
68 Lee HW, Chon YE, Kim BK, Yip TC, Tse YK, Wong GL, Wong VW, Chan HL, Ahn SH. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. Eur J Intern Med 2021;84:68-73. [PMID: 33288393 DOI: 10.1016/j.ejim.2020.10.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Yu HC, Tseng JC, Lu LY, Hu JC, Chen YH, Hsu CL, Wu PC, Mar GY, Lin KH. Monitoring by viral load and quantitative hepatitis B surface antigen in patients with hepatitis B virus infection receiving immunosuppressive therapy. Eur J Gastroenterol Hepatol 2021;33:107-13. [PMID: 32243344 DOI: 10.1097/MEG.0000000000001707] [Reference Citation Analysis]
70 Attar BM. CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated. Clin Liver Dis (Hoboken). 2020;15:25-30. [PMID: 32104574 DOI: 10.1002/cld.893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Yeh ML, Liang PC, Huang CI, Hsieh MH, Lin YH, Jang TY, Wei YJ, Hsu PY, Hsu CT, Wang CW, Hsieh MY, Lin ZY, Chen SC, Huang CF, Huang JF, Dai CY, Chuang WL, Yu ML. Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. J Gastroenterol Hepatol 2021. [PMID: 34318943 DOI: 10.1111/jgh.15640] [Reference Citation Analysis]
72 Gulbay M, Ciliz DS, Celikbas AK, Ocalan DT, Sayin B, Ozbay BO, Alp E. Intravoxel incoherent motion parameters in the evaluation of chronic hepatitis B virus-induced hepatic injury: fibrosis and capillarity changes. Abdom Radiol (NY) 2020;45:2345-57. [PMID: 32162021 DOI: 10.1007/s00261-020-02430-9] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Li J, Le MH, Barakat MT, Cheung RC, Nguyen MH. The Changing Epidemiology of Liver Disease Among US Children and Adolescents From 1999 to 2016. Am J Gastroenterol 2021. [PMID: 34328446 DOI: 10.14309/ajg.0000000000001386] [Reference Citation Analysis]
74 Wang G, Tanaka A, Zhao H, Jia J, Ma X, Harada K, Wang FS, Wei L, Wang Q, Sun Y, Hong Y, Rao H, Efe C, Lau G, Payawal D, Gani R, Lindor K, Jafri W, Omata M, Sarin SK. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int 2021;15:223-57. [PMID: 33942203 DOI: 10.1007/s12072-021-10170-1] [Reference Citation Analysis]
75 Zhou K, Wahed AS, Cooper S, Di Bisceglie AM, Fontana RJ, Ghany MG, Khalili M, Lok AS, Perrillo R, Lee WM, Lau DTY, Sterling R, Janssen HLA, Terrault NA. Phase Transition Is Infrequent Among North American Adults With e-Antigen-Negative Chronic Hepatitis B and Low-Level Viremia. Am J Gastroenterol 2019;114:1753-63. [PMID: 31658127 DOI: 10.14309/ajg.0000000000000400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
76 Almeida PH, Matielo CEL, Curvelo LA, Rocco RA, Felga G, Della Guardia B, Boteon YL. Update on the management and treatment of viral hepatitis. World J Gastroenterol 2021;27:3249-61. [PMID: 34163109 DOI: 10.3748/wjg.v27.i23.3249] [Reference Citation Analysis]
77 Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera-de la Tijera F, Aloman C, Rıza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology 2021;73:2099-109. [PMID: 33713486 DOI: 10.1002/hep.31797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
78 Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671-722. [PMID: 31863477 DOI: 10.1002/hep.31065] [Cited by in Crossref: 104] [Cited by in F6Publishing: 78] [Article Influence: 104.0] [Reference Citation Analysis]
79 Lee H, Lee SY, Mtengezo JT, Makin M, Park JH, Thompson L. Cancer Screening and Diagnostic Tests in Global Contexts: Case Study and Concept Analysis. Asia Pac J Oncol Nurs 2019;6:86-93. [PMID: 30599021 DOI: 10.4103/apjon.apjon_59_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
80 Sun Y, Wu X, Zhou J, Meng T, Wang B, Chen S, Liu H, Wang T, Zhao X, Wu S, Kong Y, Ou X, Wee A, Theise ND, Qiu C, Zhang W, Lu F, Jia J, You H. Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy. Clin Gastroenterol Hepatol. 2020;18:2582-2591.e6. [PMID: 32147592 DOI: 10.1016/j.cgh.2020.03.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
81 Kao JH, Hu TH, Jia J, Kurosaki M, Lim YS, Lin HC, Sinn DH, Tanaka Y, Wai-Sun Wong V, Yuen MF. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther 2020;52:1540-50. [PMID: 32951256 DOI: 10.1111/apt.16097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Shim JJ, Kim GA, Oh CH, Kim JW, Myung J, Kim BH, Oh IH. Reduced liver cancer mortality with regular clinic follow-up among patients with chronic hepatitis B: A nationwide cohort study. Cancer Med 2020;9:7781-91. [PMID: 32857923 DOI: 10.1002/cam4.3421] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Shin SK, Yim HJ, Kim JH, Lee CU, Yeon JE, Suh SJ, Jung YK, Kim YS, Kim JH, Kwon OS. Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis. Gut Liver 2021;15:430-9. [PMID: 33115966 DOI: 10.5009/gnl20074] [Reference Citation Analysis]
84 Rodriguez PL, McCune S, Sakai L, Engstrom-Melnyk J, Marins E. Evaluation of Contamination Risk by the cobas e 602 Serology Module Before Viral Load Testing on the cobas 6800 System. Sex Transm Dis 2020;47:S32-4. [PMID: 31895305 DOI: 10.1097/OLQ.0000000000001125] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, Ramji A, Chen CY, Tam E, Bae H, Ma X, Flaherty JF, Gaggar A, Lau A, Liu Y, Wu G, Suri V, Tan SK, Subramanian GM, Trinh H, Yoon SK, Agarwal K, Lim YS, Chan HLY. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol 2020;5:441-53. [PMID: 32087795 DOI: 10.1016/S2468-1253(19)30421-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 31.0] [Reference Citation Analysis]
86 Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection. Liver Int. 2019;39:1868-1875. [PMID: 31136052 DOI: 10.1111/liv.14155] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 19.5] [Reference Citation Analysis]
87 Blanchet M, Sinnathamby V, Vaillant A, Labonté P. Inhibition of HBsAg secretion by nucleic acid polymers in HepG2.2.15 cells. Antiviral Res 2019;164:97-105. [PMID: 30771404 DOI: 10.1016/j.antiviral.2019.02.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
88 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yan Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver 2020;14:232-47. [PMID: 31158948 DOI: 10.5009/gnl18546] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
89 Congly SE, Brahmania M. Variable access to antiviral treatment of chronic hepatitis B in Canada: a descriptive study. CMAJ Open 2019;7:E182-9. [PMID: 30926602 DOI: 10.9778/cmajo.20180108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Surial B, Béguelin C, Chave JP, Stöckle M, Boillat-Blanco N, Doco-Lecompte T, Bernasconi E, Fehr J, Günthard HF, Schmid P, Walti LN, Furrer H, Rauch A, Wandeler G; and the Swiss HIV Cohort Study. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study. J Acquir Immune Defic Syndr 2020;85:227-32. [PMID: 32925387 DOI: 10.1097/QAI.0000000000002429] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
91 Dezanet LNC, Miailhes P, Lascoux-Combe C, Chas J, Maylin S, Gabassi A, Rougier H, Delaugerre C, Lacombe K, Boyd A. Profiles of liver fibrosis evolution during long-term tenofovir treatment in HIV-positive patients coinfected with hepatitis B. Liver Int 2021. [PMID: 34297463 DOI: 10.1111/liv.15019] [Reference Citation Analysis]
92 Michitaka K, Hiraoka A, Ninomiya T, Ohno N, Watanabe T, Yoshida O, Tokumoto Y, Abe M, Hiasa Y. The Effect of the Hepatitis B Vaccine Derived from Genotype C on Infants Born to Mothers Infected with Genotype D. Intern Med 2020;59:2825-30. [PMID: 33191369 DOI: 10.2169/internalmedicine.5090-20] [Reference Citation Analysis]
93 Byrne R, Carey I, Agarwal K. Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Therap Adv Gastroenterol 2018;11:1756284818786108. [PMID: 30034532 DOI: 10.1177/1756284818786108] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
94 McNaughton AL, D'Arienzo V, Ansari MA, Lumley SF, Littlejohn M, Revill P, McKeating JA, Matthews PC. Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood. Gastroenterology 2019;156:384-99. [PMID: 30268787 DOI: 10.1053/j.gastro.2018.07.058] [Cited by in Crossref: 44] [Cited by in F6Publishing: 34] [Article Influence: 14.7] [Reference Citation Analysis]
95 Liang LY, Wong GL. Unmet need in chronic hepatitis B management. Clin Mol Hepatol 2019;25:172-80. [PMID: 30754963 DOI: 10.3350/cmh.2018.0106] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 15.0] [Reference Citation Analysis]
96 Dandri M, Bertoletti A, Lütgehetmann M. Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition. Semin Immunopathol 2021. [PMID: 34019142 DOI: 10.1007/s00281-021-00864-x] [Reference Citation Analysis]
97 Kaneko S, Kurosaki M, Inada K, Kirino S, Hayakawa Y, Yamashita K, Osawa L, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2021. [PMID: 34057248 DOI: 10.1111/jgh.15563] [Reference Citation Analysis]
98 Mak LY, Huang Q, Wong DK, Stamm L, Cheung KS, Ko KL, Yan R, Ouyang L, Fung J, Seto WK, Yuen MF. Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy. J Gastroenterol 2021;56:479-88. [PMID: 33772643 DOI: 10.1007/s00535-021-01780-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Kirino S, Tamaki N, Kaneko S, Kurosaki M, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Yasui Y, Nakanishi H, Tsuchiya K, Itakura J, Takahashi Y, Izumi N. Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. J Gastroenterol Hepatol. 2020;35:1595-1601. [PMID: 31975419 DOI: 10.1111/jgh.14990] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
100 Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int. 2019;13:665-673. [PMID: 31559604 DOI: 10.1007/s12072-019-09989-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 9.5] [Reference Citation Analysis]
101 Maraolo AE, Gentile I, Buonomo AR, Pinchera B, Borgia G. Current evidence on the management of hepatitis B in pregnancy. World J Hepatol 2018;10:585-94. [PMID: 30310536 DOI: 10.4254/wjh.v10.i9.585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
102 Song JE, Lee CH, Kim BS. Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice. Korean J Intern Med. 2019;34:802-810. [PMID: 30959583 DOI: 10.3904/kjim.2019.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
103 Shankaraiah RC, Gramantieri L, Fornari F, Sabbioni S, Callegari E, Negrini M. Animal Models of Hepatocellular Carcinoma Prevention. Cancers (Basel) 2019;11:E1792. [PMID: 31739536 DOI: 10.3390/cancers11111792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
104 Ninomiya M, Inoue J, Krueger EW, Chen J, Cao H, Masamune A, McNiven MA. The Exosome-Associated Tetraspanin CD63 Contributes to the Efficient Assembly and Infectivity of the Hepatitis B Virus. Hepatol Commun 2021;5:1238-51. [PMID: 34278172 DOI: 10.1002/hep4.1709] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Chang SH. Prevention of HBV Recurrence After Liver Transplant: Long-Term Results. Transplant Proc 2021;53:1707-10. [PMID: 33994187 DOI: 10.1016/j.transproceed.2021.04.006] [Reference Citation Analysis]
106 Kim SU, Seo YS, Lee HA, Kim MN, Lee YR, Lee HW, Park JY, Kim DY, Ahn SH, Han K, Hwang SG, Rim KS, Um SH, Tak WY, Kweon YO, Kim BK, Park SY. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea. Journal of Hepatology 2019;71:456-64. [DOI: 10.1016/j.jhep.2019.03.028] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 34.5] [Reference Citation Analysis]
107 Doran Brubaker S, Ward JW, Hiebert L, Morgan RL. Developing an Evidence Base for the Delivery of Hepatitis B Virus Birth Dose Vaccination: An Evidence Map and Critical Appraisal of Systematic Reviews and Guidelines. Clin Liver Dis (Hoboken) 2021;17:375-81. [PMID: 34136145 DOI: 10.1002/cld.1103] [Reference Citation Analysis]
108 Li Y, Wu S. Liver stiffness measured with two-dimensional shear wave elastography comparable to histopathology falls dominantly on the severe liver fibrosis. Clin Hemorheol Microcirc 2021. [PMID: 34334386 DOI: 10.3233/CH-211223] [Reference Citation Analysis]
109 Puigvehí M, Moctezuma-Velázquez C, Villanueva A, Llovet JM. The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP Rep 2019;1:120-30. [PMID: 32039360 DOI: 10.1016/j.jhepr.2019.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
110 Hu J, Zhang X, Gu J, Yang M, Zhang X, Zhao H, Li L. Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B. Eur J Gastroenterol Hepatol 2019;31:817-23. [PMID: 30543572 DOI: 10.1097/MEG.0000000000001336] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
111 Shiels MS, O'Brien TR. Recent Decline in Hepatocellular Carcinoma Rates in the United States. Gastroenterology. 2020;158:1503-1505.e2. [PMID: 31962125 DOI: 10.1053/j.gastro.2019.12.030] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
112 Cheng K, Shi J, Liu Z, Jia Y, Qin Q, Zhang H, Wan S, Niu Z, Lu L, Sun J, Xue J, Lu C, Wei X, Guo L, Zhang F, Zhou D, Tang Y, Hu Y, Huang Y, Chen Y, Lau WY, Cheng S, Liu S. A panel of five plasma proteins for the early diagnosis of hepatitis B virus-related hepatocellular carcinoma in individuals at risk. EBioMedicine 2020;52:102638. [PMID: 32014820 DOI: 10.1016/j.ebiom.2020.102638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
113 Wang K, Lin W, Kuang Z, Fan R, Liang X, Peng J, Guo Y, Chen J, Liu Z, Hu X, Wu Y, Shen S, Sun J, Hou J. Longitudinal Change of Body Mass Index Is Associated With Alanine Aminotransferase Elevation After Complete Viral Suppression in Chronic Hepatitis B Patients. J Infect Dis 2019;220:1469-76. [PMID: 31370059 DOI: 10.1093/infdis/jiz326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
114 Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. Int J Mol Sci. 2020;21. [PMID: 32023902 DOI: 10.3390/ijms21030949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
115 Solitano V, Plaz Torres MC, Pugliese N, Aghemo A. Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations? Viruses 2021;13:1048. [PMID: 34205966 DOI: 10.3390/v13061048] [Reference Citation Analysis]
116 Rashidi-Alavijeh J, Straub K, Achterfeld A, Wedemeyer H, Willuweit K, Herzer K. Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience. Transpl Infect Dis 2021;23:e13522. [PMID: 33217163 DOI: 10.1111/tid.13522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Xun Z, Lin J, Yu Q, Liu C, Huang J, Shang H, Guo J, Ye Y, Wu W, Zeng Y, Wu S, Xu S, Chen T, Chen J, Ou Q. Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function. Cell Mol Immunol 2021;18:461-71. [PMID: 33432062 DOI: 10.1038/s41423-020-00601-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Park JH, Choi J, Jun DW, Han SW, Yeo YH, Nguyen MH. Low Alanine Aminotransferase Cut-Off for Predicting Liver Outcomes; A Nationwide Population-Based Longitudinal Cohort Study. J Clin Med 2019;8:E1445. [PMID: 31514449 DOI: 10.3390/jcm8091445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
119 Shiels MS, Engels EA, Yanik EL, McGlynn KA, Pfeiffer RM, O'Brien TR. Incidence of hepatocellular carcinoma among older Americans attributable to hepatitis C and hepatitis B: 2001 through 2013. Cancer 2019;125:2621-30. [PMID: 30980394 DOI: 10.1002/cncr.32129] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
120 Inoue J, Akahane T, Nakayama H, Kimura O, Kobayashi T, Kisara N, Sato T, Morosawa T, Izuma M, Kakazu E, Ninomiya M, Iwata T, Takai S, Nakamura T, Sano A, Niitsuma H, Masamune A; THERME Study Group. Comparison of hepatitis B virus genotypes B and C among chronically hepatitis B virus-infected patients who received nucleos(t)ide analogs: A multicenter retrospective study. Hepatol Res 2019;49:1263-74. [PMID: 31254482 DOI: 10.1111/hepr.13398] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
121 Mak LY, Liu SH, Yap DY, Seto WK, Wong DK, Fung J, Chan TM, Lai CL, Yuen MF. In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. Dig Dis Sci 2019;64:3630-41. [PMID: 31280390 DOI: 10.1007/s10620-019-05717-0] [Reference Citation Analysis]
122 Huff J, Andersen R. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older. Ann Pharmacother 2020;54:262-76. [PMID: 31537106 DOI: 10.1177/1060028019877128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
123 Arnone OC, Serranti D, Bartolini E, Mastrangelo G, Stinco M, Trapani S, Ricci S, Resti M, Indolfi G. Chronic hepatitis B in children, report of a single-centre longitudinal study on 152 children. J Viral Hepat. 2020;27:1344-1351. [PMID: 32853482 DOI: 10.1111/jvh.13382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Chilaka VN, Konje JC. Viral Hepatitis in pregnancy. Eur J Obstet Gynecol Reprod Biol 2021;256:287-96. [PMID: 33259998 DOI: 10.1016/j.ejogrb.2020.11.052] [Reference Citation Analysis]
125 Lee D, Yun BC, Seo KI, Han BH, Lee SU, Park ET, Lee JW, Jeong J. Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate. Medicine (Baltimore) 2019;98:e18351. [PMID: 31852136 DOI: 10.1097/MD.0000000000018351] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Araujo NM, Teles SA, Spitz N. Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region. Front Microbiol 2020;11:616023. [PMID: 33381105 DOI: 10.3389/fmicb.2020.616023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
127 Li X, Liu X, Wang W. IL-35: A Novel Immunomodulator in Hepatitis B Virus-Related Liver Diseases. Front Cell Dev Biol 2021;9:614847. [PMID: 33777929 DOI: 10.3389/fcell.2021.614847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Nasir M, Wu GY. Prevention of HBV Recurrence after Liver Transplant: A Review. J Clin Transl Hepatol 2020;8:150-60. [PMID: 32832395 DOI: 10.14218/JCTH.2020.00003] [Reference Citation Analysis]
129 Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. World J Gastrointest Pharmacol Ther 2021;12:56-78. [PMID: 34316384 DOI: 10.4292/wjgpt.v12.i4.56] [Reference Citation Analysis]
130 Yazaki S, Yamauchi T, Higashi T. High hepatitis B virus screening rate among patients receiving systemic anticancer treatment in Japan. Int J Clin Oncol 2020;25:1327-33. [PMID: 32200482 DOI: 10.1007/s10147-020-01655-4] [Reference Citation Analysis]
131 Wong GL, Wen WH, Pan CQ. Hepatitis B-management of acute infection and active inflammation in pregnancy-a hepatologist's perspective. Best Pract Res Clin Obstet Gynaecol 2020;68:54-65. [PMID: 32340799 DOI: 10.1016/j.bpobgyn.2020.03.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Liu CH, Yang SS, Peng CY, Lin WT, Liu CJ, Su TH, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment. J Viral Hepat 2020;27:568-75. [PMID: 31981264 DOI: 10.1111/jvh.13265] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
133 Yeh ML, Huang JF, Yu ML, Chuang WL. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. Expert Rev Gastroenterol Hepatol 2021;15:427-35. [PMID: 33338385 DOI: 10.1080/17474124.2021.1866985] [Reference Citation Analysis]
134 Xia M, Chi H, Wu Y, Hansen BE, Li Z, Liu S, Liao G, Zhang X, Zhou B, Hou J, Sun J, Janssen HLA, Peng J. Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment. Aliment Pharmacol Ther 2021;54:709-14. [PMID: 34275138 DOI: 10.1111/apt.16538] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
135 Rizzetto M, Hamid S, Negro F. The changing context of hepatitis D. J Hepatol. 2021;74:1200-1211. [PMID: 33484770 DOI: 10.1016/j.jhep.2021.01.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
136 Stroffolini T, Ciancio A, Furlan C, Vinci M, Niro GA, Russello M, Colloredo G, Morisco F, Coppola N, Babudieri S, Ferrigno L, Sagnelli C, Sagnelli E; Collaborating group. Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019. Eur J Clin Microbiol Infect Dis 2021;40:607-14. [PMID: 33029767 DOI: 10.1007/s10096-020-04065-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
137 Chang K, Chang M, Lee C, Chang C, Wu J, Ni Y, Wen W, Shyu M, Lai M, Chen S, Hu J, Lin HH, Hsu J, Mu S, Lin Y, Liu C, Chen D, Lin L, Chen H; The Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study). Decreased neonatal hepatitis B virus (HBV) viremia by maternal tenofovir treatment predicts reduced chronic HBV infection in children born to highly viremic mothers. Aliment Pharmacol Ther 2019;50:306-16. [DOI: 10.1111/apt.15321] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
138 Koh C, Da BL, Glenn JS. HBV/HDV Coinfection: A Challenge for Therapeutics. Clin Liver Dis 2019;23:557-72. [PMID: 31266627 DOI: 10.1016/j.cld.2019.04.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
139 Da BL, Surana P, Takyar V, Kleiner DE, Heller T, Koh C. Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection. J Viral Hepat 2020;27:428-36. [PMID: 31742822 DOI: 10.1111/jvh.13235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
140 Wang X, Wu B. Critical issues in the diagnosis and treatment of liver cirrhosis. Gastroenterol Rep (Oxf) 2019;7:227-30. [PMID: 31413829 DOI: 10.1093/gastro/goz024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
141 Lee HW, Lee HW, Lee JS, Roh YH, Lee H, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B. J Hepatocell Carcinoma 2021;8:467-76. [PMID: 34079776 DOI: 10.2147/JHC.S300382] [Reference Citation Analysis]
142 Zhang YT, Liu J, Pan XB, Gao YD, Hu YF, Lin L, Cheng HJ, Chen GY. Successful treatment of infantile hepatitis B with lamivudine: A case report. World J Clin Cases 2021;9:3442-8. [PMID: 34002156 DOI: 10.12998/wjcc.v9.i14.3442] [Reference Citation Analysis]
143 Bollerup S, Hallager S, Baek O, Krarup H, Madsen LG, Thielsen P, Balslev U, Mens H, Barfod T, Rye Clausen M, Hobolth L, Gerstoft J, Weis N. Implementation of treatment recommendations for chronic hepatitis B in patients attending specialized hospital care in Denmark - a region wide study. Scand J Gastroenterol 2020;55:843-7. [PMID: 32568561 DOI: 10.1080/00365521.2020.1779803] [Reference Citation Analysis]
144 Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Kimura M, Maehara O, Shimazaki T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N;  NORTE Study Group. Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. Hepatol Res. 2019;49:1294-1304. [PMID: 31260579 DOI: 10.1111/hepr.13399] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
145 Rattanachaisit P, Suksawatamnuay S, Sriphoosanaphan S, Thanapirom K, Thaimai P, Siripon N, Sittisomwong S, Poovorawan Y, Komolmit P. Stability of hepatitis B virus pregenomic RNA in plasma specimens under various temperatures and storage conditions. PeerJ 2021;9:e11207. [PMID: 33954043 DOI: 10.7717/peerj.11207] [Reference Citation Analysis]
146 Ciardi MR, Iannetta M, Zingaropoli MA, Salpini R, Aragri M, Annecca R, Pontecorvo S, Altieri M, Russo G, Svicher V, Mastroianni CM, Vullo V. Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis. Open Forum Infect Dis 2019;6:ofy356. [PMID: 30697576 DOI: 10.1093/ofid/ofy356] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 8.0] [Reference Citation Analysis]
147 Zhang Y, Xu W, Zhu X, Li X, Li J, Shu X, Lai J, Xie J, Xie C, Peng L. The 48-week safety and therapeutic effects of tenofovir alafenamide in hbv-related acute-on-chronic liver failure: A prospective cohort study. J Viral Hepat. 2021;28:592-600. [PMID: 33423348 DOI: 10.1111/jvh.13468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Yoshida K, Desbiolles A, Feldman SF, Ahn SH, Alidjinou EK, Atsukawa M, Bocket L, Brunetto MR, Buti M, Carey I, Caviglia GP, Chen EQ, Cornberg M, Enomoto M, Honda M, Zu Siederdissen CH, Ishigami M, Janssen HLA, Maasoumy B, Matsui T, Matsumoto A, Nishiguchi S, Riveiro-Barciela M, Takaki A, Tangkijvanich P, Toyoda H, van Campenhout MJH, Wang B, Wei L, Yang HI, Yano Y, Yatsuhashi H, Yuen MF, Tanaka E, Lemoine M, Tanaka Y, Shimakawa Y. Hepatitis B Core-Related Antigen to Indicate High Viral Load: Systematic Review and Meta-Analysis of 10,397 Individual Participants. Clin Gastroenterol Hepatol 2021;19:46-60.e8. [PMID: 32360825 DOI: 10.1016/j.cgh.2020.04.045] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
149 Hoogeveen RC, Boonstra A. Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection. Front Immunol 2020;11:401. [PMID: 32194573 DOI: 10.3389/fimmu.2020.00401] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
150 Chen YP, Huang LW, Lin XY, Hu XM, Liang XE, Jiang RL. Alanine aminotransferase influencing performances of routine available tests detecting hepatitis B-related cirrhosis. J Viral Hepat 2020;27:826-36. [PMID: 32187804 DOI: 10.1111/jvh.13293] [Reference Citation Analysis]
151 Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, Lee SJ, Lim YS. Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. Radiology 2019;292:390-7. [PMID: 31210614 DOI: 10.1148/radiol.2019190035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
152 Lok AS, Perrillo R, Lalama CM, Fried MW, Belle SH, Ghany MG, Khalili M, Fontana RJ, Sterling RK, Terrault N, Feld JJ, Di Bisceglie AM, Lau DTY, Hassan M, Janssen HLA; Hepatitis B Research Network (HBRN). Low Incidence of Adverse Outcomes in Adults With Chronic Hepatitis B Virus Infection in the Era of Antiviral Therapy. Hepatology 2021;73:2124-40. [PMID: 32936969 DOI: 10.1002/hep.31554] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
153 Huang C, Shen D, Sun S, Huang Y, Xin Y, Luo H, Chen Y, Zhou Z, Liu F, Chen X. Effect of Fufang Biejia Ruangan Tablet on lowering biochemical and virological parameters of hepatic fibrosis in patients with chronic hepatitis B: Protocol for a systematic review and meta-analysis of randomized controlled trials and cohort studies. Medicine (Baltimore) 2019;98:e15297. [PMID: 31027094 DOI: 10.1097/MD.0000000000015297] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
154 Jourdain G, Ngo-Giang-Huong N, Khamduang W. Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications. Infect Drug Resist 2019;12:977-87. [PMID: 31118703 DOI: 10.2147/IDR.S171695] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
155 Wübbolding M, Lopez Alfonso JC, Lin CY, Binder S, Falk C, Debarry J, Gineste P, Kraft ARM, Chien RN, Maasoumy B, Wedemeyer H, Jeng WJ, Meyer Hermann M, Cornberg M, Höner Zu Siederdissen C. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB. Hepatol Commun 2021;5:97-111. [PMID: 33437904 DOI: 10.1002/hep4.1626] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
156 Lim YS, Gwak GY, Choi J, Lee YS, Byun KS, Kim YJ, Yoo BC, Kwon SY, Lee HC. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. J Hepatol 2019;71:35-44. [PMID: 30876946 DOI: 10.1016/j.jhep.2019.02.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
157 Toy M, Hutton D, McCulloch K, Romero N, Revill PA, Penicaud MC, So S, Cowie BC. The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia. Liver Int 2021. [PMID: 34328697 DOI: 10.1111/liv.15027] [Reference Citation Analysis]
158 Poiteau L, Wlassow M, Hézode C, Pawlotsky JM, Chevaliez S. Evaluation of the Xpert HBV Viral Load for hepatitis B virus molecular testing. J Clin Virol 2020;129:104481. [PMID: 32512377 DOI: 10.1016/j.jcv.2020.104481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
159 Tseng TC, Choi J, Nguyen MH, Peng CY, Siakavellas S, Papatheodoridis G, Wang CC, Lim YS, Lai HC, Trinh HN, Wong C, Wong C, Zhang J, Li J, Kao JH. One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. Hepatol Int 2021;15:105-13. [PMID: 33547557 DOI: 10.1007/s12072-020-10124-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Chang X, Wang J, Chen Y, Long Q, Song L, Li Q, Liu H, Shang Q, Yu Z, Jiang L, Xiao G, Li L, Chen L, Wang X, Li Z, Chen D, Dong Z, An L, Tan L, Chen Y, Yang Y. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection. EBioMedicine 2021;67:103389. [PMID: 34004423 DOI: 10.1016/j.ebiom.2021.103389] [Reference Citation Analysis]
161 Enomoto H, Aizawa N, Hasegawa K, Ikeda N, Sakai Y, Yoh K, Takata R, Yuri Y, Kishino K, Shimono Y, Ishii N, Takashima T, Nishimura T, Nishikawa H, Iwata Y, Iijima H, Nishiguchi S. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients. Int J Mol Sci 2020;21:E3089. [PMID: 32349377 DOI: 10.3390/ijms21093089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
162 Boucheron P, Lu Y, Yoshida K, Zhao T, Funk AL, Lunel-Fabiani F, Guingané A, Tuaillon E, van Holten J, Chou R, Bulterys M, Shimakawa Y. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis. Lancet Infect Dis 2021;21:85-96. [PMID: 32805201 DOI: 10.1016/S1473-3099(20)30593-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 20.0] [Reference Citation Analysis]
163 Rodríguez-Tajes S, Pocurull A, Lens S, Mariño Z, Olivas I, Soy G, Alonso A, Vilella A, Forns X. Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis. J Viral Hepat 2021;28:1019-24. [PMID: 33763966 DOI: 10.1111/jvh.13509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
164 Tan CJ, Kumar R, Koomanan N, Loo WS, Farid M, Tao M, Somasundaram N, Poon E, Chan JY, Yang VS, Chang E, Lim ST, Chow WC, Chan A, Tang T. Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. Pharmacotherapy 2021;41:332-41. [PMID: 33547823 DOI: 10.1002/phar.2508] [Reference Citation Analysis]
165 Udompap P, Tanwandee T, Gani R. Affordability of Antiviral Therapy in Asia-Pacific Countries and Its Impact on Public Health Outcomes.Clin Liver Dis (Hoboken). 2020;16:249-253. [PMID: 33489097 DOI: 10.1002/cld.977] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Wang G, Guan J, Khan NU, Li G, Shao J, Zhou Q, Xu L, Huang C, Deng J, Zhu H, Chen Z. Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus. Gut Pathog 2021;13:22. [PMID: 33845868 DOI: 10.1186/s13099-021-00421-9] [Reference Citation Analysis]
167 Spence AB, Levy ME, Monroe A, Castel A, Timpone J, Horberg M, Adams-Campbell L, Kumar P. Cancer Incidence and Cancer Screening Practices Among a Cohort of Persons Receiving HIV Care in Washington, DC. J Community Health 2021;46:75-85. [PMID: 32424501 DOI: 10.1007/s10900-020-00844-6] [Reference Citation Analysis]
168 Wani MA, Sodhi JS, Zargar SA, Yatoo GN, Shah A, Aziz SA, Geelani S, Haq I, Gulzar GM, Khan M, Haq I. Entecavir is Safe and Effective in Long Term for the Treatment of Hepatitis B in Immunocompromised Children. J Clin Exp Hepatol 2020;10:150-4. [PMID: 32189930 DOI: 10.1016/j.jceh.2019.04.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
169 Ren H. On the way towards the eradication of chronic hepatitis B. J Viral Hepat 2019;26 Suppl 1:3-4. [PMID: 31380587 DOI: 10.1111/jvh.13158] [Reference Citation Analysis]
170 Fricker ZP, Reddy KR. When (and When Not) to Treat Patients With HBV Infection. Clin Gastroenterol Hepatol 2019;17:2644-7. [PMID: 31154025 DOI: 10.1016/j.cgh.2019.05.039] [Reference Citation Analysis]
171 Lee BW, Lee YH, Park CY, Rhee EJ, Lee WY, Kim NH, Choi KM, Park KG, Choi YK, Cha BS, Lee DH; Korean Diabetes Association (KDA) Fatty Liver Research Group. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association. Diabetes Metab J 2020;44:382-401. [PMID: 32431115 DOI: 10.4093/dmj.2020.0010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
172 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex 2021:S0375-0906(21)00061-6. [PMID: 34384668 DOI: 10.1016/j.rgmx.2021.04.002] [Reference Citation Analysis]
173 Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70:1-187. [PMID: 34292926 DOI: 10.15585/mmwr.rr7004a1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Astbury S, Costa Nunes Soares MM, Peprah E, King B, Jardim ACG, Shimizu JF, Jalal P, Saeed CH, Sabeer FT, Irving WL, Tarr AW, McClure CP. Nanopore sequencing from extraction-free direct PCR of dried serum spots for portable hepatitis B virus drug-resistance typing. J Clin Virol 2020;129:104483. [PMID: 32544862 DOI: 10.1016/j.jcv.2020.104483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
175 Rodríguez-Tajes S, Miralpeix A, Costa J, López-Suñé E, Laguno M, Pocurull A, Lens S, Mariño Z, Forns X. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy. J Viral Hepat 2021;28:89-94. [PMID: 32969557 DOI: 10.1111/jvh.13410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
176 Wedemeyer H. The widespread rarity of HBsAg loss in chronic hepatitis B. Lancet Gastroenterol Hepatol 2019;4:190-2. [PMID: 30679108 DOI: 10.1016/S2468-1253(18)30384-4] [Reference Citation Analysis]
177 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
178 Wang H, Wen B, Chang X, Wu Q, Wen W, Zhou F, Guo Y, Ji Y, Gu Y, Lai Q, He Q, Li J, Chen J, Hou J. Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis. Journal of Hepatology 2021;74:584-92. [DOI: 10.1016/j.jhep.2020.09.034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 9.0] [Reference Citation Analysis]
179 Koc ÖM, Kremer C, Hens N, Bielen R, Busschots D, Van Damme P, Robaeys G. Early detection of chronic hepatitis B and risk factor assessment in Turkish migrants, Middle Limburg, Belgium. PLoS One 2020;15:e0234740. [PMID: 32716949 DOI: 10.1371/journal.pone.0234740] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Rasche A, Lehmann F, Goldmann N, Nagel M, Moreira-Soto A, Nobach D, de Oliveira Carneiro I, Osterrieder N, Greenwood AD, Steinmann E, Lukashev AN, Schuler G, Glebe D, Drexler JF; Equid HBV Consortium. A hepatitis B virus causes chronic infections in equids worldwide. Proc Natl Acad Sci U S A 2021;118:e2013982118. [PMID: 33723007 DOI: 10.1073/pnas.2013982118] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
181 Honda T, Yamada N, Murayama A, Shiina M, Aly HH, Kato A, Ito T, Ishizu Y, Kuzuya T, Ishigami M, Murakami Y, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Ishikawa T, Fujishiro M, Muramatsu M, Wakita T, Kato T. Amino Acid Polymorphism in Hepatitis B Virus Associated With Functional Cure. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00159-4. [PMID: 34352407 DOI: 10.1016/j.jcmgh.2021.07.013] [Reference Citation Analysis]
182 Singh L, Indermun S, Govender M, Kumar P, du Toit LC, Choonara YE, Pillay V. Drug Delivery Strategies for Antivirals against Hepatitis B Virus. Viruses 2018;10:E267. [PMID: 29772748 DOI: 10.3390/v10050267] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
183 Cuenca-Gómez JÁ, Lozano-Serrano AB, Cabezas-Fernández MT, Soriano-Pérez MJ, Vázquez-Villegas J, Estévez-Escobar M, Cabeza-Barrera I, Salas-Coronas J. Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice. BMC Infect Dis 2018;18:568. [PMID: 30428845 DOI: 10.1186/s12879-018-3469-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
184 Tu Y, Chen D, Pan T, Chen Z, Xu J, Jin L, Sheng L, Jin X, Wang X, Lan X, Ge Y, Sun H, Chen Y. Inhibition of miR-431-5p attenuated liver apoptosis through KLF15/p53 signal pathway in S100 induced autoimmune hepatitis mice. Life Sci 2021;280:119698. [PMID: 34111466 DOI: 10.1016/j.lfs.2021.119698] [Reference Citation Analysis]
185 Lee DH. Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease. Endocrinol Metab (Seoul) 2020;35:243-59. [PMID: 32615709 DOI: 10.3803/EnM.2020.35.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
186 Pascual S, Miralles C, Bernabé JM, Irurzun J, Planells M. Surveillance and diagnosis of hepatocellular carcinoma: A systematic review. World J Clin Cases 2019;7:2269-86. [PMID: 31531321 DOI: 10.12998/wjcc.v7.i16.2269] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
187 Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: An Update on Evidence-Based Management. Obstet Gynecol Surv. 2020;75:557-565. [PMID: 32997148 DOI: 10.1097/ogx.0000000000000831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Kumada T, Toyoda H, Tada T, Yasuda S, Tanaka J. Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. Liver Cancer 2020;9:518-28. [PMID: 33083278 DOI: 10.1159/000507933] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
189 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 7.7] [Reference Citation Analysis]
190 Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, Ooho A, Satoh T, Kawano A, Kajiwara E, Takahashi K, Azuma K, Kato M, Shimoda S, Hayashi J;  Kyushu University Liver Disease Study (KULDS) Group. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578-1589. [PMID: 32304611 DOI: 10.1111/liv.14482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
191 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model. Eur J Gastroenterol Hepatol 2019;31:1452-9. [PMID: 31082998 DOI: 10.1097/MEG.0000000000001434] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
192 Bollinger RC, Thio CL, Sulkowski MS, McKenzie-White J, Thomas DL, Flexner C. Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV. Lancet HIV 2020;7:e443-8. [PMID: 31870675 DOI: 10.1016/S2352-3018(19)30342-X] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
193 Bahardoust M, Mokhtare M, Barati M, Bagheri-Hosseinabadi Z, Karimi Behnagh A, Keyvani H, Agah S. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study. J Infect Chemother 2020;26:1265-71. [PMID: 32762882 DOI: 10.1016/j.jiac.2020.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
194 Wang J, Xia J, Yan X, Yang Y, Wei J, Xiong Y, Wu W, Liu Y, Chen Y, Jia B, Chen Z, Zhang Z, Ding W, Huang R, Wu C. The gamma-glutamyl transpeptidase to platelet ratio predicts liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase. Clin Res Hepatol Gastroenterol 2020;44:913-22. [PMID: 32147439 DOI: 10.1016/j.clinre.2020.01.011] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
195 Nogami A, Saito S, Hasegawa H, Yoneda M, Harada K, Fujikawa H. Lymphoepithelioma-like cholangiocarcinoma with Epstein-Barr virus infection treated by radiofrequency ablation. Clin J Gastroenterol 2021;14:638-44. [PMID: 33400192 DOI: 10.1007/s12328-020-01303-4] [Reference Citation Analysis]
196 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for liver cirrhosis 2020. Hepatol Res 2021;51:725-49. [PMID: 34228859 DOI: 10.1111/hepr.13678] [Reference Citation Analysis]
197 Liu C, Su T, Liu C, Hong C, Yang H, Tseng T, Chen P, Chen D, Kao J. Sofosbuvir‐based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection. Journal of Gastroenterology and Hepatology 2019;34:1620-5. [DOI: 10.1111/jgh.14615] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
198 Jeng WJ, Lok AS. Should Treatment Indications for Chronic Hepatitis B Be Expanded? Clin Gastroenterol Hepatol. 2020;. [PMID: 32434068 DOI: 10.1016/j.cgh.2020.04.091] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
199 Stockdale AJ, Silungwe NM, Shawa IT, Kreuels B, Gordon MA, Geretti AM. Diagnostic performance evaluation of hepatitis B e antigen rapid diagnostic tests in Malawi. BMC Infect Dis 2021;21:487. [PMID: 34044776 DOI: 10.1186/s12879-021-06134-3] [Reference Citation Analysis]
200 Koffas A, Petersen J, Kennedy PT. Reasons to consider early treatment in chronic hepatitis B patients. Antiviral Res 2020;177:104783. [PMID: 32217150 DOI: 10.1016/j.antiviral.2020.104783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
201 Zhao M, Zou H, Chen Y, Duan Z. Mechanism and Antiviral Therapy in Preventing Mother-to-Child Transmission During Pregnancy with Hepatitis B Virus Infection. Hepat Mon 2019;19. [DOI: 10.5812/hepatmon.81903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Lee HW, Kim SU, Park JY, Baatarkhuu O, Kim DY, Ahn SH, Han KH, Kim BK. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. Clin Transl Gastroenterol 2019;10:e00036. [PMID: 31107725 DOI: 10.14309/ctg.0000000000000036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
203 Mentha N, Clément S, Negro F, Alfaiate D. A review on hepatitis D: From virology to new therapies. J Adv Res 2019;17:3-15. [PMID: 31193285 DOI: 10.1016/j.jare.2019.03.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 18.0] [Reference Citation Analysis]
204 Malek AE, Nieto Y, Szvalb AD, Siddiqui S, Shafi MA, Hwang JP, Raad II, Torres HA. Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib. Clin Lymphoma Myeloma Leuk 2020;20:e124-7. [PMID: 31932250 DOI: 10.1016/j.clml.2019.12.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
205 Pritchard H, Hwang JP, Angelidakis G, Yibirin M, Wang L, Miller E, Torres HA. Hepatitis B virus reactivation in cancer patients receiving direct-acting antivirals for hepatitis C virus infection. J Viral Hepat 2021;28:844-8. [PMID: 33523503 DOI: 10.1111/jvh.13478] [Reference Citation Analysis]
206 Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, Wang B, Zhan S, Kong Y, Jia J, You H, Yang H. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.02.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
207 Ling SC, Lin HS, Murray KF, Rosenthal P, Mogul D, Rodriguez-Baez N, Schwarzenberg SJ, Teckman J, Schwarz KB; Hepatitis B Research Network (HBRN). Chronic Hepatitis Is Common and Often Untreated Among Children with Hepatitis B Infection in the United States and Canada. J Pediatr 2021:S0022-3476(21)00458-3. [PMID: 34022250 DOI: 10.1016/j.jpeds.2021.05.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
208 Muhammad H, Tehreem A, Hammami MB, Ting PS, Idilman R, Gurakar A. Hepatitis D virus and liver transplantation: Indications and outcomes. World J Hepatol 2021;13:291-9. [PMID: 33815673 DOI: 10.4254/wjh.v13.i3.291] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
209 Hu Q, Wang Q, Zhang Y, Tao S, Zhang X, Liu X, Li X, Jiang X, Huang C, Xu W, Qi X, Chen L, Li Q, Huang Y. Baseline serum exosome-derived miRNAs predict HBeAg seroconversion in chronic hepatitis B patients treated with peginterferon. J Med Virol 2021;93:4939-48. [PMID: 33666247 DOI: 10.1002/jmv.26916] [Reference Citation Analysis]
210 Zhang ZQ, Shi BS, Lu W, Liu DP, Huang D, Feng YL. Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection. Can J Infect Dis Med Microbiol 2019;2019:6545642. [PMID: 31949546 DOI: 10.1155/2019/6545642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Nakamura A, Miyoshi H, Kimura M, Maehara O, Yamada R, Kitagataya T, Yamamoto K, Shigesawa T, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N;  NORTE Study Group. Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. J Gastroenterol. 2021;56:168-180. [PMID: 33211179 DOI: 10.1007/s00535-020-01750-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
212 Berg T, Lampertico P. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol 2021;75:474-80. [PMID: 33957187 DOI: 10.1016/j.jhep.2021.04.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
213 Chen S, Zhou J, Wu X, Meng T, Wang B, Liu H, Wang T, Zhao X, Kong Y, Wu S, Ou X, Jia J, Sun Y, You H. Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B. Hepatol Int 2021;15:611-20. [PMID: 33677771 DOI: 10.1007/s12072-021-10162-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Ghany MG, Feld JJ, Chang KM, Chan HLY, Lok ASF, Visvanathan K, Janssen HLA. Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad. Lancet Gastroenterol Hepatol 2020;5:406-17. [PMID: 32057301 DOI: 10.1016/S2468-1253(19)30344-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 11.0] [Reference Citation Analysis]
215 Kushner T, Sperling RS, Dieterich D. Family Counseling for Hepatitis B and Hepatitis C. Clin Liver Dis (Hoboken) 2019;13:93-7. [PMID: 31061700 DOI: 10.1002/cld.754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
216 Minor MM, Hollinger FB, McNees AL, Jung SY, Jain A, Hyser JM, Bissig KD, Slagle BL. Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex. Cells. 2020;9. [PMID: 32235678 DOI: 10.3390/cells9040834] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
217 Hsu Y, Wong GL, Chen C, Peng C, Yeh M, Cheung K, Toyoda H, Huang C, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai P, Huang Y, Wong C, Huang R, Jang T, Hoang J, Yang H, Li J, Lee D, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen M, Yu M, Nguyen MH. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. Am J Gastroenterol 2020;115:271-80. [DOI: 10.14309/ajg.0000000000000428] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 17.0] [Reference Citation Analysis]
218 Gane E, Verdon DJ, Brooks AE, Gaggar A, Nguyen AH, Subramanian GM, Schwabe C, Dunbar PR. Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol. 2019;71:900-907. [PMID: 31306680 DOI: 10.1016/j.jhep.2019.06.028] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 38.0] [Reference Citation Analysis]
219 Sonderup MW, Dusheiko G, Desalegn H, Lemoine M, Tzeuton C, Taylor-Robinson SD, Spearman CW. Hepatitis B in sub-Saharan Africa-How many patients need therapy? J Viral Hepat 2020;27:560-7. [PMID: 31800145 DOI: 10.1111/jvh.13247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
220 Nicolini LA, Orsi A, Tatarelli P, Viscoli C, Icardi G, Sticchi L. A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals. Int J Environ Res Public Health 2019;16:E3307. [PMID: 31505743 DOI: 10.3390/ijerph16183307] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
221 Yip TC, Wong VW, Chan HL, Tse YK, Lui GC, Wong GL. Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. Gastroenterology. 2020;158:215-225.e6. [PMID: 31574268 DOI: 10.1053/j.gastro.2019.09.025] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 32.0] [Reference Citation Analysis]
222 Higuera-de la Tijera F, Servín-Caamaño A, Servín-Abad L. Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination. World J Gastroenterol 2021;27:4004-17. [PMID: 34326610 DOI: 10.3748/wjg.v27.i26.4004] [Reference Citation Analysis]
223 Li J, Le AK, Chaung KT, Henry L, Hoang JK, Cheung R, Nguyen MH. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver Int. 2020;40:1052-1061. [PMID: 32086988 DOI: 10.1111/liv.14415] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
224 Tseng CH, Hsu YC, Chen TH, Ji F, Chen IS, Tsai YN, Hai H, Thuy LTT, Hosaka T, Sezaki H, Borghi JA, Cheung R, Enomoto M, Nguyen MH. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:1039-1052. [PMID: 33007228 DOI: 10.1016/s2468-1253(20)30249-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
225 Kang NL, Zhang JM, Lin MX, Chen XD, Huang ZX, Zhu YY, Liu YR, Zeng DW. Serum ceruloplasmin can predict liver fibrosis in hepatitis B virus-infected patients. World J Gastroenterol 2020;26:3952-62. [PMID: 32774069 DOI: 10.3748/wjg.v26.i27.3952] [Reference Citation Analysis]
226 Hong YS, Ryu S, Chang Y, Caínzos-Achirica M, Kwon MJ, Zhao D, Shafi T, Lazo M, Pastor-Barriuso R, Shin H, Cho J, Guallar E. Hepatitis B virus infection and development of chronic kidney disease: a cohort study. BMC Nephrol 2018;19:353. [PMID: 30537940 DOI: 10.1186/s12882-018-1154-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
227 Kim S, Lee Y, Bang SM, Bak H, Yim SY, Lee YS, Yoo YJ, Jung YK, Kim JH, Seo YS, Yim HJ, Um SH, Byun KS, Yeon JE. Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients. J Clin Med 2021;10:1840. [PMID: 33922708 DOI: 10.3390/jcm10091840] [Reference Citation Analysis]
228 Veronese P, Dodi I, Esposito S, Indolfi G. Prevention of vertical transmission of hepatitis B virus infection. World J Gastroenterol 2021;27:4182-93. [PMID: 34326618 DOI: 10.3748/wjg.v27.i26.4182] [Reference Citation Analysis]
229 Ortonne V, Wlassow M, Bouvier-Alias M, Melica G, Poveda JD, Laperche S, Pawlotsky JM, Chevaliez S. Diagnosis and Monitoring of Hepatitis B Virus Infection Using the Cobas® HBV Test for Use on the Cobas® 4800 System. Microorganisms 2021;9:573. [PMID: 33799562 DOI: 10.3390/microorganisms9030573] [Reference Citation Analysis]
230 Yu JH, Suh YJ, Jin YJ, Heo NY, Jang JW, You CR, An HY, Lee JW. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir. Eur J Gastroenterol Hepatol. 2019;31:865-872. [PMID: 30694912 DOI: 10.1097/meg.0000000000001357] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 15.0] [Reference Citation Analysis]
231 Zhou K, Dodge JL, Grab J, Poltavskiy E, Terrault NA. Mortality in adults with chronic hepatitis B infection in the United States: a population-based study. Aliment Pharmacol Ther 2020;52:382-9. [PMID: 32432816 DOI: 10.1111/apt.15803] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Chen Y, Wang Y, Chen Y, Yu Z, Chi X, Hu KQ, Li Q, Tan L, Xiang D, Shang Q, Lei C, Chen L, Hu X, Wang J, Liu H, Lu W, Chi W, Dong Z, Wang X, Li Z, Xiao H, Chen D, Bai W, Zhang C, Xiao G, Qi X, Chen J, Zhou L, Sun H, Deng M, Qi X, Zhang Z, Qi X, Yang Y. A Novel Noninvasive Program for Staging Liver Fibrosis in Untreated Patients With Chronic Hepatitis B. Clin Transl Gastroenterol 2019;10:1-12. [PMID: 31033506 DOI: 10.14309/ctg.0000000000000033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
233 Khadka S, Pandit R, Dhital S, Baniya JB, Tiwari S, Shrestha B, Pandit S, Sato F, Fujita M, Sharma M, Tsunoda I, Mishra SK. Evaluation of Five International HBV Treatment Guidelines: Recommendation for Resource-Limited Developing Countries Based on the National Study in Nepal. Pathophysiology 2020;27:3-13. [PMID: 34321716 DOI: 10.3390/pathophysiology27010002] [Reference Citation Analysis]
234 Liu R, Guo J, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Li M, Xie Y. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. Clin Exp Med 2019;19:309-20. [PMID: 31111345 DOI: 10.1007/s10238-019-00560-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
235 Haider M, Flocco G, Lopez R, Carey W. Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab. BMJ Open 2020;10:e043672. [PMID: 33323450 DOI: 10.1136/bmjopen-2020-043672] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
236 Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int 2020;14:958-72. [PMID: 33185803 DOI: 10.1007/s12072-020-10099-x] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
237 Li MH, Chen QQ, Zhang L, Lu HH, Sun FF, Zeng Z, Lu Y, Yi W, Xie Y. Association of cytokines with hepatitis B virus and its antigen. J Med Virol 2020. [PMID: 32662892 DOI: 10.1002/jmv.26301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
238 Huang RJ, Sharp N, Talamoa R, Kapphahn K, Sathye V, Lin B, Srinivasan M, Palaniappan LP. Disaggregated mortality from gastrointestinal cancers in Asian Americans: Analysis of United States death records. Int J Cancer 2021;148:2954-63. [PMID: 33527405 DOI: 10.1002/ijc.33490] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Lin SR, Yang TY, Peng CY, Lin YY, Dai CY, Wang HY, Su TH, Tseng TC, Liu IJ, Cheng HR, Shen YC, Wu FY, Liu CJ, Chen DS, Chen PJ, Yang HC, Kao JH. Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. JHEP Rep 2021;3:100254. [PMID: 33870157 DOI: 10.1016/j.jhepr.2021.100254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
240 Li T, Liang Y, Zhang M, Liu F, Zhang L, Yang B, Wang L. Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatol Res 2021;51:633-40. [PMID: 33772988 DOI: 10.1111/hepr.13641] [Reference Citation Analysis]
241 Yao TT, Pan J, Qian JD, Cheng H, Wang Y, Wang GQ. Shear wave elastography may be sensitive and more precise than transient elastography in predicting significant fibrosis. World J Clin Cases 2020;8:3730-42. [PMID: 32953849 DOI: 10.12998/wjcc.v8.i17.3730] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
242 Liu LZ, Sun J, Hou J, Chan HLY. Improvements in the management of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2018;12:1153-66. [DOI: 10.1080/17474124.2018.1530986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
243 Papatheodoridi M, Papatheodoridis G. Can we stop nucleoside analogues before HBsAg loss? J Viral Hepat. 2019;26:936-941. [PMID: 30803099 DOI: 10.1111/jvh.13091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
244 Luo H, Tan N, Kang Q, Pan J, Chen H, Xi H, Yu M, Xu X. Hepatitis B virus pregenomic RNA status can reveal the long-term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues. J Viral Hepat 2020;27:323-8. [PMID: 31667945 DOI: 10.1111/jvh.13227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
245 Lenci I, Milana M, Grassi G, Manzia TM, Gazia C, Tisone G, Angelico R, Baiocchi L. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? World J Gastroenterol 2020;26:2166-76. [PMID: 32476783 DOI: 10.3748/wjg.v26.i18.2166] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Verna EC. Updated Hepatitis B Guidance: Implications for liver transplant patients. Liver Transpl 2018;24:465-9. [PMID: 29466838 DOI: 10.1002/lt.25037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
247 Shan S, You H, Niu J, Shang J, Xie W, Zhang Y, Li X, Ren H, Tang H, Ding H, Wang X, Nan Y, Dou X, Han T, Zhang L, Liu X, Deng C, Cheng J, Wang X, Xie Q, Lin S, Huang Y, Xu Y, Xiong Y, Li W, Yan X, Piao H, Huang W, Lu Q, Gong W, Li S, Hu X, Zhang X, Liu S, Li Y, Yang D, Li H, Yang C, Cheng M, Zhang L, Zheng H, Luo X, Lin F, Wang L, Xu G, Xu X, Wei L, Hou J, Duan Z, Zhuang H, Yang X, Kong Y, Jia J; CR-HepB study group, Beijing, China. Baseline Characteristics and Treatment Patterns of the Patients Recruited to the China Registry of Hepatitis B. J Clin Transl Hepatol 2019;7:322-8. [PMID: 31915601 DOI: 10.14218/JCTH.2019.00052] [Reference Citation Analysis]
248 Ahn JC, Ahn J. Hepatitis B: Standard and Novel Treatment Options. Clin Liver Dis (Hoboken) 2018;12:19-23. [PMID: 30988904 DOI: 10.1002/cld.719] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
249 Ding Y, Liu K, Xu Y, Zhao Q, Lou S, Xiang X, Yan L, Cao Z, Xie Q, Zhu C, Bao S, Wang H. Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma. Cancer Med 2020;9:3057-69. [PMID: 32150664 DOI: 10.1002/cam4.2968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
250 Myint A, Tong MJ, Beaven SW. Reactivation of Hepatitis B Virus: A Review of Clinical Guidelines. Clin Liver Dis (Hoboken) 2020;15:162-7. [PMID: 32395244 DOI: 10.1002/cld.883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
251 Hwang JP, Feld JJ, Hammond SP, Wang SH, Alston-Johnson DE, Cryer DR, Hershman DL, Loehrer AP, Sabichi AL, Symington BE, Terrault N, Wong ML, Somerfield MR, Artz AS. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update.J Clin Oncol. 2020;38:3698-3715. [PMID: 32716741 DOI: 10.1200/JCO.20.01757] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 17.0] [Reference Citation Analysis]
252 Gu Y, Huang Z, Li X, Chen Y, Liao C, Bi Y, Huang Y. Serum HBV pregenomic RNA exhibited opposite associations with NKdim and NKbright cell immunity in treatment-naïve chronic hepatitis B patients. Biosci Rep 2021;41:BSR20210600. [PMID: 34151357 DOI: 10.1042/BSR20210600] [Reference Citation Analysis]
253 Li J, Ma M, Wang X, Jiang W. Prevention and treatment of new hepatitis B after living donor liver transplantation in children. Transl Pediatr 2021;10:1610-7. [PMID: 34295775 DOI: 10.21037/tp-20-485] [Reference Citation Analysis]
254 Teng W, Liu YC, Jeng WJ, Su CW. Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers (Basel) 2021;13:1729. [PMID: 33917345 DOI: 10.3390/cancers13071729] [Reference Citation Analysis]
255 Terrault NA, Brown RS, Lok AS, Wong JB, Bzowej NH, Chang K, Hwang JP, Jonas MM, Mcmahon BJ. Reply. Hepatology 2018;68:1658-60. [DOI: 10.1002/hep.30137] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
256 Wu CS, Zhao Q, Zhang J, Wang JW, Qian Y, Fan YC, Wang K. Methylation status of the stimulator of interferon genes promoter in patients with chronic hepatitis B. Medicine (Baltimore) 2018;97:e13904. [PMID: 30593207 DOI: 10.1097/MD.0000000000013904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
257 Khue PM, Thuy Linh NT, Vinh VH, Dung LV, Nguyen Van B. Hepatitis B Infection and Mother-to-Child Transmission in Haiphong, Vietnam: A Cohort Study with Implications for Interventions. Biomed Res Int 2020;2020:4747965. [PMID: 32884940 DOI: 10.1155/2020/4747965] [Reference Citation Analysis]
258 Koutsianas C, Thomas K, Vassilopoulos D. Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations. Ther Adv Musculoskelet Dis. 2020;12:1759720X20912646. [PMID: 32206094 DOI: 10.1177/1759720x20912646] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
259 Farag MS, Fung S, Tam E, Doucette K, Wong A, Ramji A, Conway B, Cooper C, Tsoi K, Wong P, Sebastiani G, Brahmania M, Haylock-Jacobs S, Coffin CS, Hansen BE, Janssen HLA. Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study. J Viral Hepat 2021;28:942-50. [PMID: 33749086 DOI: 10.1111/jvh.13500] [Reference Citation Analysis]
260 Hwang JP, Huang D, Vierling JM, Suarez-Almazor ME, Shih YT, Chavez-MacGregor M, Duan Z, Giordano SH, Hershman DL, Fisch MJ, Cantor SB. Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. JCO Clin Cancer Inform 2019;3:1-12. [PMID: 30892921 DOI: 10.1200/CCI.18.00097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
261 Lombardi A, Mondelli MU. Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. Aliment Pharmacol Ther 2019;50:872-84. [PMID: 31378985 DOI: 10.1111/apt.15449] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
262 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Reference Citation Analysis]
263 Rogan SC, Beigi RH. Treatment of Viral Infections During Pregnancy. Clinics in Perinatology 2019;46:235-56. [DOI: 10.1016/j.clp.2019.02.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
264 Salvadori N, Fan B, Teeyasoontranon W, Ngo-Giang-Huong N, Phanomcheong S, Luvira A, Puangsombat A, Suwannarat A, Srirompotong U, Putiyanun C, Cressey TR, Decker L, Khamduang W, Harrison L, Tierney C, Shepherd JA, Kourtis AP, Bulterys M, Siberry GK, Jourdain G. Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus. Clin Infect Dis 2019;69:144-6. [PMID: 30924492 DOI: 10.1093/cid/ciy982] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
265 Lee JH. Old hepatitis B virus never dies: It just hides itself within the host genome. Clin Mol Hepatol 2021;27:107-9. [PMID: 33353287 DOI: 10.3350/cmh.2020.0324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Kim M, Lee Y, Yoon JS, Lee M, Kye SS, Kim SW, Cho Y. The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. Cancers (Basel) 2021;13:2301. [PMID: 34064988 DOI: 10.3390/cancers13102301] [Reference Citation Analysis]
267 Adesina OA, Akanbi OA, Opaleye OO, Japhet MO, Wang B, Oluyege AO, Klink P, Bock CT. Detection of Q129H Immune Escape Mutation in Apparently Healthy Hepatitis B Virus Carriers in Southwestern Nigeria. Viruses 2021;13:1273. [PMID: 34210073 DOI: 10.3390/v13071273] [Reference Citation Analysis]
268 Yip TC, Wong GL, Wong VW, Tse YK, Liang LY, Hui VW, Lee HW, Lui GC, Chan HL. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. J Hepatol. 2020;72:847-854. [PMID: 31857194 DOI: 10.1016/j.jhep.2019.12.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 12.5] [Reference Citation Analysis]
269 Chen S, Zhang Z, Wang Y, Fang M, Zhou J, Li Y, Dai E, Feng Z, Wang H, Yang Z, Li Y, Huang X, Jia J, Li S, Huang C, Tong L, Xiao X, He Y, Duan Y, Zhu S, Gao C. Quasispecies pattern of hepatitis B virus predicts hepatocellular carcinoma using deep-sequencing and machine learning. J Infect Dis. 2020;. [PMID: 33049037 DOI: 10.1093/infdis/jiaa647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
270 Abaalkhail FA, Al-Hamoudi WK, Khathlan A, Alghamdi S, Alghamdi M, Alqahtani SA, Sanai FM. SASLT practice guidelines for the management of Hepatitis B virus - An update. Saudi J Gastroenterol 2021;27:115-26. [PMID: 33976009 DOI: 10.4103/sjg.sjg_539_20] [Reference Citation Analysis]
271 Thompson LA, Heath LJ, Freml H, Delate T. Universal hepatitis B screening and management in patients with cancer who received immunosuppressive chemotherapy. J Oncol Pharm Pract 2020;26:1141-6. [PMID: 31789111 DOI: 10.1177/1078155219889116] [Reference Citation Analysis]
272 Hayakawa M, Umeyama H, Iwadate M, Taguchi YH, Yano Y, Honda T, Itami-Matsumoto S, Kozuka R, Enomoto M, Tamori A, Kawada N, Murakami Y. Development of a novel anti-hepatitis B virus agent via Sp1. Sci Rep 2020;10:47. [PMID: 31913341 DOI: 10.1038/s41598-019-56842-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Ji JH, Park SY, Son WJ, Shin HJ, Lee H, Lee HW, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. External validation of CAGE-B and SAGE-B scores for Asian chronic hepatitis B patients with well-controlled viremia by antivirals. J Viral Hepat 2021;28:951-8. [PMID: 33763928 DOI: 10.1111/jvh.13506] [Reference Citation Analysis]
274 Liang LY, Wong VW, Tse YK, Yip TC, Lui GC, Chan HL, Wong GL. Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2019;49:1509-1517. [PMID: 31025388 DOI: 10.1111/apt.15269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
275 Yang SS, Cai CW, Ma XQ, Xu J, Yu CB. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis. Hepatobiliary Pancreat Dis Int 2020;19:507-14. [PMID: 33051132 DOI: 10.1016/j.hbpd.2020.09.007] [Reference Citation Analysis]
276 Li J, Zhang D, Zhang X. The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report. Infect Drug Resist 2021;14:1013-7. [PMID: 33758517 DOI: 10.2147/IDR.S295060] [Reference Citation Analysis]
277 Reynolds G, Haeusler G, Slavin MA, Teh B, Thursky K. Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach? Support Care Cancer 2021. [PMID: 33763725 DOI: 10.1007/s00520-021-06116-w] [Reference Citation Analysis]
278 Tziomalos K, Neokosmidis G, Mavromatidis G, Dinas K. Novel insights in the prevention of perinatal transmission of hepatitis B. World J Hepatol 2018;10:795-8. [PMID: 30533180 DOI: 10.4254/wjh.v10.i11.795] [Reference Citation Analysis]
279 Gentile G, Antonelli G. HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review. Viruses. 2019;11. [PMID: 31717647 DOI: 10.3390/v11111049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
280 Hercun J, Koh C, Heller T. Hepatitis Delta. Gastroenterology Clinics of North America 2020;49:239-52. [DOI: 10.1016/j.gtc.2020.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
281 Zhao Q, Liu K, Zhu X, Yan L, Ding Y, Xu Y, Lou S, Zhao G, Xie Q, Gao Y, Bao S, Wang H. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase. Antiviral Res 2020;184:104953. [PMID: 33065138 DOI: 10.1016/j.antiviral.2020.104953] [Reference Citation Analysis]
282 Ziogas DC, Kostantinou F, Cholongitas E, Anastasopoulou A, Diamantopoulos P, Haanen J, Gogas H. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. J Immunother Cancer 2020;8:e000943. [PMID: 33067316 DOI: 10.1136/jitc-2020-000943] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
283 Kim HN. Chronic Hepatitis B and HIV Coinfection: A Continuing Challenge in the Era of Antiretroviral Therapy. Curr Hepatol Rep 2020;19:345-53. [PMID: 33796434 DOI: 10.1007/s11901-020-00541-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
284 Huang YS, Cheng CY, Liou BH, Lu PL, Cheng SH, Lee YT, Liu CE, Sun HY, Yang CJ, Tang HJ, Lin SP, Ho MW, Huang SH, Tsai HC, Lee CH, Hung CC; Taiwan HIV Study Group. Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients. J Acquir Immune Defic Syndr 2021;86:473-81. [PMID: 33273214 DOI: 10.1097/QAI.0000000000002589] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
285 Yuen MF, Wong DK, Schluep T, Lai CL, Ferrari C, Locarnini S, Lo RC, Gish RG, Hamilton J, Wooddell CI, Mak LY, Given BD. Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. Gut 2021:gutjnl-2020-323445. [PMID: 33712437 DOI: 10.1136/gutjnl-2020-323445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
286 Wang M, Chen L, Dong M, Li J, Zhu B, Yang Z, Gong Q, Han Y, Yu D, Zhang D, Zoulim F, Zhang J, Zhang X. Viral quasispecies quantitative analysis: a novel approach for appraising the immune tolerant phase of chronic hepatitis B virus infection. Emerg Microbes Infect 2021;10:842-51. [PMID: 33870846 DOI: 10.1080/22221751.2021.1919033] [Reference Citation Analysis]
287 Salyani A, Shah J, Adam R, Otieno G, Mbugua E, Shah R. Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults. PLoS One 2021;16:e0244947. [PMID: 33406137 DOI: 10.1371/journal.pone.0244947] [Reference Citation Analysis]
288 Hou W, Huo Z, Du Y, Wang C, Syn WK. Characteristics of amino acid substitutions within the "a" determinant region of hepatitis B virus in chronically infected patients with coexisting HBsAg and anti-HBs. Clin Res Hepatol Gastroenterol 2020;44:923-31. [PMID: 31624004 DOI: 10.1016/j.clinre.2019.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
289 Chang TS, Yang YH, Chen WM, Shen CH, Tung SY, Yen CW, Hsieh YY, Lee CP, Tsai ML, Hung CH, Lu SN. Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep. 2021;11:1365. [PMID: 33446835 DOI: 10.1038/s41598-020-80523-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
290 Lee HA, Lee HW, Kim IH, Park SY, Sinn DH, Yu JH, Seo YS, Um SH, Lee JI, Lee KS, Lee CH, Tak WY, Kweon YO, Kang W, Paik YH, Lee JW, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther 2020;52:196-204. [PMID: 32452564 DOI: 10.1111/apt.15741] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
291 Wen WH, Chen HL, Shih TT, Wu JF, Ni YH, Lee CN, Zhao LL, Lai MW, Mu SC, Tung YC, Hsu HY, Chang MH; Taiwan Study Group for the Prevention of Mother-to-Infant Transmission of HBV (PreMIT study)(‡). Long-term growth and bone development in children of HBV-infected mothers with and without fetal exposure to tenofovir disoproxil fumarate. J Hepatol 2020;72:1082-7. [PMID: 32044401 DOI: 10.1016/j.jhep.2020.01.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
292 Bath RM, Doering BE, Nailor MD, Goodlet KJ. Pharmacotherapy-Induced Hepatitis B Reactivation Among Patients With Prior Functional Cure: A Systematic Review. Ann Pharmacother 2019;53:294-310. [PMID: 30203666 DOI: 10.1177/1060028018800501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
293 Han Z, Zhang Y, Zhou J, Wang Q, Huang Y, Hou H. Risk of mother-to-child transmission of hepatitis B virus after fetal blood sampling: a report of six cases. BMC Infect Dis 2021;21:716. [PMID: 34330230 DOI: 10.1186/s12879-021-06423-x] [Reference Citation Analysis]
294 Liem KS, Gehring AJ, Feld JJ, Janssen HL. Challenges With Stopping Long-term Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B. Gastroenterology 2020;158:1185-90. [DOI: 10.1053/j.gastro.2019.10.050] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
295 Lai MW, Chang MH. Updates in the management of hepatitis B in children. Expert Rev Gastroenterol Hepatol 2019;13:1065-76. [PMID: 31663387 DOI: 10.1080/17474124.2019.1686975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
296 Xiao D, Wang J, Chen Z, Jin X, Xie Y, Yan D, Yang J. Restricted TcR β chain CDR3 clonotype is associated with resolved acute hepatitis B subjects. BMC Infect Dis 2021;21:111. [PMID: 33485302 DOI: 10.1186/s12879-021-05816-2] [Reference Citation Analysis]
297 Lee BT, Chang M, Lim C, Bae HS, Fong TL. Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients. JGH Open 2021;5:258-63. [PMID: 33553665 DOI: 10.1002/jgh3.12481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
298 Zheng Y, Zhu L, Patrick D, Li Y, Xu F, Zhang L, Song M, Cheng X, Chen B, Chen Y, Lu X, Wang H. Work-health-personal life conflicts in naive patients with chronic hepatitis B receiving initial treatment in China: a qualitative study. BMJ Open 2020;10:e035688. [PMID: 32928849 DOI: 10.1136/bmjopen-2019-035688] [Reference Citation Analysis]
299 Mobini S, Chizari M, Mafakher L, Rismani E, Rismani E. Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus. Front Immunol 2020;11:2074. [PMID: 33042118 DOI: 10.3389/fimmu.2020.02074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
300 Langerová H, Lubyová B, Zábranský A, Hubálek M, Glendová K, Aillot L, Hodek J, Strunin D, Janovec V, Hirsch I, Weber J. Hepatitis B Core Protein Is Post-Translationally Modified through K29-Linked Ubiquitination. Cells 2020;9:E2547. [PMID: 33256078 DOI: 10.3390/cells9122547] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
301 Rybicka M, Woziwodzka A, Sznarkowska A, Romanowski T, Stalke P, Dręczewski M, Verrier ER, Baumert TF, Bielawski KP. Liver Cirrhosis in Chronic Hepatitis B Patients Is Associated with Genetic Variations in DNA Repair Pathway Genes. Cancers (Basel) 2020;12:E3295. [PMID: 33171788 DOI: 10.3390/cancers12113295] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
302 Hu Y, Ye Y, Ye L, Wang X, Yu H. Efficacy and safety of interferon alpha therapy in children with chronic hepatitis B: A long-term follow-up cohort study from China. Medicine (Baltimore) 2019;98:e16683. [PMID: 31393369 DOI: 10.1097/MD.0000000000016683] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
303 Lu M, Shih Y, Hsieh T, Lin J. Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis. Journal of the Formosan Medical Association 2020;119:886-7. [DOI: 10.1016/j.jfma.2019.10.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
304 Lee YS, Bang SM, Lee YS. Benefits and Risks of Antiviral Treatment during Pregnancy in Patients with Chronic Hepatitis B. J Clin Med 2021;10:2320. [PMID: 34073357 DOI: 10.3390/jcm10112320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
305 Wang K, Lu X, Zhou H, Gao Y, Zheng J, Tong M, Wu C, Liu C, Huang L, Jiang T, Meng F, Lu Y, Ai H, Xie XY, Yin LP, Liang P, Tian J, Zheng R. Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study. Gut. 2019;68:729-741. [PMID: 29730602 DOI: 10.1136/gutjnl-2018-316204] [Cited by in Crossref: 130] [Cited by in F6Publishing: 115] [Article Influence: 43.3] [Reference Citation Analysis]
306 Poola S, Sanaka S, Sewell K, Tillmann HL. Hepatitis B surface antibody titres and hepatitis B reactivation with direct-acting antiviral therapy for hepatitis C. J Viral Hepat 2021;28:373-82. [PMID: 33047433 DOI: 10.1111/jvh.13421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
307 Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 2021;73:1108-23. [PMID: 34101376 DOI: 10.1002/art.41752] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
308 Ludwig H, Boccadoro M, Moreau P, San-Miguel J, Cavo M, Pawlyn C, Zweegman S, Facon T, Driessen C, Hajek R, Dimopoulos MA, Gay F, Avet-Loiseau H, Terpos E, Zojer N, Mohty M, Mateos MV, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, Engelhardt M, van de Donk N, Leleu X, Goldschmidt H, Beksac M, Nijhof I, Abildgaard N, Bringhen S, Sonneveld P. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 2021;35:31-44. [PMID: 32814840 DOI: 10.1038/s41375-020-01016-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
309 Le MH, Yeo YH, Cheung R, Wong VW, Nguyen MH. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016. J Intern Med 2020;287:711-22. [DOI: 10.1111/joim.13035] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
310 Kim TS, Sinn DH, Kang W, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Hepatitis B virus DNA levels and overall survival in hepatitis B-related hepatocellular carcinoma patients with low-level viremia. J Gastroenterol Hepatol 2019;34:2028-35. [PMID: 31157456 DOI: 10.1111/jgh.14750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
311 Fong TL, Lee BT, Chang M, Nasanbayar K, Tsogtoo E, Boldbaatar D, Dashdorj ED, Clifford NE, Dashdorj AN, Bang BR, Chida T, Lim C, Sugiyama M, Mizokami M, Dashdorj NJ, Liu P, Glenn JS, Dashdorj ND, Saito T. High Prevalence of Chronic Viral Hepatitis and Liver Fibrosis Among Mongols in Southern California. Dig Dis Sci 2021;66:2833-9. [PMID: 32770488 DOI: 10.1007/s10620-020-06499-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
312 Smolders EJ, Burger DM, Feld JJ, Kiser JJ. Review article: clinical pharmacology of current and investigational hepatitis B virus therapies. Aliment Pharmacol Ther. 2020;51:231-243. [PMID: 31840863 DOI: 10.1111/apt.15581] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
313 Bhamidimarri KR, Pan CQ. Update in the Management of Chronic Hepatitis B in Pregnancy. Curr Hepatology Rep 2018;17:475-84. [DOI: 10.1007/s11901-018-0437-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
314 Li N, Fan X, Wang X, Deng H, Zhang K, Zhang X, Han Q, Lv Y, Liu Z. Autophagy-Related 5 Gene rs510432 Polymorphism Is Associated with Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Infection. Immunol Invest 2019;48:378-91. [PMID: 30907204 DOI: 10.1080/08820139.2019.1567532] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
315 Sagnelli C, Pisaturo M, Calò F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol 2019;25:3299-312. [PMID: 31341357 DOI: 10.3748/wjg.v25.i26.3299] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
316 Hou J, Cui F, Ding Y, Dou X, Duan Z, Han G, Jia J, Mao Q, Li J, Li Z, Liu Z, Wei L, Xie Q, Yang X, Zhang H, Zhuang H. Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. Clin Gastroenterol Hepatol 2019; 17: 1929-1936. e1. [PMID: 30312789 DOI: 10.1016/j.cgh.2018.10.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
317 Bixler D, Annambholta P, Abara WE, Collier MG, Jones J, Mixson-Hayden T, Basavaraju SV, Ramachandran S, Kamili S, Moorman A. Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017. Am J Transplant. 2019;19:2570-2582. [PMID: 30861300 DOI: 10.1111/ajt.15352] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
318 Park ES, Lee AR, Kim DH, Lee JH, Yoo JJ, Ahn SH, Sim H, Park S, Kang HS, Won J, Ha YN, Shin GC, Kwon SY, Park YK, Choi BS, Lee YB, Jeong N, An Y, Ju YS, Yu SJ, Chae HB, Yu KS, Kim YJ, Yoon JH, Zoulim F, Kim KH. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol. 2019;70:1093-1102. [PMID: 30794889 DOI: 10.1016/j.jhep.2019.02.006] [Cited by in Crossref: 65] [Cited by in F6Publishing: 46] [Article Influence: 32.5] [Reference Citation Analysis]
319 Ramsey SD, Unger JM, Baker LH, Little RF, Loomba R, Hwang JP, Chugh R, Konerman MA, Arnold K, Menter AR, Thomas E, Michels RM, Jorgensen CW, Burton GV, Bhadkamkar NA, Hershman DL. Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices. JAMA Oncol 2019;5:497-505. [PMID: 30653226 DOI: 10.1001/jamaoncol.2018.6437] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 30.0] [Reference Citation Analysis]
320 Lee SW, Choi J, Kim SU, Lim YS. Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clin Mol Hepatol 2021;27:402-12. [PMID: 34157830 DOI: 10.3350/cmh.2021.0179] [Reference Citation Analysis]
321 Manne V, Gochanour E, Kowdley KV. Current perspectives into the evaluation and management of hepatitis B: a review. Hepatobiliary Surg Nutr 2019;8:361-9. [PMID: 31489305 DOI: 10.21037/hbsn.2019.02.09] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
322 Hwang JP, Torres HA. Hepatitis B virus and hepatitis C virus infection in immunocompromised patients. Curr Opin Infect Dis 2018;31:535-41. [PMID: 30299355 DOI: 10.1097/QCO.0000000000000500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
323 Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021;27:1497-506. [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Reference Citation Analysis]
324 Lim TS, Lee JS, Kim BK, Lee HW, Jeon MY, Kim SU, Park JY, Kim DY, Han KH, Ahn SH. An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. J Viral Hepat 2020;27:316-22. [PMID: 31639240 DOI: 10.1111/jvh.13222] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
325 Liu J, Xu B, Chen T, Chen J, Feng J, Xu C, Liu L, Hu Y, Zhou YH. Presence of hepatitis B virus markers in umbilical cord blood: Exposure to or infection with the virus? Dig Liver Dis 2019;51:864-9. [PMID: 30528568 DOI: 10.1016/j.dld.2018.11.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
326 Xing YF, Wei CS, Zhou TR, Huang DP, Zhong WC, Chen B, Jin H, Hu XY, Yang ZY, He Q, Jiang KP, Jiang JM, Hu ZB, Deng X, Yang F, Li FY, Zhao G, Wang LC, Mi YQ, Gong ZJ, Guo P, Wu JH, Shi WQ, Yang HZ, Zhou DQ, Tong GD. Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients. World J Gastroenterol 2020;26:4501-22. [PMID: 32874061 DOI: 10.3748/wjg.v26.i30.4501] [Reference Citation Analysis]
327 Flecken T, Meier MA, Skewes-Cox P, Barkan DT, Heim MH, Wieland SF, Holdorf MM. Mapping the Heterogeneity of Histone Modifications on Hepatitis B Virus DNA Using Liver Needle Biopsies Obtained from Chronically Infected Patients. J Virol 2019;93:e02036-18. [PMID: 30787147 DOI: 10.1128/JVI.02036-18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
328 Lee HM, Ahn J, Kim WR, Lim JK, Nguyen M, Pan CQ, Kim D, Mannalithara A, Te H, Trinh H, Chu D, Tran T, Woog J, Lok AS. A Comparison Between Community and Academic Practices in the USA in the Management of Chronic Hepatitis B Patients Receiving Entecavir: Results of the ENUMERATE Study. Dig Dis Sci 2019;64:358-66. [PMID: 30238203 DOI: 10.1007/s10620-018-5281-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
329 Sonneveld MJ, van Oord GW, van Campenhout MJ, De Man RA, Janssen HLA, de Knegt RJ, Boonstra A, van der Eijk AA. Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues. J Viral Hepat 2019;26:828-34. [PMID: 30896057 DOI: 10.1111/jvh.13097] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
330 Yang Y, Huang A, Zhao Y. Spontaneous loss of chronic HBV infection markers in treatment-naïve children: a systematic review and pooled meta-analyses. Expert Rev Anti Infect Ther 2021;19:649-60. [PMID: 33164585 DOI: 10.1080/14787210.2021.1845652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
331 Pan CQ, Li MH, Zeng HH, Zhang Y, Cao WH, Wang Y, Zhou MF, Hu YH, Wan G, Xie Y, Yi W. Developmental Consequences of Prenatal Telbivudine Exposure during the Third Trimester. Clin Gastroenterol Hepatol 2021;19:1061-3. [PMID: 32371166 DOI: 10.1016/j.cgh.2020.04.056] [Reference Citation Analysis]
332 Wu Y, Huang H, Luo Y. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:610500. [PMID: 33613534 DOI: 10.3389/fimmu.2020.610500] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
333 Charlton MR, Alam A, Shukla A, Dashtseren B, Lesmana CRA, Duger D, Payawal DA, Duy Cuong D, Jargalsaikhan G, Cua IHY, Sollano JD, Singh KR, Madan K, Win KM, Kyi KP, Tun KS, Salih M, Rastogi M, Saraf N, Thuy PTT, Hien PTD, Gani RA, Mohamed R, Tanwandee T, Piratvisuth T, Sukeepaisarnjaroen W, Naing W, Hashmi ZY. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol 2020;55:811-23. [PMID: 32666200 DOI: 10.1007/s00535-020-01698-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
334 Chularojanamontri L, Nimanong S, Wongpraparut C, Silpa-Archa N, Chaiyabutr C, Charoenpipatsin N. Impact of long-term systemic treatment for psoriasis on liver disease in psoriasis patients with coexisting hepatitis B virus infection. Dermatol Ther 2020;33:e14008. [PMID: 32654402 DOI: 10.1111/dth.14008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
335 Wellhöner F, Döscher N, Woelfl F, Vital M, Plumeier I, Kahl S, Potthoff A, Manns MP, Pieper DH, Cornberg M, Wedemeyer H, Heidrich B. Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis. Hepatology 2021;74:72-82. [PMID: 33411981 DOI: 10.1002/hep.31700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
336 Childs-Kean LM, Egelund EF, Jourjy J. Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection. Pharmacotherapy 2018;38:1051-7. [PMID: 30120841 DOI: 10.1002/phar.2174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
337 Liu WC, Wu IC, Chiu YC, Tseng KC, Chen CY, Chiu HC, Cheng PN, Chang TT. Genotyping of immune-related loci associated with delayed HBeAg seroconversion in immune-active chronic hepatitis B patients. Antiviral Res 2020;176:104719. [PMID: 32004619 DOI: 10.1016/j.antiviral.2020.104719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
338 Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT;  IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
339 Berke JM, Dehertogh P, Vergauwen K, Mostmans W, Vandyck K, Raboisson P, Pauwels F. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379. Antimicrob Agents Chemother. 2020;64:e02439-19. [PMID: 32094138 DOI: 10.1128/aac.02439-19] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 13.0] [Reference Citation Analysis]
340 Liu R, Chen Y, Guo J, Li M, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Zhang H, Xie Y. The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients. BMC Infect Dis 2020;20:590. [PMID: 32778058 DOI: 10.1186/s12879-020-05320-z] [Reference Citation Analysis]
341 Delli Pizzi A, Mastrodicasa D, Cianci R, Serafini FL, Mincuzzi E, Di Fabio F, Giammarino A, Mannetta G, Basilico R, Caulo M. Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. Can Assoc Radiol J 2020;:846537120923982. [PMID: 32436394 DOI: 10.1177/0846537120923982] [Reference Citation Analysis]
342 Alghamdi S, Fleckenstein J. Liver Disease in Pregnancy and Transplant. Curr Gastroenterol Rep 2019;21:43. [PMID: 31346820 DOI: 10.1007/s11894-019-0711-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
343 Wu CF, Fong TM, Wu SS, Saab S. Hepatitis B Surface Antigen Levels Are Related to Spontaneous Hepatitis B Surface Antigen Seroconversion in Inactive Hepatitis B Carriers. J Clin Gastroenterol 2020;54:573-6. [PMID: 32049690 DOI: 10.1097/MCG.0000000000001324] [Reference Citation Analysis]
344 Liu CH, Huang YJ, Yang SS, Chang CH, Yang SS, Sun HY, Liu CJ, Liu WC, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Hung CC, Kao JH. Generic sofosbuvir-based interferon-free direct acting antiviral agents for patients with chronic hepatitis C virus infection: a real-world multicenter observational study. Sci Rep 2018;8:13699. [PMID: 30209349 DOI: 10.1038/s41598-018-32060-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
345 Cryer AM, Imperial JC. Hepatitis B in Pregnant Women and their Infants. Clin Liver Dis 2019;23:451-62. [PMID: 31266619 DOI: 10.1016/j.cld.2019.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
346 Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Reference Citation Analysis]
347 Zhang ZQ, Shi BS, Lu W, Liu DP, Huang D, Feng YL. Quantitative HBcrAg and HBcAb versus HBsAg and HBV DNA in predicting liver fibrosis levels of chronic hepatitis B patients. Gastroenterol Hepatol 2020;43:526-36. [PMID: 32921478 DOI: 10.1016/j.gastrohep.2020.03.017] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
348 Chen MH, Lee IC, Chen MH, Hou MC, Tsai CY, Huang YH. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Ann Rheum Dis 2021:annrheumdis-2021-220774. [PMID: 34187776 DOI: 10.1136/annrheumdis-2021-220774] [Reference Citation Analysis]
349 Wu Z, Ma AL, Xie Q, Zhang XQ, Cheng J, Zhang DZ, Wang GQ, Zhao H. Significant histological changes and satisfying antiviral efficacy in chronic hepatitis B virus infection patients with normal alanine aminotransferase. Antiviral therapy decision in chronic HBV patients with normal ALT. Clin Res Hepatol Gastroenterol 2021;45:101463. [PMID: 32571749 DOI: 10.1016/j.clinre.2020.05.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
350 Campos-Valdez M, Monroy-Ramírez HC, Armendáriz-Borunda J, Sánchez-Orozco LV. Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability. Viruses 2021;13:1167. [PMID: 34207116 DOI: 10.3390/v13061167] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
351 Shang J, Liu H, Wen Q, M Ise R, Tu Y, Bai L, Tang H. Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B throughout pregnancy. Int J Infect Dis 2021;105:626-31. [PMID: 33722684 DOI: 10.1016/j.ijid.2021.03.023] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
352 Zhou X, Cai BB, Hou XQ, Kang XK, Xu XX, Wang WM. Development and validation of a risk score for predicting mortality after resection of primary hepatocellular carcinoma. Aging (Albany NY) 2020;12:11878-92. [PMID: 32568098 DOI: 10.18632/aging.103360] [Reference Citation Analysis]
353 Tran S, Jeong D, Henry L, Cheung RC, Nguyen MH. Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study. Am J Gastroenterol 2021;116:1885-95. [PMID: 33927125 DOI: 10.14309/ajg.0000000000001271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
354 Yang X, Zhong X, Liao H, Lai Y. Efficacy of antiviral therapy during the second or the third trimester for preventing mother-to-child hepatitis B virus transmission: a systematic review and meta-analysis. Rev Inst Med Trop Sao Paulo 2020;62:e13. [PMID: 32074216 DOI: 10.1590/S1678-9946202062013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
355 Wang T, Smith DA, Campbell C, Mokaya J, Freeman O, Salih H, McNaughton AL, Cripps S, Várnai KA, Noble T, Woods K, Collier J, Jeffery K, Davies J, Barnes E, Matthews PC. Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study. BMC Infect Dis 2021;21:610. [PMID: 34174833 DOI: 10.1186/s12879-021-06226-0] [Reference Citation Analysis]
356 Tovo CV, Ahlert M, Panke C, de Mattos ÂZ, de Mattos AA. Treatment of hepatitis B virus infection in chronic infection with HBeAg-positive adult patients (immunotolerant patients): a systematic review. Eur J Gastroenterol Hepatol 2021;33:605-9. [PMID: 32947420 DOI: 10.1097/MEG.0000000000001907] [Reference Citation Analysis]
357 Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS;  Taormina Workshop on Occult HBV Infection Faculty Members. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019;71:397-408. [PMID: 31004683 DOI: 10.1016/j.jhep.2019.03.034] [Cited by in Crossref: 113] [Cited by in F6Publishing: 89] [Article Influence: 56.5] [Reference Citation Analysis]
358 Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. Sci Rep 2019;9:2508. [PMID: 30792468 DOI: 10.1038/s41598-019-39043-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
359 Ma JL, He LL, Jiang Y, Yang JR, Li P, Zang Y, Wei HS. New model predicting gastroesophageal varices and variceal hemorrhage in patients with chronic liver disease. Ann Hepatol 2020;19:287-94. [PMID: 32197976 DOI: 10.1016/j.aohep.2019.12.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
360 Feld JJ, Krassenburg LAP. What Comes First: Treatment of Viral Hepatitis or Liver Cancer? Dig Dis Sci 2019;64:1041-9. [PMID: 30874985 DOI: 10.1007/s10620-019-05518-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
361 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Reference Citation Analysis]
362 Tariq H, Kamal MU, Makker J, Azam S, Pirzada UA, Mehak V, Kumar K, Patel H. Hepatitis in slaughterhouse workers. World J Hepatol 2019;11:37-49. [PMID: 30705717 DOI: 10.4254/wjh.v11.i1.37] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
363 Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology. 2021;73:661-673. [PMID: 32324905 DOI: 10.1002/hep.31289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
364 Nicastro E, Mangili B, Giacomet V, Benincaso AR, Di Giorgio A, Sansotta N, Callegaro A, D’antiga L. Longitudinal Immune Phenotype Assessment and Serological Outcome in Foreign-born Children With Chronic Hepatitis B. Journal of Pediatric Gastroenterology & Nutrition 2020;71:381-7. [DOI: 10.1097/mpg.0000000000002804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
365 Lee H, Kim BK, Jang S, Ahn SH. Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression. Clin Transl Gastroenterol 2021;12:e00299. [PMID: 33600103 DOI: 10.14309/ctg.0000000000000299] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Sripongpun P, Kim WR, Mannalithara A, Kwong A, Daugherty T, Goel A, Kwo PY. Tenofovir Alafenamide Attenuates Effects of Diabetes and Body Mass on Serum Alanine Aminotransferase Activities in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol. 2020;. [PMID: 33285291 DOI: 10.1016/j.cgh.2020.11.047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
367 Lu F, Ni Y. Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience. Pediatr Gastroenterol Hepatol Nutr 2020;23:311. [DOI: 10.5223/pghn.2020.23.4.311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
368 Xun Z, Liu C, Yu QQ, Lin JP, Huang JL, Yang TW, Wu WN, Wu SH, Ou QS. Albumin-bilirubin score is associated with response to pegylated interferon and nucleos(t)ide analogues in chronic hepatitis B patients. Clin Chim Acta 2020;502:120-7. [PMID: 31891671 DOI: 10.1016/j.cca.2019.12.020] [Reference Citation Analysis]
369 Hsu YC, Tseng CH, Huang YT, Yang HI. Application of Risk Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: Current Status and Future Perspective. Semin Liver Dis 2021;41:285-97. [PMID: 34161993 DOI: 10.1055/s-0041-1730924] [Reference Citation Analysis]
370 Verbinnen T, Hodari M, Talloen W, Berke JM, Blue D, Yogaratnam J, Vandenbossche J, Shukla U, De Meyer S, Lenz O. Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy. J Viral Hepat 2020;27:1127-37. [PMID: 32579776 DOI: 10.1111/jvh.13351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
371 Vaillant A. Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure. Viruses 2021;13:745. [PMID: 33922828 DOI: 10.3390/v13050745] [Reference Citation Analysis]
372 Chen F, Chen YL, Chen TW, Li R, Pu Y, Zhang XM, Li HJ, Tang S, Cao JM, Yang JQ. Liver lobe based intravoxel incoherent motion diffusion weighted imaging in hepatitis B related cirrhosis: Association with child-pugh class and esophageal and gastric fundic varices. Medicine (Baltimore) 2020;99:e18671. [PMID: 31914057 DOI: 10.1097/MD.0000000000018671] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
373 Zeng G, Gill US, Kennedy PTF. Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis. Gut 2020;69:1907-12. [PMID: 32451325 DOI: 10.1136/gutjnl-2020-321627] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
374 Lee HW, Park SY, Lee M, Lee EJ, Lee J, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. An optimized hepatocellular carcinoma prediction model for chronic hepatitis B with well-controlled viremia. Liver Int. 2020;40:1736-1743. [PMID: 32239602 DOI: 10.1111/liv.14451] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
375 Mak L, Seto W, Yuen M. Future Therapies for Functional Cure of Chronic HBV: Review of Investigational Drugs in Phase 1 and 2 Development. Curr Hepatology Rep 2019;18:503-11. [DOI: 10.1007/s11901-019-00494-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
376 Guvenir M, Arikan A. Hepatitis B Virus: From Diagnosis to Treatment. Pol J Microbiol 2020;69:391-9. [PMID: 33574867 DOI: 10.33073/pjm-2020-044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
377 Jing W, Liu J, Liu M. Eliminating mother-to-child transmission of HBV: progress and challenges in China. Front Med 2020;14:21-9. [PMID: 31974872 DOI: 10.1007/s11684-020-0744-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
378 Inoue J, Sato K, Ninomiya M, Masamune A. Envelope Proteins of Hepatitis B Virus: Molecular Biology and Involvement in Carcinogenesis. Viruses 2021;13:1124. [PMID: 34208172 DOI: 10.3390/v13061124] [Reference Citation Analysis]
379 Maraolo AE. Choosing the appropriate pharmacotherapy for hepatitis B during pregnancy: what are the considerations? Expert Opin Pharmacother 2021;22:1083-6. [PMID: 33797300 DOI: 10.1080/14656566.2021.1909571] [Reference Citation Analysis]
380 Rana U, Driedger M, Sereda P, Pan S, Ding E, Wong A, Walmsley S, Klein M, Kelly D, Loutfy M, Thomas R, Sanche S, Kroch A, Machouf N, Roy-Gagnon MH, Hogg R, Cooper CL; Canadian Observational Cohort (CANOC) Collaboration. Characteristics and outcomes of antiretroviral-treated HIV-HBV co-infected patients in Canada? BMC Infect Dis 2019;19:982. [PMID: 31752729 DOI: 10.1186/s12879-019-4617-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
381 Sayan M, Yıldırım FS, Akhan S, Yıldırım AA, Şirin G, Cabalak M, Demir M, Can S, Ersöz G, Altıntaş E, Ensaroğlu F, Akbulut A, Şener A, Deveci A. NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey. Int J Infect Dis 2020;95:84-9. [PMID: 32302766 DOI: 10.1016/j.ijid.2020.03.061] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Li Z, Duan X, Hu Y, Zhou M, Liu M, Kang K, Cai H, Yi W, Fu D, Gao X. Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother-to-Child Transmission of Hepatitis B Virus: A Real-World Study. Biomed Res Int 2020;2020:1374276. [PMID: 32420317 DOI: 10.1155/2020/1374276] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
383 Li X, Zhang L, Qiu M, Huang Y, Xiao H, Lu B, Jiang Y, Long F, Lin H, He J, Wu Q, Zhang M, Wang L, Zhu X, Gong M, Sun X, Sun J, Sun F, Lu W, Xu W, Chen G, Li Z, Gan D, Yang X, Du H, Ye Y. Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in China. Trials 2020;21:708. [PMID: 32787905 DOI: 10.1186/s13063-020-04417-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
384 Atteya A, Ahmad A, Daghstani D, Mushtaq K, Yassin MA. Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Cancer Control 2020;27:1073274820976594. [PMID: 33297765 DOI: 10.1177/1073274820976594] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
385 Gilman C, Heller T, Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies. World J Gastroenterol. 2019;25:4580-4597. [PMID: 31528088 DOI: 10.3748/wjg.v25.i32.4580] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
386 Mao QG, Liang HQ, Yin YL, Tang JM, Yang JE, Wu CC, Chen Y, Zhang MY, Liu YY, Zheng XT, Zhuang LY, Chen SD. Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B. Clin Res Hepatol Gastroenterol 2021;:101758. [PMID: 34303003 DOI: 10.1016/j.clinre.2021.101758] [Reference Citation Analysis]
387 Wani MA, Sodhi JS, Yatoo GN, Shah A, Geelani S, Zargar SA, Gulzar GM, Khan M, Aziz SA. Clinical Profile and Efficacy of Antivirals in Hepatitis B Virus Reactivation, in Patients With Cancer Receiving Chemotherapy. J Clin Exp Hepatol 2020;10:590-8. [PMID: 33311896 DOI: 10.1016/j.jceh.2020.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
388 Li L, Li B, Zhang M. HBV DNA levels impact the prognosis of hepatocellular carcinoma patients with microvascular invasion. Medicine (Baltimore) 2019;98:e16308. [PMID: 31277172 DOI: 10.1097/MD.0000000000016308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
389 Wu Z, Dong X, Wang G, Zhao H; China HepB-Related Fibrosis Assessment Research Group. Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal. J Viral Hepat 2019;26:287-96. [PMID: 30380162 DOI: 10.1111/jvh.13030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
390 Ha Y, Chon YE, Kim MN, Lee JH, Hwang SG. Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate. Sci Rep 2020;10:13537. [PMID: 32782369 DOI: 10.1038/s41598-020-70433-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
391 Kim MA, Kim SU, Sinn DH, Jang JW, Lim YS, Ahn SH, Shim JJ, Seo YS, Baek YH, Kim SG, Kim YS, Kim JH, Choe WH, Yim HJ, Lee HW, Kwon JH, Lee SW, Jang JY, Kim HY, Park Y, Kim GA, Yang H, Lee HA, Koh M, Lee YS, Kim M, Chang Y, Kim YJ, Yoon JH, Zoulim F, Lee JH. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut 2020;69:2214-22. [PMID: 32209606 DOI: 10.1136/gutjnl-2019-320015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
392 Lee HW, Park JY, Lee JW, Yoon KT, Kim CW, Park H, Kim YS, Paik SK, Lee JI, Kim BK, Han KH, Ahn SH. Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. Clin Gastroenterol Hepatol 2019;17:1348-1355.e2. [PMID: 30613003 DOI: 10.1016/j.cgh.2018.10.037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
393 Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, Tang H. Hepatitis B Virus Infection: Overview. Adv Exp Med Biol 2020;1179:1-16. [PMID: 31741331 DOI: 10.1007/978-981-13-9151-4_1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
394 Hui VW, Yip TC, Wong VW, Tse YK, Chan HL, Lui GC, Wong GL. Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. Clin Transl Gastroenterol 2021;12:e00324. [PMID: 33750746 DOI: 10.14309/ctg.0000000000000324] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
395 Lee HM, Banini BA. Updates on Chronic HBV: Current Challenges and Future Goals. Curr Treat Options Gastro 2019;17:271-91. [DOI: 10.1007/s11938-019-00236-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 13.5] [Reference Citation Analysis]
396 Wong GL, Yuen BW, Chan HL, Tse YK, Yip TC, Lam KL, Lui GC, Wong VW. Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. Liver Int. 2019;39:271-279. [PMID: 30179316 DOI: 10.1111/liv.13953] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
397 Lee HY, Oh H, Park CH, Yeo YH, Nguyen MH, Jun DW. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis. World J Gastroenterol. 2019;25:2961-2972. [PMID: 31249453 DOI: 10.3748/wjg.v25.i23.2961] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
398 Liu Y, Chen R, Liu W, Si L, Li L, Li X, Yao Z, Liao H, Wang J, Li Y, Zhao J, Xu D. Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs. Antiviral Res 2021;189:105058. [PMID: 33711338 DOI: 10.1016/j.antiviral.2021.105058] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
399 El-Nabi SH, El-Garawani I, Ismail F, Abdelsameea E. Anti-HBc and hepatitis B virus DNA among HBsAg-negative blood donors from the main central blood bank units in Eastern Libya. Transfus Med 2020;30:401-5. [PMID: 32894893 DOI: 10.1111/tme.12711] [Reference Citation Analysis]
400 Liu K, Wong VWS, Liang LY, Lui GCY, Chan HLY, Wong GLH. Clinical outcomes and management of patients with chronic hepatitis B and liver stiffness measurement in the grey zone. Liver Int 2019;39:494-502. [PMID: 30417579 DOI: 10.1111/liv.14001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
401 Sedano R, Castro L, Venegas M, Miranda J, Hurtado C, Poniachik J, Brahm J. Liver transplantation in acute liver failure due to Hepatitis B. Two clinical cases. Ann Hepatol 2021;21:100107. [PMID: 31623992 DOI: 10.1016/j.aohep.2019.06.012] [Reference Citation Analysis]
402 Suresh M, Menne S. Application of the woodchuck animal model for the treatment of hepatitis B virus-induced liver cancer. World J Gastrointest Oncol 2021;13:509-35. [PMID: 34163570 DOI: 10.4251/wjgo.v13.i6.509] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Asselah T, Loureiro D, Boyer N, Mansouri A. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. The Lancet Gastroenterology & Hepatology 2019;4:883-92. [DOI: 10.1016/s2468-1253(19)30190-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 11] [Article Influence: 13.5] [Reference Citation Analysis]
404 Hsu YC, Nguyen MH, Mo LR, Wu MS, Yang TH, Chen CC, Tseng CH, Tai CM, Wu CY, Lin JT, Tanaka Y, Chang CY. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk. Aliment Pharmacol Ther. 2019;49:107-115. [PMID: 30450681 DOI: 10.1111/apt.15058] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 10.7] [Reference Citation Analysis]
405 Li J, Wu Z, Wang GQ, Zhao H. Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients. Chin Med J (Engl) 2021;134:1160-7. [PMID: 33734135 DOI: 10.1097/CM9.0000000000001418] [Reference Citation Analysis]
406 Fanning GC, Zoulim F, Hou J, Bertoletti A. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18:827-844. [PMID: 31455905 DOI: 10.1038/s41573-019-0037-0] [Cited by in Crossref: 118] [Cited by in F6Publishing: 102] [Article Influence: 59.0] [Reference Citation Analysis]
407 Gu L, Yao Q, Shen Z, He Y, Ng DM, Yang T, Chen B, Chen P, Mao F, Yu Q. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2020;35:1467-1476. [PMID: 32180249 DOI: 10.1111/jgh.15036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
408 Yamai T, Hikita H, Fukuoka M, Fukutomi K, Murai K, Nakabori T, Yamada R, Miyakawa K, Watashi K, Ryo A, Kodama T, Sakamori R, Tatsumi T, Takehara T. SIRT1 enhances hepatitis virus B transcription independent of hepatic autophagy. Biochem Biophys Res Commun 2020;527:64-70. [PMID: 32446392 DOI: 10.1016/j.bbrc.2020.04.031] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
409 Fontana RJ, Avigan MI, Janssen HLA, Regev A, Mishra P, Gaggar A, Brown N, Wat C, Mendez P, Anderson RT, Given B, Miller V, Beumont M. Liver safety assessment in clinical trials of new agents for chronic hepatitis B. J Viral Hepat 2020;27:96-109. [PMID: 31828894 DOI: 10.1111/jvh.13223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
410 Wu CC, Kumar R. Hepatitis B reactivation in patients with hepatitis B core antibody positive and surface antigen negative on immunosuppressants. WJMA 2019;7:209-17. [DOI: 10.13105/wjma.v7.i5.209] [Reference Citation Analysis]
411 Coffin CS, Zhou K, Terrault NA. New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology 2019;156:355-368.e3. [PMID: 30472225 DOI: 10.1053/j.gastro.2018.11.037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 11.7] [Reference Citation Analysis]
412 Yeh ML, Huang CI, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Dai CY, Yu ML, Chuang WL. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. J Infect Dis 2019;219:1224-33. [PMID: 30452671 DOI: 10.1093/infdis/jiy648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
413 Yeo YH, Le MH, Chang ET, Henry L, Nguyen MH. Prevalence of Undetectable Vaccine-Induced Immunity Against Hepatitis B Virus in US Adults at High Risk for Infection. Hepatology 2019;69:1385-97. [PMID: 30246260 DOI: 10.1002/hep.30285] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
414 Yin XR, Liu ZH, Liu J, Liu YY, Xie L, Tao LB, Jia JD, Cui FQ, Zhuang GH, Hou JL. First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China. Chin Med J (Engl) 2019;132:2315-24. [PMID: 31567376 DOI: 10.1097/CM9.0000000000000445] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Liu CH, Liu CJ, Hung CC, Hsieh SM, Su TH, Sun HY, Tseng TC, Chen PJ, Chen DS, Kao JH. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan. Liver Int 2020;40:758-68. [PMID: 31710759 DOI: 10.1111/liv.14295] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
416 Lim TS, Kim JK. Is liver biopsy still useful in the era of non-invasive tests? Clin Mol Hepatol 2020;26:302-4. [PMID: 32646204 DOI: 10.3350/cmh.2020.0081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
417 Lee YT, Wang JJ, Luu M, Tseng HR, Rich NE, Lu SC, Nissen NN, Noureddin M, Singal AG, Yang JD. State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States. Hepatology 2021. [PMID: 33728665 DOI: 10.1002/hep.31811] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
418 Buti M, Marcos-Fosch C, Esteban R. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide. Liver Int 2021;41 Suppl 1:9-14. [PMID: 34155802 DOI: 10.1111/liv.14848] [Reference Citation Analysis]
419 Alhajeri H, Abutiban F, Al-Adsani W, Al-Awadhi A, Aldei A, AlEnizi A, Alhadhood N, Al-Herz A, Alkandari W, Dehrab A, Muhanna Ghanem AA, Hasan E, Hayat S, Saleh K, Tarakmeh H, Ali Y. Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis. Rheumatol Int 2019;39:1483-97. [PMID: 31309293 DOI: 10.1007/s00296-019-04372-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
420 Luo X, Wang Y. Analysis of the Effect of Health Management of Chronic Diseases and Metabolic Disorders under the Guidance of B-Ultrasound. J Healthc Eng 2021;2021:6648611. [PMID: 33604009 DOI: 10.1155/2021/6648611] [Reference Citation Analysis]
421 Fadriquela A, Kim CS, Lee KJ, Kang SH, Kim MY, Lee JH. Soluble type immune checkpoint regulators using multiplex luminex immunoassay in chronic hepatitis B patients. J Clin Pathol 2021:jclinpath-2020-207125. [PMID: 34016716 DOI: 10.1136/jclinpath-2020-207125] [Reference Citation Analysis]
422 Liang LY, Lee HW, Wong VW, Yip TC, Tse YK, Hui VW, Lui GC, Chan HL, Wong GL. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clin Mol Hepatol 2021;27:499-509. [PMID: 33631920 DOI: 10.3350/cmh.2020.0333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Wu IC, Liu WC, Chiu YC, Chiu HC, Cheng PN, Chang TT. Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss. Microorganisms 2021;9:1146. [PMID: 34073483 DOI: 10.3390/microorganisms9061146] [Reference Citation Analysis]
424 Wong GL, Wong VW, Yuen BW, Tse YK, Yip TC, Luk HW, Lui GC, Chan HL. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. J Hepatol. 2020;72:57-66. [PMID: 31499132 DOI: 10.1016/j.jhep.2019.08.023] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
425 Verbinnen T, Tan Y, Wang G, Dehertogh P, Vergauwen K, Neefs J, Jacoby E, Lenz O, Berke JM. Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A–H clinical isolates and core site-directed mutants in vitro. Journal of Antimicrobial Chemotherapy 2020;75:2526-34. [DOI: 10.1093/jac/dkaa179] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
426 Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: An evidence-based approach. World J Gastroenterol. 2019;25:1550-1559. [PMID: 30983815 DOI: 10.3748/wjg.v25.i13.1550] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 30] [Article Influence: 19.0] [Reference Citation Analysis]
427 Wassner C, Bradley N, Lee Y. A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide. J Int Assoc Provid AIDS Care 2020;19:2325958220919231. [PMID: 32295453 DOI: 10.1177/2325958220919231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 10.0] [Reference Citation Analysis]
428 Strasser SI, Thompson AJ, Roberts SK, George J; Clinical Cases in Hepatitis 2018 Steering Committee. Clinical Cases in Hepatitis: Towards improving liver disease management in Australia. J Gastroenterol Hepatol 2019;34 Suppl 1:5-15. [PMID: 31282011 DOI: 10.1111/jgh.14720] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
429 Huang YS, Sun HY, Chang SY, Chuang YC, Cheng A, Huang SH, Huang YC, Chen GJ, Lin KY, Su YC, Liu WC, Hung CC. Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection. Hepatol Int 2019;13:431-9. [PMID: 31177505 DOI: 10.1007/s12072-019-09953-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
430 Shah PA, Choudhry S, Reyes KJC, Lau DTY. An update on the management of chronic hepatitis D. Gastroenterol Rep (Oxf) 2019;7:396-402. [PMID: 32494363 DOI: 10.1093/gastro/goz052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
431 Lai CL, Wong DK, Wong GT, Seto WK, Fung J, Yuen MF. Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed. JHEP Rep. 2020;2:100112. [PMID: 32462119 DOI: 10.1016/j.jhepr.2020.100112] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
432 Gao X, Duan X, Cai H, Hu Y, Liu M, Kang K, Zhou M, Fu D, Yi W. Pregnancy Outcome of Women with Chronic Hepatitis B who Discontinued Antiviral Treatment before or in the Early Pregnancy. Int J Med Sci 2020;17:170-5. [PMID: 32038100 DOI: 10.7150/ijms.38410] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
433 Huang H, Ning M, Liu J, Chen J, Feng J, Dai Y, Hu Y, Zhou YH. Is hepatitis B antigen in cord blood an immunotolerogen playing a critical role in the pathogenesis of chronic hepatitis B? Hum Vaccin Immunother 2019;15:2192-4. [PMID: 31099706 DOI: 10.1080/21645515.2019.1619409] [Reference Citation Analysis]
434 Zheng Y, Wu J, Ding C, Xu K, Yang S, Li L. Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study. Virol J 2020;17:132. [PMID: 32859216 DOI: 10.1186/s12985-020-01393-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
435 Tamori A, Kimura K, Kioka K, Enomoto H, Odagiri N, Kozuka R, Uchida-Kobayashi S, Enomoto M, Kawada N, Mizokami M. Outcome of nucleos(t)ide analog intervention in patients with preventive or on-demand therapy for hepatitis B virus reactivation. J Med Virol 2021;93:3679-87. [PMID: 32940921 DOI: 10.1002/jmv.26526] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Kushner T, Sarkar M. Chronic Hepatitis B in Pregnancy. Clin Liver Dis (Hoboken) 2018;12:24-8. [PMID: 30988905 DOI: 10.1002/cld.727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
437 Aslam A, Campoverde Reyes KJ, Malladi VR, Ishtiaq R, Lau DTY. Management of chronic hepatitis B during pregnancy. Gastroenterol Rep (Oxf). 2018;6:257-262. [PMID: 30430013 DOI: 10.1093/gastro/goy025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
438 Lee HW, Kim BK. How does low-level viremia affect the prognosis of patients with chronic hepatitis B? Clin Mol Hepatol 2020;26:376-7. [PMID: 32521991 DOI: 10.3350/cmh.2020.0121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
439 Ahmed FA, Bajaifar MS, Ahmed MA, Alalwan A, Sanai FA, Albeladi K, Aljumah AA, Sanai FM. Quantitative HBsAg levels do not identify hepatic fibrosis in HBeAg-negative chronic hepatitis B patients. Saudi J Gastroenterol 2019;25:286-92. [PMID: 31044750 DOI: 10.4103/sjg.SJG_80_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
440 Sun X, Hu D, Yang Z, Liu Z, Wang J, Chen J, Xu L, Zhou Z, Chen M, Zhang Y. Baseline HBV Loads Do Not Affect the Prognosis of Patients with Hepatocellular Carcinoma Receiving Anti-Programmed Cell Death-1 Immunotherapy. J Hepatocell Carcinoma 2020;7:337-45. [PMID: 33294424 DOI: 10.2147/JHC.S278527] [Reference Citation Analysis]
441 Mokaya J, Burn EAO, Tamandjou CR, Goedhals D, Barnes EJ, Andersson M, Pinedo-Villanueva R, Matthews PC. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa. BMC Public Health 2019;19:829. [PMID: 31242901 DOI: 10.1186/s12889-019-7095-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
442 Li K, Qin L, Jiang S, Li A, Zhang C, Liu G, Sun J, Sun H, Zhao Y, Li N, Zhang Y. The signature of HBV-related liver disease in peripheral blood mononuclear cell DNA methylation. Clin Epigenetics 2020;12:81. [PMID: 32513305 DOI: 10.1186/s13148-020-00847-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
443 Demirtas CO, Brunetto MR. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it? WJG 2021;27:5536-54. [DOI: 10.3748/wjg.v27.i33.5536] [Reference Citation Analysis]
444 Niu JX, Xu Y, Wu DP. [Progress in the research of HBV reactivation in patients undergoing hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi 2021;42:348-52. [PMID: 33979984 DOI: 10.3760/cma.j.issn.0253-2727.2021.04.016] [Reference Citation Analysis]
445 Huang DQ, Yeo YH, Tan E, Takahashi H, Yasuda S, Saruwatari J, Tanaka K, Oniki K, Kam LY, Muthiah MD, Hyogo H, Ono M, Barnett SD, Li J, Zou B, Fung J, Lee TY, Wong VW, Yuen MF, Dan YY, Lim SG, Cheung R, Toyoda H, Eguchi Y, Nguyen MH. ALT Levels for Asians With Metabolic Diseases: A Meta-analysis of 86 Studies With Individual Patient Data Validation. Hepatol Commun 2020;4:1624-36. [PMID: 33163833 DOI: 10.1002/hep4.1593] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
446 Ekpanyapong S, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed? Clin Liver Dis. 2020;24:317-333. [PMID: 32620274 DOI: 10.1016/j.cld.2020.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
447 Fabrizi F, Cerutti R, Ridruejo E. Hepatitis B virus infection as a risk factor for chronic kidney disease. Expert Rev Clin Pharmacol 2019;12:867-74. [PMID: 31456441 DOI: 10.1080/17512433.2019.1657828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
448 Yamauchi R, Takeyama Y, Takata K, Fukunaga A, Sakurai K, Tanaka T, Fukuda H, Fukuda S, Kunimoto H, Umeda K, Morihara D, Yokoyama K, Irie M, Shakado S, Sakisaka S, Hirai F. Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate. Intern Med 2020;59:1163-6. [PMID: 31956202 DOI: 10.2169/internalmedicine.3805-19] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
449 Hardikar W. Viral hepatitis. J Paediatr Child Health 2019;55:1038-43. [DOI: 10.1111/jpc.14562] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
450 Unal C, Tanacan A, Ziyadova G, Fadiloglu E, Beksac MS. Effect of viral load on pregnancy outcomes in chronic hepatitis B infection. J Obstet Gynaecol Res 2019;45:1837-42. [PMID: 31332897 DOI: 10.1111/jog.14065] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
451 Hess L, Riesenberg K, Rolston KVI, Nesher L. Administering an additional hepatitis B vaccination dose after 18 years maintains adequate long-term protection levels in healthcare workers. Infect Dis (Lond) 2020;52:330-5. [PMID: 31983251 DOI: 10.1080/23744235.2020.1718201] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
452 Park S, Park ES, Koo JE, Park YK, Lee AR, Dezhbord M, Cho ES, Ahn SH, Kim DH, Lee JH, Lee HC, Kim KH. Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization. Liver Int 2020;40:1564-77. [PMID: 32216026 DOI: 10.1111/liv.14446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
453 Anteby R, Klang E, Horesh N, Nachmany I, Shimon O, Barash Y, Kopylov U, Soffer S. Deep learning for noninvasive liver fibrosis classification: A systematic review. Liver Int 2021. [PMID: 34008300 DOI: 10.1111/liv.14966] [Reference Citation Analysis]
454 Chinese Society of Lymphoma, Chinese Anti-cancer Association., Chinese Society of Hematology, Chinese Medical Association. [The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021)]. Zhonghua Xue Ye Xue Za Zhi 2021;42:441-6. [PMID: 34384148 DOI: 10.3760/cma.j.issn.0253-2727.2021.06.001] [Reference Citation Analysis]
455 Fan R, Zhou B, Xu M, Tan D, Niu J, Wang H, Ren H, Chen X, Wang M, Ning Q, Shi G, Sheng J, Tang H, Bai X, Liu S, Lu F, Peng J, Sun J, Xie Q, Hou J; Chronic Hepatitis B Study Consortium. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. Clin Gastroenterol Hepatol 2020;18:719-727.e7. [PMID: 31362119 DOI: 10.1016/j.cgh.2019.07.046] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 15.5] [Reference Citation Analysis]
456 Liu Y, Li H, Yan X, Wei J. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B. J Viral Hepat 2019;26 Suppl 1:69-76. [PMID: 31380585 DOI: 10.1111/jvh.13154] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
457 Wong T, Bloom RD. Management and treatment of the HCV-infected kidney transplant patient. Semin Dial 2019;32:169-78. [PMID: 30536995 DOI: 10.1111/sdi.12766] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
458 Zhang X, Zhou Y, Chen C, Fang W, Cai X, Zhang X, Zhao M, Zhang B, Jiang W, Lin Z, Ma Y, Yang Y, Huang Y, Zhao H, Xu R, Hong S, Zhang L. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition. J Immunother Cancer 2019;7:322. [PMID: 31753012 DOI: 10.1186/s40425-019-0808-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 27] [Article Influence: 20.5] [Reference Citation Analysis]
459 Sun SW, Liu QP, Xu X, Zhu FP, Zhang YD, Liu XS. Direct Comparison of Four Presurgical Stratifying Schemes for Prediction of Microvascular Invasion in Hepatocellular Carcinoma by Gadoxetic Acid-Enhanced MRI. J Magn Reson Imaging 2020;52:433-47. [PMID: 31943465 DOI: 10.1002/jmri.27043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
460 Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: Immunological Response, Natural Course and Pregnancy Outcomes. J Clin Med 2021;10:2926. [PMID: 34210105 DOI: 10.3390/jcm10132926] [Reference Citation Analysis]
461 Koc ÖM, Hens N, Bielen R, Van Damme P, Robaeys G. Hepatitis B virus prevalence and risk factors in hard-to-reach Turkish population living in Belgium: A protocol for screening. Medicine (Baltimore) 2019;98:e15412. [PMID: 31045797 DOI: 10.1097/MD.0000000000015412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
462 Wang L, Wang Y, Liu S, Zhai X, Zhou G, Lu F, Zhao J. Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population. J Gastroenterol 2019;54:1096-105. [PMID: 31134334 DOI: 10.1007/s00535-019-01594-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
463 Li X, Xing Y, Zhou D, Xiao H, Zhou Z, Han Z, Sun X, Li S, Zhang L, Li Z, Zhang P, Zhang J, Zhang N, Cao X, Zao X, Du H, Tong G, Chi X, Gao Y, Ye Y. A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels. Front Med (Lausanne) 2021;8:688091. [PMID: 34150818 DOI: 10.3389/fmed.2021.688091] [Reference Citation Analysis]
464 Wong GL, Wong VW, Yuen BW, Tse YK, Luk HW, Yip TC, Hui VW, Liang LY, Lui GC, Chan HL. An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. Hepatology 2020;71:444-55. [PMID: 31237366 DOI: 10.1002/hep.30833] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
465 Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Akbar SMF, Cohen D, Nayagam S, Jeng A, Ceesay A, Sanneh B, Baldeh I, Imaizumi M, Moriyama K, Aoyagi K, D'Alessandro U, Mishiro S, Chemin I, Mendy M, Thursz MR, Lemoine M. Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. Clin Infect Dis 2020;70:1442-52. [PMID: 31102406 DOI: 10.1093/cid/ciz412] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
466 Liu H, Hou J, Zhang X. Targeting cIAPs, a New Option for Functional Cure of Chronic Hepatitis B Infection? Virol Sin 2018;33:459-61. [PMID: 30374825 DOI: 10.1007/s12250-018-0062-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
467 Li C, Li ZC, Ma L, Li LQ, Zhong JH, Xiang BD, Gong WF. Perioperative antiviral therapy improves the prognosis of HBV DNA-negative patients with HBV-related hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2020;14:749-56. [PMID: 32552297 DOI: 10.1080/17474124.2020.1784727] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
468 Pan CQ, Chang TT, Bae SH, Brunetto M, Seto WK, Coffin CS, Tan SK, Mo S, Flaherty JF, Gaggar A, Nguyen MH, Çelen MK, Thompson A, Gane EJ. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. PLoS One 2021;16:e0251552. [PMID: 33984038 DOI: 10.1371/journal.pone.0251552] [Reference Citation Analysis]
469 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
470 Su F, Weiss NS, Beste LA, Moon AM, Jin GY, Green P, Berry K, Ioannou GN. Screening is associated with a lower risk of hepatocellular carcinoma-related mortality in patients with chronic hepatitis B. J Hepatol 2021;74:850-9. [PMID: 33245934 DOI: 10.1016/j.jhep.2020.11.023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
471 Da BL, Rahman F, Lai WC, Kleiner DE, Heller T, Koh C. Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened? Am J Gastroenterol 2021;116:206-9. [PMID: 33027083 DOI: 10.14309/ajg.0000000000000954] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Athavale AM, Hart PD, Itteera M, Cimbaluk D, Patel T, Alabkaa A, Arruda J, Singh A, Rosenberg A, Kulkarni H. Development and Validation of a Deep Learning Model to Quantify Interstitial Fibrosis and Tubular Atrophy From Kidney Ultrasonography Images. JAMA Netw Open 2021;4:e2111176. [PMID: 34028548 DOI: 10.1001/jamanetworkopen.2021.11176] [Reference Citation Analysis]
473 Wagner J, Yuen L, Littlejohn M, Sozzi V, Jackson K, Suri V, Tan S, Feierbach B, Gaggar A, Marcellin P, Buti Ferret M, Janssen HLA, Gane E, Chan HLY, Colledge D, Rosenberg G, Bayliss J, Howden BP, Locarnini SA, Wong D, Thompson AT, Revill PA. Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase. Hepatology 2021;73:1652-70. [PMID: 32780526 DOI: 10.1002/hep.31516] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
474 Cornberg M, Lok AS, Terrault NA, Zoulim F, Berg T, Brunetto MR, Buchholz S, Buti M, Chan HL, Chang K, Dandri M, Dusheiko G, Feld JJ, Ferrari C, Ghany M, Janssen HL, Kennedy P, Lampertico P, Liang J, Locarnini S, Maini MK, Mishra P, Papatheodoridis G, Petersen J, Schlottmann S, Wang S, Wedemeyer H. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. Journal of Hepatology 2020;72:539-57. [DOI: 10.1016/j.jhep.2019.11.003] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 60.0] [Reference Citation Analysis]
475 Mogul DB, Brereton N, Carson KA, Pittarelli M, Daniel H, Torbenson M, Schwarz KB. Development of a Dietary Methyl Donor Food Frequency Questionnaire to Assess Folate and Vitamin B12 Status in Children with Chronic Hepatitis B Virus Infection. J Pediatr 2018;203:41-46.e2. [PMID: 30243534 DOI: 10.1016/j.jpeds.2018.07.088] [Reference Citation Analysis]
476 Spradling PR, Xing J, Harris AM, Ly KN. Estimated prevalence and number of persons with isolated antibody to hepatitis B core antigen and associated occult hepatitis B, United States, 2001-2018. J Infect Dis 2021:jiab366. [PMID: 34252183 DOI: 10.1093/infdis/jiab366] [Reference Citation Analysis]
477 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 11.5] [Reference Citation Analysis]
478 Kuo MH, Tseng CW, Lee CH, Tung CH, Tseng KC, Lai NS. Moderate Risk of Hepatitis B Virus Reactivation in HBsAg-/HBcAb+ Carriers Receiving Rituximab for Rheumatoid Arthritis. Sci Rep 2020;10:2456. [PMID: 32051458 DOI: 10.1038/s41598-020-59406-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
479 Dou Y, Li C, Li L, Guo J, Zhang J. Bioresponsive drug delivery systems for the treatment of inflammatory diseases. J Control Release 2020;327:641-66. [PMID: 32911014 DOI: 10.1016/j.jconrel.2020.09.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 19.0] [Reference Citation Analysis]
480 Hadziyannis E, Laras A. Viral Biomarkers in Chronic HBeAg Negative HBV Infection. Genes (Basel) 2018;9:E469. [PMID: 30262738 DOI: 10.3390/genes9100469] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
481 Howell J, Pedrana A, Schroeder SE, Scott N, Aufegger L, Atun R, Baptista-Leite R, Hirnschall G, 't Hoen E, Hutchinson SJ, Lazarus JV, Olufunmilayo L, Peck R, Sharma M, Sohn AH, Thompson A, Thursz M, Wilson D, Hellard M. A global investment framework for the elimination of hepatitis B. J Hepatol 2021;74:535-49. [PMID: 32971137 DOI: 10.1016/j.jhep.2020.09.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
482 Li G, Xu M, Yue T, Gu W, Tan L. Life-long passion for antiviral research and drug development: 80th birthday of Prof. Dr. Erik De Clercq. Biochem Pharmacol 2021;185:114485. [PMID: 33617841 DOI: 10.1016/j.bcp.2021.114485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
483 Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol 2020;14:565-78. [PMID: 32448008 DOI: 10.1080/17474124.2020.1774364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
484 Chang KC, Lee CY, Chang TS, Hung CH, Chen WM, Chen MY, Huang TJ, Chiu WN, Hu JH, Lin YC, Huang WC, Hsu NT, Lu SN. Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening. J Formos Med Assoc 2021;120:847-53. [PMID: 32896456 DOI: 10.1016/j.jfma.2020.08.031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
485 Su F, Berry K, Ioannou GN. No difference in hepatocellular carcinoma risk between chronic hepatitis B patients treated with entecavir versus tenofovir. Gut. [DOI: 10.1136/gutjnl-2019-319867] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
486 Jones JM, Kracalik I, Levi ME, Bowman JS 3rd, Berger JJ, Bixler D, Buchacz K, Moorman A, Brooks JT, Basavaraju SV. Assessing Solid Organ Donors and Monitoring Transplant Recipients for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus Infection - U.S. Public Health Service Guideline, 2020. MMWR Recomm Rep 2020;69:1-16. [PMID: 32584804 DOI: 10.15585/mmwr.rr6904a1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 16.0] [Reference Citation Analysis]
487 Papatheodoridi A, Chatzigeorgiou A, Chrysavgis L, Lembessis P, Loglio A, Facchetti F, Cholongitas E, Koutsilieris M, Lampertico P, Papatheodoridis G. Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients. J Viral Hepat 2021;28:464-74. [PMID: 33260272 DOI: 10.1111/jvh.13446] [Reference Citation Analysis]
488 Zhang L, Wang Z. Circular RNA hsa_circ_0004812 impairs IFN-induced immune response by sponging miR-1287-5p to regulate FSTL1 in chronic hepatitis B. Virol J 2020;17:40. [PMID: 32188476 DOI: 10.1186/s12985-020-01314-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
489 Chen S, Huang H, Huang W. A noninvasive model to predict liver histology for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase < 2 upper limit of normal. BMC Gastroenterol 2021;21:4. [PMID: 33407146 DOI: 10.1186/s12876-020-01576-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
490 Kim GA, Han S, Choi GH, Choi J, Lim YS. Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther 2020;51:1169-79. [PMID: 32291781 DOI: 10.1111/apt.15725] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 15.0] [Reference Citation Analysis]
491 Kwon JH, Song MJ, Jang JW, Bae SH, Choi JY, Yoon SK, Kim HY, Kim CW, Song DS, Chang UI, Yang JM, You CR, Choi SW, Lee HL, Lee SW, Han NI, Nam SW, Kim SG, Kim YS, Kim SH, Lee BS, Lee TH, Cho EY. Efficacy and Safety of Tenofovir Disoproxil Fumarate in Treatment-Naïve Patients with Chronic Hepatitis B in Korea. Dig Dis Sci 2019;64:2039-48. [PMID: 30725293 DOI: 10.1007/s10620-019-05489-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
492 Varley CD, Winthrop KL. Long-Term Safety of Rituximab (Risks of Viral and Opportunistic Infections). Curr Rheumatol Rep 2021;23:74. [PMID: 34269903 DOI: 10.1007/s11926-021-01037-3] [Reference Citation Analysis]
493 Lee JH, Kim BK, Park SY, Tak WY, Park JY, Kim DY, Ahn SH, Sinn DH, Kim SU. The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus-related hepatocellular carcinoma. Eur J Intern Med 2021;89:48-55. [PMID: 33810942 DOI: 10.1016/j.ejim.2021.02.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
494 Pardee M. Diagnosis and Management of Hepatitis B and C. Nurs Clin North Am 2019;54:277-84. [PMID: 31027666 DOI: 10.1016/j.cnur.2019.02.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
495 Zhou H, Long J, Hu H, Tian CY, Lin SD. Liver stiffness and serum markers for excluding high-risk varices in patients who do not meet Baveno VI criteria. World J Gastroenterol. 2019;25:5323-5333. [PMID: 31558876 DOI: 10.3748/wjg.v25.i35.5323] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
496 Hu Y, Ye YZ, Ye LJ, Wang XH, Yu H. Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China. World J Pediatr 2019;15:595-600. [PMID: 31487005 DOI: 10.1007/s12519-019-00303-w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
497 Spearman CW. Chronic hepatitis B: identifying who needs to be treated and improving linkage to care. Lancet Gastroenterol Hepatol 2021;6:83-5. [PMID: 33197398 DOI: 10.1016/S2468-1253(20)30332-0] [Reference Citation Analysis]
498 Hou J, Ning Q, Duan Z, Chen Y, Xie Q, Wang FS, Zhang L, Wu S, Tang H, Li J, Lin F, Yang Y, Gong G, Flaherty JF, Gaggar A, Mo S, Cheng C, Camus G, Chen C, Huang Y, Jia J, Zhang M; GS-US-320-0110 and GS-US-320-0108 China Investigators. 3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China. J Clin Transl Hepatol 2021;9:324-34. [PMID: 34221918 DOI: 10.14218/JCTH.2020.00145] [Reference Citation Analysis]
499 Giráldez-Gallego Á, Rodríguez-Seguel E, Manuel Pascasio-Acevedo J. Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question. J Viral Hepat 2021;28:1329-30. [PMID: 34185939 DOI: 10.1111/jvh.13563] [Reference Citation Analysis]
500 Thompson MA, Horberg MA, Agwu AL, Colasanti JA, Jain MK, Short WR, Singh T, Aberg JA. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2020:ciaa1391. [PMID: 33225349 DOI: 10.1093/cid/ciaa1391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
501 Rungsakulkij N, Suragul W, Mingphruedhi S, Tangtawee P, Muangkaew P, Aeesoa S. Prognostic factors in patients with HBV-related hepatocellular carcinoma following hepatic resection. Infect Agent Cancer 2018;13:20. [PMID: 29930697 DOI: 10.1186/s13027-018-0192-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
502 Smith TE, Kister I. Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies. Curr Neurol Neurosci Rep 2021;21:36. [PMID: 34009478 DOI: 10.1007/s11910-021-01117-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
503 Kim SU, Chon YE, Seo YS, Lee HW, Lee HA, Kim MN, Min IK, Park JY, Kim DY, Ahn SH, Tak WY, Kim BK, Park SY. A multi‐centre study of trends in hepatitis B virus‐related hepatocellular carcinoma risk over time during long‐term entecavir therapy. J Viral Hepat 2020;27:1352-8. [DOI: 10.1111/jvh.13384] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
504 Romano C, Esposito S, Ferrara R, Cuomo G. Tailoring biologic therapy for real-world rheumatoid arthritis patients. Expert Opin Biol Ther 2021;21:661-74. [PMID: 33147106 DOI: 10.1080/14712598.2021.1847268] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
505 Schwarz KB, Lombardero M, Di Bisceglie AM, Murray KF, Rosenthal P, Ling SC, Cloonan YK, Rodriguez-Baez N, Schwarzenberg SJ, Hoofnagle JH, Teckman J; Hepatitis B Research Network (HBRN). Phenotypes of Chronic Hepatitis B in Children From a Large North American Cohort. J Pediatr Gastroenterol Nutr 2019;69:588-94. [PMID: 31436702 DOI: 10.1097/MPG.0000000000002467] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
506 Adjei CA, Stutterheim SE, Naab F, Ruiter RAC. Barriers to chronic Hepatitis B treatment and care in Ghana: A qualitative study with people with Hepatitis B and healthcare providers. PLoS One. 2019;14:e0225830. [PMID: 31794577 DOI: 10.1371/journal.pone.0225830] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
507 Xia M, Liao G, Chen H, Wu Y, Fan R, Zhang X, Peng J. Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment. Clin Immunol 2019;198:31-8. [PMID: 30503407 DOI: 10.1016/j.clim.2018.11.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
508 Toy M, Hutton D, Harris AM, Nelson N, Salomon JA, So S. Cost-Effectiveness of One-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States. Clin Infect Dis 2021:ciab405. [PMID: 33956937 DOI: 10.1093/cid/ciab405] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
509 Wu T, Wu N, Ma YX, Wu J, Gao Y, Pan XB. Role of hepatitis B antibody in predicting reactivation of resolved hepatitis B virus infection in leukemia patients. Antiviral Res 2020;177:104765. [PMID: 32171856 DOI: 10.1016/j.antiviral.2020.104765] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
510 Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol 2021;27:1691-715. [PMID: 33967551 DOI: 10.3748/wjg.v27.i16.1691] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
511 Wei MT, Le AK, Chang MS, Hsu H, Nguyen P, Zhang JQ, Wong C, Wong C, Cheung R, Nguyen MH. Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. J Med Virol 2019;91:1288-94. [PMID: 30776311 DOI: 10.1002/jmv.25433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
512 Ma Z, Zhang E, Gao S, Xiong Y, Lu M. Toward a Functional Cure for Hepatitis B: The Rationale and Challenges for Therapeutic Targeting of the B Cell Immune Response. Front Immunol 2019;10:2308. [PMID: 31608073 DOI: 10.3389/fimmu.2019.02308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
513 Cao J, Gong J, Tsia Hin Fong CJ, Xiao C, Lin G, Li X, Jie Y, Chong Y. Prediction Model of HBsAg Seroclearance in Patients with Chronic HBV Infection. Biomed Res Int. 2020;2020:6820179. [PMID: 32855968 DOI: 10.1155/2020/6820179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
514 Huang Z, Zhou J, Lu X, Zhang T, Xu S, Jin J, Zheng R, Chen S. How does liver steatosis affect diagnostic performance of 2D-SWE.SSI: assessment from aspects of steatosis degree and pathological types. Eur Radiol 2021;31:3207-15. [PMID: 33119813 DOI: 10.1007/s00330-020-07288-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
515 Biolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M, Grieco A. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs 2021;35:861-80. [PMID: 34319570 DOI: 10.1007/s40263-021-00842-9] [Reference Citation Analysis]
516 Tian F, Houle SKD, Alsabbagh MW, Wong WWL. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada. Pharmacoeconomics 2020;38:181-92. [PMID: 31691902 DOI: 10.1007/s40273-019-00852-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
517 Jeon MY, Kim BK, Kim SU. Assessment of fibrotic burden among chronic hepatitis B virus-infected patients with normal transaminase level. Clin Mol Hepatol 2018;24:367-9. [PMID: 30227702 DOI: 10.3350/cmh.2018.1008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
518 Niizuma K, Ogawa Y, Kogure T, Tominaga T. Case reports of latent HBV hepatitis in patients after neurosurgical treatment for hypothalamic and pituitary tumors. BMC Infect Dis 2020;20:230. [PMID: 32188424 DOI: 10.1186/s12879-020-04971-2] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
519 Kim HS, El-Serag HB. Tenofovir vs. entecavir in reducing hepatocellular carcinoma risk in patients with chronic HBV infection?-Still an unsolved question. Hepatobiliary Surg Nutr 2021;10:119-22. [PMID: 33575300 DOI: 10.21037/hbsn-2020-3] [Reference Citation Analysis]
520 Tamaki N, Kurosaki M, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa Y, Wang W, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir. JGH Open 2020;4:429-32. [PMID: 32514449 DOI: 10.1002/jgh3.12273] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
521 Indolfi G, Abdel-Hady M, Bansal S, Debray D, Smets F, Czubkowski P, van der Woerd W, Samyn M, Jahnel J, Gupte G, Zellos A, Mozer-Glassberg Y, Verkade HJ, Sokal E, Fischler B. Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies. J Pediatr Gastroenterol Nutr. 2020;70:527-538. [PMID: 31977956 DOI: 10.1097/mpg.0000000000002628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
522 Mak L, Seto W, Fung J, Yuen M. Novel developments of hepatitis B: treatment goals, agents and monitoring tools. Expert Review of Clinical Pharmacology 2019;12:109-20. [DOI: 10.1080/17512433.2019.1567327] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
523 Geng J, Bao H, Chen Y, Shi L, Geng J, Wang Q, Yu H. Nucleos(t)ide analogues for the treatment of chronic hepatitis B: a systematic review with network meta-analysis. Expert Rev Anti Infect Ther 2020;18:823-34. [PMID: 32329638 DOI: 10.1080/14787210.2020.1760843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
524 Kirino S, Tamaki N, Kurosaki M, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. J Viral Hepat 2021;28:787-94. [PMID: 33484033 DOI: 10.1111/jvh.13473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
525 Lin S, Fu Y, Wu W, Chen T, Chen N, Xun Z, Liu C, Ou Q, Zeng Y, Huang H. The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone. Int J Med Sci 2020;17:1458-63. [PMID: 32624702 DOI: 10.7150/ijms.45658] [Reference Citation Analysis]
526 Armas Cayarga A, Perea Hernández Y, González González YJ, Figueredo Lago JE, Valdivia Álvarez IY, Gómez Cordero I, Santos Hernández N, Vega Sánchez H, La Rosa Hernández D, Martínez Pérez EL. Performance characteristics of a fast real-time PCR assay for hepatitis B virus DNA quantification. Biologicals 2019;58:22-7. [PMID: 30718130 DOI: 10.1016/j.biologicals.2019.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
527 Zhang W, Aryan M, Qian S, Cabrera R, Liu X. A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis. Gastroenterology Res 2021;14:139-56. [PMID: 34267829 DOI: 10.14740/gr1405] [Reference Citation Analysis]
528 Yin X, Han G, Zhang H, Wang M, Zhang W, Gao Y, Zhong M, Wang X, Zhong X, Shen G, Yang C, Liu H, Liu Z, Chan PL, Bulterys M, Cui F, Zhuang H, Liu Z, Hou J. A Real-world Prospective Study of Mother-to-child Transmission of HBV in China Using a Mobile Health Application (Shield 01). J Clin Transl Hepatol 2020;8:1-8. [PMID: 32274339 DOI: 10.14218/JCTH.2019.00057] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
529 Borojevic B, Chauhan A, Patterson S. Liver failure from delayed hepatitis B reactivation in anti-HBc-positive patient following rituximab for B-cell lymphoma. BMJ Case Rep 2021;14:e243526. [PMID: 34244190 DOI: 10.1136/bcr-2021-243526] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
530 Yendewa GA, Lakoh S, Yendewa SA, Bangura K, Lawrence H, Patiño L, Jiba DF, Vandy AO, Murray MJS, Massaquoi SP, Deen GF, Sahr F, Hoffmann CJ, Jacobson JM, Poveda E, Aguilera A, Salata RA. Prevalence of hepatitis B surface antigen and serological markers of other endemic infections in HIV-infected children, adolescents and pregnant women in Sierra Leone: A cross-sectional study. Int J Infect Dis 2021;102:45-52. [PMID: 33002619 DOI: 10.1016/j.ijid.2020.09.1459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
531 Aslam A, Ishtiaq R, Lau DTY. Timely Administration of Birth Dose Hepatitis B Virus Vaccine May Break the Chain of Perinatal Transmission. Hepatology 2019;69:2284-6. [PMID: 30372542 DOI: 10.1002/hep.30332] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
532 Roade L, Loglio A, Borghi M, Riveiro-Barciela M, Soffredini R, Facchetti F, di Paolo D, Tabernero D, Lunghi G, Esteban R, Buti M, Lampertico P. Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. Dig Liver Dis 2020;52:1164-9. [PMID: 32703729 DOI: 10.1016/j.dld.2020.06.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
533 Chen L, Lin L, Zhou H, Tang W, Wang H, Cai W, Bao S, Guo S, Xie Q. Peginterferon and Entecavir Combination Therapy Improves Outcome of Non-Early Response Hepatitis B e Antigen-Positive Patients. Open Forum Infect Dis 2020;7:ofaa462. [PMID: 33889654 DOI: 10.1093/ofid/ofaa462] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
534 Dimond C, Negroiu A, M Hughes D, Patel J. Fatal hepatitis B reactivation in a patient receiving chemoradiation for cervical cancer. J Oncol Pharm Pract 2021;27:1296-301. [PMID: 33054690 DOI: 10.1177/1078155220964256] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
535 Zhou Y, Hu Y, Liu X, Yang H. CSOG MFM Committee Guideline: Management of Hepatitis B During Pregnancy and Prevention of Mother-to-Child Transmission of Hepatitis B Virus (2020). Maternal-Fetal Medicine 2021;3:7-17. [DOI: 10.1097/fm9.0000000000000087] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
536 Gao X, Yang HI, Trinh H, Jeong D, Li J, Zhang J, Le A, Hoang J, Nguyen P, Henry L, Nguyen MH. Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis. Eur J Gastroenterol Hepatol 2020;32:1207-11. [PMID: 32129773 DOI: 10.1097/MEG.0000000000001639] [Reference Citation Analysis]
537 Kawashima K, Isogawa M, Hamada-Tsutsumi S, Baudi I, Saito S, Nakajima A, Tanaka Y. Type I Interferon Signaling Prevents Hepatitis B Virus-Specific T Cell Responses by Reducing Antigen Expression. J Virol 2018;92:e01099-18. [PMID: 30209178 DOI: 10.1128/JVI.01099-18] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
538 Ghany MG, Block TM. Disease Pathways and Mechanisms of Potential Drug Targets. Clin Liver Dis (Hoboken) 2018;12:12-8. [PMID: 30988903 DOI: 10.1002/cld.735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
539 Rodríguez-Tajes S, Lens S, Forns X. Reply to: Optimal hepatitis B vaccination schedule for cirrhotic patients: a still unanswered question. J Viral Hepat 2021;28:1331-2. [PMID: 34048102 DOI: 10.1111/jvh.13555] [Reference Citation Analysis]
540 Lee JH, Lee YB, Cho EJ, Yu SJ, Yoon JH, Kim YJ. Entecavir Plus Pegylated Interferon and Sequential HBV Vaccination Increases HBsAg Seroclearance: A Randomized Controlled Proof-of-Concept Study. Clin Infect Dis 2020:ciaa807. [PMID: 32556157 DOI: 10.1093/cid/ciaa807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
541 Liu Z, Huang CJ, Huang YH, Pan MH, Lee MH, Yu KJ, Pfeiffer RM, Viard M, Yuki Y, Gao X, Carrington M, Chen CJ, Hildesheim A, Yang HI; REVEAL-HBV Study Group. HLA zygosity increases risk of hepatitis B virus-associated hepatocellular carcinoma. J Infect Dis 2021:jiab207. [PMID: 33852009 DOI: 10.1093/infdis/jiab207] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
542 Li N, Fan X, Wang X, Deng H, Zhang K, Zhang X, Wang Y, Han Q, Lv Y, Liu Z. PRDM1 levels are associated with clinical diseases in chronic HBV infection and survival of patients with HBV-related hepatocellular carcinoma. Int Immunopharmacol 2019;73:156-62. [PMID: 31100710 DOI: 10.1016/j.intimp.2019.05.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
543 Wong RJ, Khalili M. A Patient-Centered Hepatitis B Virus (HBV) Educational Intervention Improves HBV Care Among Underserved Safety-Net Populations. J Clin Gastroenterol 2020;54:642-7. [PMID: 31688365 DOI: 10.1097/MCG.0000000000001276] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
544 Liaw YF. Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat. Hepatology. 2021;73:843-852. [PMID: 32810321 DOI: 10.1002/hep.31525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
545 Wang X, Xu H, Wang Y, Shen C, Ma L, Zhao C. MicroRNA-124a contributes to glucocorticoid resistance in acute-on-chronic liver failure by negatively regulating glucocorticoid receptor alpha. Ann Hepatol 2020;19:214-21. [PMID: 31628069 DOI: 10.1016/j.aohep.2019.08.007] [Reference Citation Analysis]
546 Chi Z, Zhao W, Li JW, Liu H, Shao C, Zhao H, Gui-Qiang W. Combination of quantitative hepatitis B core antibody (qHBcAb) and aspartate aminotransferase (AST) can accurately diagnose immune tolerance of chronic hepatitis B virus infection based on liver biopsy. Clin Res Hepatol Gastroenterol 2020;:101563. [PMID: 33272888 DOI: 10.1016/j.clinre.2020.10.008] [Reference Citation Analysis]
547 Sastre L, Ruiz P, Costa J, Forns X. Severe hepatitis B reactivation during direct-acting antiviral treatment in "the absence" of hepatitis B surface antigen. Int J Infect Dis 2019;79:47-9. [PMID: 30496851 DOI: 10.1016/j.ijid.2018.11.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
548 Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. WJH 2021;13:1042-57. [DOI: 10.4254/wjh.v13.i9.1042] [Reference Citation Analysis]
549 Huang CZ, Zhang J, Zhang L, Yu CH, Mo Y, Mo LY. Serum vitamin D and vitamin-D-binding protein levels in children with chronic hepatitis B. World J Gastroenterol 2021;27:255-66. [PMID: 33519140 DOI: 10.3748/wjg.v27.i3.255] [Reference Citation Analysis]
550 Cai Y, Yin W. The Multiple Functions of B Cells in Chronic HBV Infection. Front Immunol 2020;11:582292. [PMID: 33381113 DOI: 10.3389/fimmu.2020.582292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
551 Li L, Ye Y, Ran Y, Liu S, Tang Q, Liu Y, Liao X, Zhang J, Xiao G, Lu J, Zhang G, He Q, Hu S. A non-invasive model for predicting liver fibrosis in HBeAg-positive patients with normal or slightly elevated alanine aminotransferase. Medicine (Baltimore) 2021;100:e25581. [PMID: 33907107 DOI: 10.1097/MD.0000000000025581] [Reference Citation Analysis]
552 Mui UN, Haley CT, Vangipuram R, Tyring SK. Human oncoviruses: Mucocutaneous manifestations, pathogenesis, therapeutics, and prevention: Hepatitis viruses, human T-cell leukemia viruses, herpesviruses, and Epstein-Barr virus. J Am Acad Dermatol 2019;81:23-41. [PMID: 30502415 DOI: 10.1016/j.jaad.2018.10.072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
553 Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf 2021;44:133-65. [PMID: 33141341 DOI: 10.1007/s40264-020-01014-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
554 Dimzova M, Bosilkovski M, Kondova-Topuzovska I, Gaseva M, Toshevki B, Petreska B, Jakimovski D. Characteristics of an Outpatient Cohort with HBeAg-Negative Chronic Hepatitis B. Open Access Maced J Med Sci 2019;7:2068-74. [PMID: 31456827 DOI: 10.3889/oamjms.2019.623] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
555 Shiffman ML, Sussman NL, Ravendhran N, Ditmyer M, Kowdley KV, Kugelmas M. Financial Compensation For Hepatologists in Different Practice Settings: Hepatology. Hepatology 2019;69:2664-71. [DOI: 10.1002/hep.30488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
556 Charre C, Levrero M, Zoulim F, Scholtès C. Non-invasive biomarkers for chronic hepatitis B virus infection management. Antiviral Res 2019;169:104553. [PMID: 31288041 DOI: 10.1016/j.antiviral.2019.104553] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
557 Dunn D, Price H, Vudriko T, Kityo C, Musoro G, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R; DART Virology Group. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings. J Acquir Immune Defic Syndr 2021;86:98-103. [PMID: 33306565 DOI: 10.1097/QAI.0000000000002517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
558 Lee HW, Kim EH, Lee J, Kim SU, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase. Clin Transl Gastroenterol 2020;11:e00140. [PMID: 32352711 DOI: 10.14309/ctg.0000000000000140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
559 Lee H, Lee YH, Kim SU, Kim HC. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. Clin Gastroenterol Hepatol 2021;19:2138-2147.e10. [PMID: 33348045 DOI: 10.1016/j.cgh.2020.12.022] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
560 Yu XP, Wen X, Li J, Zheng YJ, Long JF, Zhao WD, Jiang PX, Wu JW, Zhu BD, Jiang QR, Yang FF, Shen ZL, Mao RC, Su ZJ, Zhang JM. A promising non-invasive index for predicting liver inflammation in chronic hepatitis B patients with alanine aminotransferase ≤2 upper limit of normal. Exp Ther Med 2018;16:4393-400. [PMID: 30542389 DOI: 10.3892/etm.2018.6751] [Reference Citation Analysis]
561 Meng Z, Chen Y, Lu M. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection. Front Immunol 2019;10:3127. [PMID: 32117201 DOI: 10.3389/fimmu.2019.03127] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 21.0] [Reference Citation Analysis]
562 Lou T, Li B, Xiong P, Jin C, Chen Y. External validation of hepatocellular carcinoma risk scores in patients with chronic hepatitis B virus infection in China. J Viral Hepat 2021. [PMID: 34218498 DOI: 10.1111/jvh.13569] [Reference Citation Analysis]
563 Zhou K, Terrault NA. Gaps in Viral Hepatitis Awareness in the United States in a Population-based Study. Clin Gastroenterol Hepatol 2020;18:188-195.e4. [PMID: 31173892 DOI: 10.1016/j.cgh.2019.05.047] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
564 Wei H, Jiang HY, Li M, Zhang T, Song B. Two-dimensional shear wave elastography for significant liver fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis. Eur J Radiol 2020;124:108839. [PMID: 31981878 DOI: 10.1016/j.ejrad.2020.108839] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
565 Joshi SS, Coffin CS. Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics. Hepatol Commun. 2020;4:157-171. [PMID: 32025602 DOI: 10.1002/hep4.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
566 Garcia-Garcia S, Cortese MF, Rodríguez-Algarra F, Tabernero D, Rando-Segura A, Quer J, Buti M, Rodríguez-Frías F. Next-generation sequencing for the diagnosis of hepatitis B: current status and future prospects. Expert Rev Mol Diagn 2021;21:381-96. [PMID: 33880971 DOI: 10.1080/14737159.2021.1913055] [Reference Citation Analysis]
567 Shiffman ML. Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver Int 2020;40 Suppl 1:22-6. [PMID: 32077612 DOI: 10.1111/liv.14359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
568 Shen Z, Gao Z, Gu C, Wu J, Wang J, Zhang J, Xie Y, Liu J. Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence. Antiviral Res 2021;190:105076. [PMID: 33865876 DOI: 10.1016/j.antiviral.2021.105076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
569 Anabire NG, Tetteh WJ, Obiri-Yaboah D, Annan I, Luuse AT, Aryee PA, Helegbe GK, Hagan OCK, Eliason S. Evaluation of hepatic and kidney dysfunction among newly diagnosed HIV patients with viral hepatitis infection in Cape Coast, Ghana. BMC Res Notes 2019;12:466. [PMID: 31366401 DOI: 10.1186/s13104-019-4513-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
570 Park JS, Gayam V, Pan CQ. Review article: preventing hepatitis B graft infection in hepatitis B patients after liver transplantation: immunoglobulin vs anti-virals. Aliment Pharmacol Ther. 2020;52:944-954. [PMID: 32743822 DOI: 10.1111/apt.15999] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
571 Shi H, Xiao G, Liao M, Zheng L, Jie Y, Lin G, Chong Y. Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure. Biomed Pharmacother 2021;134:111118. [PMID: 33341047 DOI: 10.1016/j.biopha.2020.111118] [Reference Citation Analysis]
572 Mak LY, Wong DK, Cheung KS, Seto WK, Fung J, Yuen MF. First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. BMC Gastroenterol 2021;21:123. [PMID: 33731023 DOI: 10.1186/s12876-021-01711-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
573 Jia F, Deng F, Tong S, Li S, Ren H, Yin W. Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis. Hepatol Int 2020;14:338-46. [PMID: 32130674 DOI: 10.1007/s12072-020-10024-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
574 Liu H, Shi Y, Hayden JC, Ryan PM, Rahmani J, Yu G. Tenofovir Treatment Has Lower Risk of Hepatocellular Carcinoma than Entecavir Treatment in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Liver Cancer 2020;9:468-76. [PMID: 32999872 DOI: 10.1159/000507253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
575 Ciupe SM. Modeling the dynamics of hepatitis B infection, immunity, and drug therapy. Immunol Rev 2018;285:38-54. [PMID: 30129194 DOI: 10.1111/imr.12686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
576 Luo W, Wu S, Chen H, Wu Y, Peng J. Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with α-interferon. J Int Med Res 2021;49:3000605211025139. [PMID: 34182813 DOI: 10.1177/03000605211025139] [Reference Citation Analysis]
577 Papatheodoridis GV, Voulgaris T, Papatheodoridi M, Kim WR. Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine. Hepatology 2020;72:2197-205. [PMID: 32602980 DOI: 10.1002/hep.31440] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
578 Martinez ARM, de Lima FD, Martins MP, Pereira IE, Miotto N, Mazo DFC, Vigani AG, da Costa LBE, Stucchi RSB, Almeida JRS, Nucci A, França MC Jr. Sensory neuronopathy is a specific and disabling neurological manifestation of autoimmune hepatitis. Eur J Neurol 2020;27:2072-8. [PMID: 32441838 DOI: 10.1111/ene.14355] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
579 Chen HS, Wu JF, Su TH, Chen HL, Hsu HY, Xia NS, Chen PJ, Chang MH. Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Children With a Normal Alanine Aminotransferase Level. Hepatology 2019;70:1903-12. [PMID: 31121067 DOI: 10.1002/hep.30788] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
580 Papatheodoridis GV, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez-gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Idilman R, Esteban R, Janssen HL, Berg T, Lampertico P. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. Journal of Hepatology 2020;72:1088-96. [DOI: 10.1016/j.jhep.2020.01.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 34.0] [Reference Citation Analysis]
581 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 37.0] [Reference Citation Analysis]
582 Ricciotti E, Wangensteen KJ, FitzGerald GA. Aspirin in Hepatocellular Carcinoma. Cancer Res 2021;81:3751-61. [PMID: 33893087 DOI: 10.1158/0008-5472.CAN-21-0758] [Reference Citation Analysis]
583 Li M, Zhang L, Lu Y, Chen Q, Lu H, Sun F, Zeng Z, Wan G, Zhao L, Xie Y. Early Serum HBsAg Kinetics as Predictor of HBsAg Loss in Patients with HBeAg-Negative Chronic Hepatitis B after Treatment with Pegylated Interferonα-2a. Virol Sin 2021;36:311-20. [PMID: 32975731 DOI: 10.1007/s12250-020-00290-7] [Reference Citation Analysis]
584 Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat 2021;28:493-507. [PMID: 33305479 DOI: 10.1111/jvh.13452] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
585 Zhang Y, Li W, Liu Z, Ye J, Zou G, Zhang Z, Li J. Combination therapy based on pegylated interferon alfa improves the therapeutic response of patients with chronic hepatitis B who exhibit high levels of hepatitis B e-antigen at 24 weeks: A retrospective observational study. Medicine (Baltimore) 2019;98:e17022. [PMID: 31490387 DOI: 10.1097/MD.0000000000017022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
586 Yip TC, Lai JC, Wong GL. Secondary prevention for hepatocellular carcinoma in patients with chronic hepatitis B: are all the nucleos(t)ide analogues the same? J Gastroenterol 2020;55:1023-36. [PMID: 32974760 DOI: 10.1007/s00535-020-01726-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
587 Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology. Clin Liver Dis 2019;23:487-92. [PMID: 31266622 DOI: 10.1016/j.cld.2019.04.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
588 Elsaid MI, Li Y, John T, Narayanan N, Catalano C, Rustgi VK. Economic and Health Care Burdens of Hepatitis Delta: A Study of Commercially Insured Adults in the United States. Hepatology 2020;72:399-411. [PMID: 31804707 DOI: 10.1002/hep.31055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
589 Kamal H, Fornes R, Simin J, Stål P, Duberg AS, Brusselaers N, Aleman S. Risk of hepatocellular carcinoma in hepatitis B and D virus co-infected patients: A systematic review and meta-analysis of longitudinal studies. J Viral Hepat 2021. [PMID: 34291520 DOI: 10.1111/jvh.13577] [Reference Citation Analysis]
590 Liu N, Yang N, Ma W, Yang S, Hu C, Li J, Zhao Y, Xu G, He Y. Efficacy of Antiviral Treatment in Liver Biopsy-Proven Immune-Tolerant Chronic Hepatitis B Patients: A Retrospective Cohort Study. Front Med (Lausanne) 2021;8:655530. [PMID: 33898489 DOI: 10.3389/fmed.2021.655530] [Reference Citation Analysis]
591 Lai P, Chen X, Qin L, Jiang Z, Luo C, Huang X, Wu S, Ling W, Wang Y, Wang J, Deng C, Huang L, Zeng L, Lu Z, Zhong L, Liao P, Li M, Chen D, Geng S, Wu P, Tang Z, Pei D, Du X, Li P, Weng J. The efficacy and safety of CAR-T cell therapy in patients with refractory ALL and concomitant HBV infection. Leukemia 2020;34:2790-3. [PMID: 32632097 DOI: 10.1038/s41375-020-0952-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
592 Lee JGH, Carruthers M, Ko HH. Reactivation of hepatitis B virus associated with immunosuppression therapy. CMAJ 2018;190:E1284. [PMID: 30373742 DOI: 10.1503/cmaj.180389] [Reference Citation Analysis]
593 Loglio A, Lampertico P. How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals? Hepatol Commun. 2020;4:5-7. [PMID: 31909351 DOI: 10.1002/hep4.1476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
594 Fernández I, Pascasio JM, Colmenero J; en nombre del grupo de trabajo para el VII consenso de la SETH., Autores participantes en el grupo de trabajo en representación de sus respectivos programas de trasplante hepático. Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation. Gastroenterol Hepatol 2020;43:169-77. [PMID: 32094045 DOI: 10.1016/j.gastrohep.2019.11.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
595 Yao X, Huang S, Zhou H, Tang S, Qin J. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. WJG 2021;27:5088-99. [DOI: 10.3748/wjg.v27.i30.5088] [Reference Citation Analysis]
596 Lim CT, Goh GBB, Li H, Lim TK, Leow WQ, Wan WK, Azhar R, Chow WC, Kumar R. Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up. Microbiol Insights 2020;13:1178636120918878. [PMID: 32435130 DOI: 10.1177/1178636120918878] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
597 Sun X, Wang C, Wang B, Yang X, Xu H, Shen M, Zhu K. Efficacy of Nucleotide/Nucleoside Analogues and Hepatitis B Immunoglobulin Therapy in Blocking Mother-to-Child Transmission of Hepatitis B in an Eastern Chinese Group. Infect Dis Obstet Gynecol 2020;2020:4305950. [PMID: 33380780 DOI: 10.1155/2020/4305950] [Reference Citation Analysis]
598 Jeon MY, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Han K, Ahn SH, Kim SU. Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma. J Viral Hepat 2020;27:932-40. [DOI: 10.1111/jvh.13313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
599 Wang JH, Hu TH, Chen CH, Hung CH, Yen YH, Chang KC, Lu SN. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. Kaohsiung J Med Sci. 2019;35:708-714. [PMID: 31430035 DOI: 10.1002/kjm2.12114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
600 Aguilera A, Trastoy R, Rodríguez-Frias F, Muñoz-Bellido JL, Melón S, Suárez A, Orduña A, Viciana I, Bernal S, García-Bujalance S, Montiel N, Molina JM, Basaras M, Fernández-Cuenca F, García-Arata I, Reina G, Ocete MD, Fuentes A, Navarro-de la Cruz D, Nieto L, Blazquez de Castro A, Buti M, Álvarez M, García F. GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000-2016). J Infect 2020;81:600-6. [PMID: 32711039 DOI: 10.1016/j.jinf.2020.07.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
601 Lee SK, Kwon JH, Lee SW, Jang JW, Nam H, Baik KW, Yoo SH, Nam SW, Sung PS, Bae SH, Choi JY, Yoon SK. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B. Liver Int 2021;41:288-94. [PMID: 33043567 DOI: 10.1111/liv.14701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
602 Li Q, Lu Q, Zhu MQ, Huang C, Yu KK, Huang YX, Zhao X, Luo XG, Zheng JM. Lower level of complement component C3 and C3a in the plasma means poor outcome in the patients with hepatitis B virus related acute-on-chronic liver failure. BMC Gastroenterol 2020;20:106. [PMID: 32293297 DOI: 10.1186/s12876-020-01258-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
603 Lei M, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Wu H, Xu MQ, Chen ZY, Wei YG. Safety of hepatitis B virus core antibody-positive grafts in liver transplantation: A single-center experience in China. World J Gastroenterol 2018;24:5525-36. [PMID: 30622380 DOI: 10.3748/wjg.v24.i48.5525] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
604 Ma Z, Lu S, Sun D, Bai M, Jiang T, Lin N, Zhou H, Zeng S, Jiang H. Roles of organic anion transporter 2 and equilibrative nucleoside transporter 1 in hepatic disposition and antiviral activity of entecavir during non-pregnancy and pregnancy. Br J Pharmacol 2019;176:3236-49. [PMID: 31166004 DOI: 10.1111/bph.14756] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
605 Muthiah MD, Tan EY, Chua SHM, Huang DQY, Bonney GK, Kow AWC, Lim SG, Dan YY, Tan PS, Lee GH, Lim BL. Nucleoside analog monotherapy for prophylaxis in Hepatitis B liver transplant patients is safe and efficacious. Hepatol Int 2020;14:57-69. [PMID: 31919678 DOI: 10.1007/s12072-019-10011-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
606 Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392:2313-2324. [PMID: 30496122 DOI: 10.1016/s0140-6736(18)31865-8] [Cited by in Crossref: 139] [Cited by in F6Publishing: 52] [Article Influence: 69.5] [Reference Citation Analysis]
607 Van Hees S, Cuypers B, Bourgeois S, Groothuismink ZMA, Meysman P, Van der Vlies P, de Knegt R, Vonghia L, Michielsen P, Francque S, Laukens K, Boonstra A, Vanwolleghem T. Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Cell Immunol 2021;362:104283. [PMID: 33548734 DOI: 10.1016/j.cellimm.2021.104283] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
608 Itakura J, Kurosaki M, Setoyama H, Simakami T, Oza N, Korenaga M, Tanaka M, Torimura T, Sakamoto N, Enomoto N, Ueno Y, Kawada N, Kaneko S, Nishiguchi S, Chayama K, Tanaka J, Izumi N, Kanto T. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. J Gastroenterol 2021;56:470-8. [PMID: 33791882 DOI: 10.1007/s00535-021-01782-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
609 Clarke WT, Miranda J, Neidich E, Hudock R, Peters MG, Kelly EM. Metabolic syndrome and liver steatosis occur at lower body mass index in US Asian patients with chronic hepatitis B. J Viral Hepat 2019;26:1164-9. [PMID: 31134715 DOI: 10.1111/jvh.13147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
610 Nanayakkara D, Schaenman J. Pretransplant Screening for Infection Exposure: Approach to the Patients with Epidemiologic and Geographic Risk Factors. In: Morris MI, Kotton CN, Wolfe C, editors. Emerging Transplant Infections. Cham: Springer International Publishing; 2020. pp. 1-30. [DOI: 10.1007/978-3-030-01751-4_9-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
611 Zeleke ED, Assefa DG, Joseph M, Bekele D, Tesfahunei HA, Getachew E, Manyazewal T. Tenofovir disoproxil fumarate for prevention of mother-to-child transmission of hepatitis B virus: A systematic review and meta-analysis of randomised control trials. Rev Med Virol 2021;:e2216. [PMID: 33483986 DOI: 10.1002/rmv.2216] [Reference Citation Analysis]
612 Xiong S, Zhu D, Liang B, Li M, Pan W, He J, Wang H, Sutter K, Dittmer U, Lu M, Liu D, Yang D, Liu J, Zheng X. Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss. EBioMedicine 2021;69:103464. [PMID: 34233260 DOI: 10.1016/j.ebiom.2021.103464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
613 Yip TC, Wong GL, Wong VW. Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact. Clin Mol Hepatol 2021;27:273-7. [PMID: 33517606 DOI: 10.3350/cmh.2021.0019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
614 Sripongpun P, Mannalithara A, Kwo PY, Kim WR. Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. Clin Gastroenterol Hepatol. 2020;18:747-749. [PMID: 31271737 DOI: 10.1016/j.cgh.2019.05.057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
615 Surana P, Kapuria D, Broadwell C, Wright EC, Takyar V, Kleiner DE, Ghany MG, Ben-Yakov G, Heller T, Liang TJ, Koh C. Longitudinal effects of Nucleos(t)ide analogue therapy in chronic hepatitis B patients and the utility of non-invasive fibrosis markers during treatment: A single-center experience for up to 17 years. Antiviral Res 2019;168:61-7. [PMID: 31125632 DOI: 10.1016/j.antiviral.2019.05.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
616 Tseng TC, Peng CY, Hsu YC, Su TH, Wang CC, Liu CJ, Yang HC, Yang WT, Lin CH, Yu ML, Lai HC, Tanaka Y, Nguyen MH, Liu CH, Chen PJ, Chen DS, Kao JH. Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy. Liver Cancer 2020;9:207-20. [PMID: 32399434 DOI: 10.1159/000504650] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
617 Hosry J, Miranda RN, Samaniego F, Angelidakis G, Torres HA. Clinicopathologic characteristics of follicular lymphoma in hepatitis C virus-infected patients. Hematol Oncol 2020;38:301-8. [PMID: 32196714 DOI: 10.1002/hon.2731] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
618 Huang PH, Hu CC, Chien CH, Chen LW, Chien RN, Lin YS, Chao M, Lin CL, Yeh CT. The Defective Allele of Aldehyde Dehydrogenase 2 Gene is Associated with Favorable Postoperative Prognosis in Hepatocellular Carcinoma. J Cancer 2019;10:5735-43. [PMID: 31737110 DOI: 10.7150/jca.33221] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
619 Paccoud O, Surgers L, Lacombe K. [Hepatitis B virus infection: Natural history, clinical manifestations and therapeutic approach]. Rev Med Interne 2019;40:590-8. [PMID: 30982550 DOI: 10.1016/j.revmed.2019.03.333] [Reference Citation Analysis]
620 Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP, Li Z, Lichauco JJ, Louthrenoo W, Luo SF, Mu R, Nash P, Ng CT, Suryana B, Wijaya LK, Yeap SS. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 2019;22:357-75. [PMID: 30809944 DOI: 10.1111/1756-185X.13513] [Cited by in Crossref: 46] [Cited by in F6Publishing: 19] [Article Influence: 23.0] [Reference Citation Analysis]
621 Cornberg M, Lok AS, Terrault NA, Zoulim F;  2019 EASL-AASLD HBV Treatment Endpoints Conference Faculty. Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference. Hepatology. 2019;. [PMID: 31713892 DOI: 10.1002/hep.31030] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
622 Hong T, Yang H, Kao J. Role of HBsAg Testing in the Management of Patients with Chronic HBV. Curr Hepatology Rep 2019;18:331-41. [DOI: 10.1007/s11901-019-00484-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
623 Calvet X, Carpio D, Rodríguez-Lago I, García-Vicuña R, Barreiro-de-Acosta M, Juanola X, Aguas M, Castillo C, Gratacós J. Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. Gastroenterol Hepatol 2021:S0210-5705(21)00056-X. [PMID: 33640469 DOI: 10.1016/j.gastrohep.2021.01.007] [Reference Citation Analysis]
624 Sonneveld MJ, Park JY, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner Zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B; CREATE Study Group. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE). Clin Gastroenterol Hepatol 2020:S1542-3565(20)31662-1. [PMID: 33309804 DOI: 10.1016/j.cgh.2020.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
625 D'souza S, Lau KC, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol. 2020;26:5759-5783. [PMID: 33132633 DOI: 10.3748/wjg.v26.i38.5759] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
626 Tall H, Adam P, Tiendrebeogo ASE, Vincent JP, Schaeffer L, von Platen C, Fernandes-Pellerin S, Sawadogo F, Bokoum A, Bouda G, Ouattara S, Ouédraogo I, Herrant M, Boucheron P, Sawadogo A, Betsem E, Essoh A, Kabore L, Ouattara A, Méda N, Hien H, Gosset A, Giles-Vernick T, Boyer S, Kania D, Vray M, Shimakawa Y. Impact of Introducing Hepatitis B Birth Dose Vaccines into the Infant Immunization Program in Burkina Faso: Study Protocol for a Stepped Wedge Cluster Randomized Trial (NéoVac Study). Vaccines (Basel) 2021;9:583. [PMID: 34206058 DOI: 10.3390/vaccines9060583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
627 Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Al-Gibbawi M, Baker JF, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken) 2021;73:924-39. [PMID: 34101387 DOI: 10.1002/acr.24596] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
628 Click B, Regueiro M. A Practical Guide to the Safety and Monitoring of New IBD Therapies. Inflamm Bowel Dis. 2019;25:831-842. [PMID: 30312391 DOI: 10.1093/ibd/izy313] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 12.0] [Reference Citation Analysis]
629 Li Q, Huang C, Xu W, Hu Q, Chen L. Accuracy of FibroScan in analysis of liver fibrosis in patients with concomitant chronic Hepatitis B and nonalcoholic fatty liver disease. Medicine (Baltimore) 2020;99:e20616. [PMID: 32502037 DOI: 10.1097/MD.0000000000020616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
630 Vittal A, Ghany MG. WHO Guidelines for Prevention, Care and Treatment of Individuals Infected with HBV: A US Perspective. Clin Liver Dis. 2019;23:417-432. [PMID: 31266617 DOI: 10.1016/j.cld.2019.04.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
631 Yoo SH, Lim TS, Lee HW, Kim JK, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Lee JI, Lee KS, Kim SU. Risk assessment of hepatocellular carcinoma and liver-related events using ultrasonography and transient elastography in patients with chronic hepatitis B. J Viral Hepat 2021. [PMID: 34185929 DOI: 10.1111/jvh.13560] [Reference Citation Analysis]
632 Mysore KR, Leung DH. Hepatitis B and C. Clin Liver Dis. 2018;22:703-722. [PMID: 30266158 DOI: 10.1016/j.cld.2018.06.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
633 Maiocchi L, Ferraioli G. A model to predict liver damage in patients with HBeAg-positive chronic HBV infection. EBioMedicine 2021;68:103422. [PMID: 34091417 DOI: 10.1016/j.ebiom.2021.103422] [Reference Citation Analysis]
634 Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J 2021;18:114. [PMID: 34082765 DOI: 10.1186/s12985-021-01589-x] [Reference Citation Analysis]
635 Huang H, Xu C, Liu L, Chen L, Zhu X, Chen J, Feng J, Chen T, Xu B, Yang J, Xu B, Pan M, Dai Y, Hu Y, Zhou YH. Increased protection of earlier use of immunoprophylaxis in preventing perinatal transmission of hepatitis B virus. Clin Infect Dis 2020:ciaa898. [PMID: 32634824 DOI: 10.1093/cid/ciaa898] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
636 Cui R, Lyu C, Li Q, Jiang Y, Mou N, Yang Z, Liu X, Deng Q, Li L. Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection. Hematol Oncol 2021;39:75-86. [PMID: 32949412 DOI: 10.1002/hon.2807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
637 Nguyen MH, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh HN, Arai T, Fukunishi S, Ogawa E, Hsu YC, Maeda M, Dang H, Tseng CH, Takahashi H, Jun DW, Watanabe T, Chuma M, Nozaki A, Kawada N, Cheung R, Enomoto M, Takaguchi K, Toyoda H. Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. Am J Gastroenterol 2021;116:1264-73. [PMID: 34074829 DOI: 10.14309/ajg.0000000000001157] [Reference Citation Analysis]
638 Wang Y, Han SB. Hepatitis B Reactivation: A Review of Clinical Guidelines. J Clin Gastroenterol 2021;55:393-9. [PMID: 33828065 DOI: 10.1097/MCG.0000000000001520] [Reference Citation Analysis]
639 Hao SR, Zhang SY, Lian JS, Jin X, Ye CY, Cai H, Zhang XL, Hu JH, Zheng L, Zhang YM, Jia HY, Yu GD, Wang XY, Gu JQ, Lu YF, Yu XP, Yu L, Xiang DR, Ye CY, Jin CL, Qiu YQ, Li LJ, Sheng JF, Liang TB, Yang YD. Liver Enzyme Elevation in Coronavirus Disease 2019: A Multicenter, Retrospective, Cross-Sectional Study. Am J Gastroenterol 2020;115:1075-83. [PMID: 32618658 DOI: 10.14309/ajg.0000000000000717] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 25.0] [Reference Citation Analysis]
640 Hu X, Wang L, Xu F. Guides concerning tenofovir exposure via breastfeeding: A comparison of drug dosages by developmental stage. Int J Infect Dis 2019;87:8-12. [PMID: 31357055 DOI: 10.1016/j.ijid.2019.07.023] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
641 Yip TC, Wong VW, Lui GC, Chow VC, Tse YK, Hui VW, Liang LY, Chan HL, Hui DS, Wong GL. Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19. Hepatology 2021. [PMID: 33961298 DOI: 10.1002/hep.31890] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
642 Zhou YH. Unnecessary to Extend Postpartum Antiviral Therapy in Pregnant Women With High Hepatitis B Viral Loads. J Clin Gastroenterol 2019;53:473-4. [PMID: 30614940 DOI: 10.1097/MCG.0000000000001169] [Reference Citation Analysis]
643 Loader M, Moravek R, Witowski SE, Driscoll LM. A clinical review of viral hepatitis. Journal of the American Academy of Physician Assistants 2019;32:15-20. [DOI: 10.1097/01.jaa.0000586300.88300.84] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
644 Cai M, Hao Y, Zhong J, Yao W, Cao X, Gu G, Qin G. Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study. Can J Gastroenterol Hepatol 2019;2019:9046260. [PMID: 31380321 DOI: 10.1155/2019/9046260] [Reference Citation Analysis]
645 Goyal A. Modeling reveals no direct role of the extent of HBV DNA integrations on the outcome of infection. J Theor Biol 2021;526:110793. [PMID: 34087271 DOI: 10.1016/j.jtbi.2021.110793] [Reference Citation Analysis]
646 Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases 2021;9:5769-81. [PMID: 34368296 DOI: 10.12998/wjcc.v9.i21.5769] [Reference Citation Analysis]
647 Trinh S, Le AK, Chang ET, Hoang J, Jeong D, Chung M, Lee MH, Wang U, Henry L, Cheung R, Nguyen MH. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir. Clin Gastroenterol Hepatol. 2019;17:948-956.e1. [PMID: 30130625 DOI: 10.1016/j.cgh.2018.08.037] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
648 Wong RJ, Jain MK, Therapondos G, Niu B, Kshirsagar O, Thamer M. Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems. Am J Gastroenterol 2021;116:1465-75. [PMID: 33661148 DOI: 10.14309/ajg.0000000000001195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
649 Yeo D, Hossain I, Lim ST, Farid M, Tao M, Quek R, Tang T, Chan A. A response to the letter to the editor on "Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study". J Oncol Pharm Pract 2018;24:478-9. [PMID: 29925294 DOI: 10.1177/1078155218782614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
650 Mak LY, Seto WK, Yuen MF. Novel Antivirals in Clinical Development for Chronic Hepatitis B Infection. Viruses 2021;13:1169. [PMID: 34207458 DOI: 10.3390/v13061169] [Reference Citation Analysis]
651 Koffas A, Kumar M, Gill US, Jindal A, Kennedy PTF, Sarin SK. Chronic hepatitis B: the demise of the 'inactive carrier' phase. Hepatol Int 2021;15:290-300. [PMID: 33638770 DOI: 10.1007/s12072-021-10137-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
652 Choi J, Kim GA, Han S, Lim YS. Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. Am J Gastroenterol 2020;115:406-14. [PMID: 31895708 DOI: 10.14309/ajg.0000000000000490] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
653 Cheung KW, Lao TT. Hepatitis B - Vertical transmission and the prevention of mother-to-child transmission. Best Pract Res Clin Obstet Gynaecol 2020;68:78-88. [PMID: 32249130 DOI: 10.1016/j.bpobgyn.2020.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
654 Wang CH, Chang KK, Lin RC, Kuo MJ, Yang CC, Tseng YT. Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study. Medicine (Baltimore) 2020;99:e19907. [PMID: 32358357 DOI: 10.1097/MD.0000000000019907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
655 Stasi C, Tiengo G, Sadalla S, Zignego AL. Treatment or Prophylaxis against Hepatitis B Virus Infection in Patients with Rheumatic Disease Undergoing Immunosuppressive Therapy: An Update. J Clin Med 2021;10:2564. [PMID: 34200522 DOI: 10.3390/jcm10122564] [Reference Citation Analysis]
656 Álvarez-López P, Riveiro-Barciela M, Oleas-Vega D, Flores-Cortes C, Román A, Perelló M, Berastegui C, Castells L, Esteban R, Buti M. Anti-HBc impacts on the risk of hepatitis B reactivation but not on survival of solid-organ transplant recipients. Medicine (Baltimore) 2020;99:e19407. [PMID: 32118794 DOI: 10.1097/MD.0000000000019407] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
657 Fragkou PC, Moschopoulos CD, Karofylakis E, Kelesidis T, Tsiodras S. Update in Viral Infections in the Intensive Care Unit. Front Med (Lausanne) 2021;8:575580. [PMID: 33708775 DOI: 10.3389/fmed.2021.575580] [Reference Citation Analysis]
658 Lee JS, Lee HA, Jeon MY, Lim TS, Kim BK, Park JY, Kim DY, Ahn SH, Um SH, Han K, Seo YS, Kim SU. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. European Journal of Gastroenterology & Hepatology 2020;32:739-47. [DOI: 10.1097/meg.0000000000001585] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
659 Harris AM, Millman AJ, Lora M, Osinubi A, Lom J, Miller LS. Hepatitis B testing, care linkage, and vaccination coverage within a registry of hepatitis C infected patients. Vaccine 2019;37:2188-93. [PMID: 30902481 DOI: 10.1016/j.vaccine.2019.03.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
660 McMahon BJ, Dusheiko G. Predicting treatment eligibility for hepatitis B in low income regions: Can treatment scores without HBV DNA testing serve the purpose? J Hepatol 2018;69:765-6. [PMID: 30007507 DOI: 10.1016/j.jhep.2018.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
661 Tsai YC, Tsai TF. Switching biologics in psoriasis - practical guidance and evidence to support. Expert Rev Clin Pharmacol 2020;13:493-503. [PMID: 32394765 DOI: 10.1080/17512433.2020.1767590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
662 Wang X, Liu X, Dang Z, Yu L, Jiang Y, Wang X, Yang Z. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Gut Liver. 2019;. [PMID: 31158948 DOI: 10.5009/gnl18546.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
663 Jeong S, Cho Y, Park SM, Kim W. Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy: A Systematic Review and Meta-analysis. J Clin Gastroenterol 2021;55:e77-86. [PMID: 33883516 DOI: 10.1097/MCG.0000000000001548] [Reference Citation Analysis]
664 Torre P, Aglitti A, Masarone M, Persico M. Viral hepatitis: Milestones, unresolved issues, and future goals. World J Gastroenterol 2021;27:4603-38. [PMID: 34366625 DOI: 10.3748/wjg.v27.i28.4603] [Reference Citation Analysis]
665 Wong GL, Lampertico P. Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB – Is one NUC better than the other? Journal of Hepatology 2019;71:453-5. [DOI: 10.1016/j.jhep.2019.05.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
666 Kumar S, Ramachandran TM. Immunotolerant Chronic Hepatitis B Infection: When Do I Treat? J Clin Exp Hepatol 2019;9:277-9. [PMID: 31024211 DOI: 10.1016/j.jceh.2018.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
667 Patil AP, Simon EG, Dutta AK, Joseph AJ, Kurien RT, Chowdhury SD. Prevalence of serological markers of hepatitis B in inflammatory bowel disease - Experience from a tertiary care centre in South India. Trop Doct 2021;51:326-31. [PMID: 34018886 DOI: 10.1177/00494755211015571] [Reference Citation Analysis]
668 Cailhol J, Lebon MC, Sherlaw W. Will my patients get their residence permit? A critical analysis of the ethical dilemmas involved in writing medical certificates for residence permits in France. BMC Med Ethics 2020;21:59. [PMID: 32660550 DOI: 10.1186/s12910-020-00500-7] [Reference Citation Analysis]
669 Liang LY, Wong VW, Toyoda H, Tse YK, Yip TC, Yuen BW, Tada T, Kumada T, Lee HW, Lui GC, Chan HL, Wong GL. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients. J Gastroenterol 2020;55:899-908. [PMID: 32556643 DOI: 10.1007/s00535-020-01700-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
670 Mak LY, Wong DK, Pollicino T, Raimondo G, Hollinger FB, Yuen MF. Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance. J Hepatol. 2020;73:952-964. [PMID: 32504662 DOI: 10.1016/j.jhep.2020.05.042] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 20.0] [Reference Citation Analysis]
671 Lee YS, Lee HS, Kim JH, Chang SW, Hyun MH, Bak H, Kim S, Lee MJ, Lee CU, Jung YK, Seo YS, Yim HJ, Yeon JE, Um SH, Byun KS. Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis. Korean J Intern Med 2021;36:76-85. [PMID: 31878771 DOI: 10.3904/kjim.2018.465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
672 Yoshida K, Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. Int J Mol Sci 2021;22:1456. [PMID: 33535672 DOI: 10.3390/ijms22031456] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
673 Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, Marcinak JF, Lewis JH, Anania FA, Seekins D, Shneider BL, Chalasani N. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther. 2020;51:90-109. [PMID: 31762074 DOI: 10.1111/apt.15579] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
674 Tufon KA, Anong DN, Meriki HD, Georges TD, Maurice M, Kouanou YS, Bolimo AF, Tony NJ, Kwenti TE, Wung NH, Nkuo-Akenji T. Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon. PLoS One 2018;13:e0203312. [PMID: 30183765 DOI: 10.1371/journal.pone.0203312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
675 Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 28.0] [Reference Citation Analysis]
676 Zhang ZQ, Shi BS, Lu W, Huang D, Wang YB, Feng YL. Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection. J Virol Methods 2021;296:114226. [PMID: 34217779 DOI: 10.1016/j.jviromet.2021.114226] [Reference Citation Analysis]
677 Kim MP, Yang JK, Jun BG, Kim YD, Cheon GJ, Jung HJ, Yoo JJ, Kim SG, Kim YS, Jeong SW, Jang JY, Kim HS, Lee SH. Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma. J Viral Hepat 2021;28:1011-8. [PMID: 33759295 DOI: 10.1111/jvh.13508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
678 Kuo MH, Tseng C, Lee C, Yang Y, Wu H, Lin H, Chu Y, Chen Y, Tseng K. Identification and management of contraindicated drug–drug interactions through pharmaceutical care programs: Experience in direct-acting antivirals therapy. Journal of the Formosan Medical Association 2021. [DOI: 10.1016/j.jfma.2021.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
679 Alsunaid SR, Ashraf H, Soubani AO. Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. Transpl Infect Dis 2018;20:e12960. [PMID: 29975806 DOI: 10.1111/tid.12960] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
680 Aretzweiler G, Leuchter S, García-Álvarez M, Simon C, Marins E, Paxinos E, Canchola J, Delgado R, Frontzek A. Analytical performance of four molecular platforms used for HIV-1, HBV and HCV viral load determinations. Expert Rev Mol Diagn 2019;19:941-9. [PMID: 31159598 DOI: 10.1080/14737159.2019.1624162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
681 Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of Hepatocellular Carcinoma in Patients Treated with Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study. JAMA Oncol. 2019;5:30-36. [PMID: 30267080 DOI: 10.1001/jamaoncol.2018.4070] [Cited by in Crossref: 108] [Cited by in F6Publishing: 88] [Article Influence: 54.0] [Reference Citation Analysis]
682 Pisaturo M, Di Caprio G, Calò F, Portunato F, Martini S, Coppola N. Management of HBV reactivation in non-oncological patients. Expert Rev Anti Infect Ther 2018;16:611-24. [PMID: 30058401 DOI: 10.1080/14787210.2018.1505501] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
683 Buonomo AR, Viceconte G, Scotto R, De Angelis M, Tozza S, Manganelli F, Lanza AG, Di Costanzo GG, Gentile I. Seronegative occult HBV reactivation complicated with fulminant acute liver failure after rituximab for chronic inflammatory demyelinating polyneuropathy. Infectious Diseases 2020;52:216-8. [DOI: 10.1080/23744235.2019.1693624] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
684 Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol Commun. 2019;3:8-19. [PMID: 30619990 DOI: 10.1002/hep4.1281] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
685 Yin GQ, Li J, Zhong B, Yang YF, Wang MR. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. World J Gastroenterol 2021;27:666-76. [PMID: 33716446 DOI: 10.3748/wjg.v27.i8.666] [Reference Citation Analysis]
686 Chevaliez S, Rodriguez C, Poiteau L, Soulier A, Donati F, Darty-Mercier M, Pioche C, Leroy V, Brodard V, Zoulim F, Brouard C, Larsen C, Semaille C, Roudot-Thoraval F, Pawlotsky JM; Hepatology Reference Centers Laboratories Network for Chronic Hepatitis B Surveillance. Primary resistance of hepatitis B virus to nucleoside and nucleotide analogues. J Viral Hepat 2019;26:278-86. [PMID: 30339311 DOI: 10.1111/jvh.13025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
687 Lee AR, Cho JY, Kim JC, Dezhbord M, Choo SY, Ahn CH, Kim NY, Shin JJ, Park S, Park ES, Won J, Kim DS, Lee JH, Kim KH. Distinctive HBV Replication Capacity and Susceptibility to Tenofovir Induced by a Polymerase Point Mutation in Hepatoma Cell Lines and Primary Human Hepatocytes. Int J Mol Sci 2021;22:1606. [PMID: 33562603 DOI: 10.3390/ijms22041606] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
688 Likhitsup A, Lok AS. Understanding the Natural History of Hepatitis B Virus Infection and the New Definitions of Cure and the Endpoints of Clinical Trials. Clin Liver Dis. 2019;23:401-416. [PMID: 31266616 DOI: 10.1016/j.cld.2019.04.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
689 Wang W, Xiong L, Wang P, Wang F, Ma Q. Major vault protein plays important roles in viral infection. IUBMB Life 2020;72:624-31. [PMID: 31769934 DOI: 10.1002/iub.2200] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
690 Ha I, Chung JW, Jang ES, Jeong SH, Kim JW. Comparison of the on-treatment risks for hepatocellular carcinoma between entecavir and tenofovir: A propensity score matching analysis. J Gastroenterol Hepatol 2020;35:1774-81. [PMID: 32154938 DOI: 10.1111/jgh.15031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
691 Li N, Fan X, Wang X, Deng H, Zhang K, Zhang X, Han Q, Lv Y, Liu Z. PRDM1 rs1010273 polymorphism is associated with overall survival of patients with hepatitis B virus-related hepatocellular carcinoma. Immunol Lett 2019;213:39-45. [PMID: 31376415 DOI: 10.1016/j.imlet.2019.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
692 Chan HLY. Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. J Gastroenterol Hepatol 2019;34:501-6. [PMID: 30402981 DOI: 10.1111/jgh.14534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
693 Wong GL, Wong VW, Hui VW, Yip TC, Tse YK, Liang LY, Lui RN, Mok TS, Chan HL, Chan SL. Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection.Am J Gastroenterol. 2021;116:1274-1283. [PMID: 33560651 DOI: 10.14309/ajg.0000000000001142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
694 Mak LY, Seto WK, Fung J, Yuen MF. Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B. Hepatol Int 2020;14:35-46. [PMID: 31745711 DOI: 10.1007/s12072-019-09998-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
695 Shih C, Wu SY, Chou SF, Yuan TT. Virion Secretion of Hepatitis B Virus Naturally Occurring Core Antigen Variants. Cells 2020;10:E43. [PMID: 33396864 DOI: 10.3390/cells10010043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
696 Jeong HM, Kim DJ. Bone Diseases in Patients with Chronic Liver Disease. Int J Mol Sci. 2019;20. [PMID: 31480433 DOI: 10.3390/ijms20174270] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
697 Ou Q, Guo J, Zeng Y, Chen H. Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection. J Viral Hepat 2020;27:224-32. [PMID: 31954089 DOI: 10.1111/jvh.13260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
698 Yoon EL. [Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients]. Korean J Gastroenterol 2019;74:258-66. [PMID: 31765554 DOI: 10.4166/kjg.2019.74.5.258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
699 Roth D, Bloom RD, Molnar MZ, Reese PP, Sawinski D, Sise ME, Terrault NA. KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. Am J Kidney Dis 2020;75:665-83. [PMID: 32279907 DOI: 10.1053/j.ajkd.2019.12.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
700 Li Q, Zhou Y, Huang C, Li W, Chen L. A novel diagnostic algorithm to predict significant liver inflammation in chronic hepatitis B virus infection patients with detectable HBV DNA and persistently normal alanine transaminase. Sci Rep 2018;8:15449. [PMID: 30337643 DOI: 10.1038/s41598-018-33412-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
701 Lee WM, King WC, Janssen HLA, Ghany MG, Fontana RJ, Fried M, Sterling RK, Feld JJ, Wang J, Mogul DB, Cooper SL, Bisceglie AMD; Hepatitis B Research Network (HBRN). Hepatitis B e antigen loss in adults and children with chronic hepatitis B living in North America: A prospective cohort study. J Viral Hepat 2021. [PMID: 34355475 DOI: 10.1111/jvh.13591] [Reference Citation Analysis]
702 Yang S, Ma X, Cai C, Wang H, Xiao F, Yu C. Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study. Front Med (Lausanne) 2021;8:637126. [PMID: 33791326 DOI: 10.3389/fmed.2021.637126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
703 Wang WT, Zhao XQ, Li GP, Chen YZ, Wang L, Han MF, Li WN, Chen T, Chen G, Xu D, Ning Q, Zhao XP. Immune response pattern varies with the natural history of chronic hepatitis B. World J Gastroenterol. 2019;25:1950-1963. [PMID: 31086463 DOI: 10.3748/wjg.v25.i16.1950] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
704 Lok J, Agarwal K. Screening for Hepatocellular Carcinoma in Chronic Hepatitis B: An Update. Viruses 2021;13:1333. [PMID: 34372539 DOI: 10.3390/v13071333] [Reference Citation Analysis]
705 Jaroenlapnopparat A, Chayanupatkul M, Tangkijvanich P. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review. J Gastroenterol Hepatol 2021. [PMID: 33811375 DOI: 10.1111/jgh.15516] [Reference Citation Analysis]
706 Meier-Stephenson V, Badmalia MD, Mrozowich T, Lau KCK, Schultz SK, Gemmill DL, Osiowy C, van Marle G, Coffin CS, Patel TR. Identification and characterization of a G-quadruplex structure in the pre-core promoter region of hepatitis B virus covalently closed circular DNA. J Biol Chem 2021;296:100589. [PMID: 33774051 DOI: 10.1016/j.jbc.2021.100589] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
707 Toka B, Eminler AT, Gönüllü E, Tozlu M, Uslan MI, Parlak E, Karabay O, Koksal AS. Rheumatologists’ awareness of hepatitis B reactivation before immunosuppressive therapy. Rheumatol Int 2019;39:2077-85. [DOI: 10.1007/s00296-019-04437-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
708 Wang JH. Application of Ultrasound Liver Elastography to the Diagnosis and Monitoring of Liver Disease. J Med Ultrasound 2019;27:1-2. [PMID: 31031528 DOI: 10.4103/JMU.JMU_108_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
709 Ogawa E, Yeo YH, Dang N, Le MH, Jeong D, Tran S, Henry L, Cheung R, Nguyen MH. Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States. JAMA Netw Open 2020;3:e201844. [PMID: 32271388 DOI: 10.1001/jamanetworkopen.2020.1844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
710 Zhang M, Li G, Shang J, Pan C, Zhang M, Yin Z, Xie Q, Peng Y, Mao Q, Xiao X, Jiang Y, Luo K, Xu Y, Ding H, Fan W, Diego V, Pourkarim MR, De Clercq E, Wang G, Gong G. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int 2020;14:212-24. [PMID: 32100261 DOI: 10.1007/s12072-020-10015-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
711 Cai Y, Dai Z, Wen S, Bhandari R. Risk factors associated with infection of blood-borne virus among people who used methamphetamine. BMC Infect Dis 2020;20:742. [PMID: 33036558 DOI: 10.1186/s12879-020-05464-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
712 Yip TC, Chan HL, Tse Y, Lam KL, Lui GC, Wong VW, Wong GL. On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. American Journal of Gastroenterology 2018;113:1629-38. [DOI: 10.1038/s41395-018-0247-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
713 Suoh M, Tamori A, Amano-Teranishi Y, Nakai T, Enomoto M, Kawasaki Y, Kioka K, Kawada N. The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B. Intern Med 2020;59:205-10. [PMID: 31941870 DOI: 10.2169/internalmedicine.3504-19] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
714 Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, Choi BI, Wilson SR, Kudo M, Barr RG. Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. Ultrasound Med Biol. 2018;44:2419-2440. [PMID: 30209008 DOI: 10.1016/j.ultrasmedbio.2018.07.008] [Cited by in Crossref: 152] [Cited by in F6Publishing: 101] [Article Influence: 50.7] [Reference Citation Analysis]
715 Nishida T, Matsubara T, Yakushijin T, Inada M. Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers. Hepatol Int 2019;13:407-15. [PMID: 31290069 DOI: 10.1007/s12072-019-09966-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
716 Ren H, Huang Y. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B. J Viral Hepat 2019;26 Suppl 1:5-31. [PMID: 31380584 DOI: 10.1111/jvh.13150] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
717 Jang BK. Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response? Clin Mol Hepatol 2020;26:312-4. [PMID: 32646206 DOI: 10.3350/cmh.2020.0099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
718 Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. PLoS One 2018;13:e0209299. [PMID: 30576344 DOI: 10.1371/journal.pone.0209299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
719 Childs L, Adrien P, Minta AA, François J, Phaïmyr Jn Charles N, Blot V, Rey-Benito G, Vanden Eng JL, Tohme RA. Prevalence of Chronic Hepatitis B Virus Infection among Children in Haiti, 2017. Am J Trop Med Hyg 2019;101:214-9. [PMID: 31115298 DOI: 10.4269/ajtmh.19-0117] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
720 Du Y, Du B, Fang X, Shu M, Zhang Y, Chung H, Sun Y, Teng J, Visalath P, Qiu H, Cai W. ALT Flare Predicts Hepatocellular Carcinoma Among Antiviral Treated Patients With Chronic Hepatitis B: A Cross-Country Cohort Study. Front Oncol 2020;10:615203. [PMID: 33552989 DOI: 10.3389/fonc.2020.615203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
721 Lin WS, Lee TT, Yang YH, Mills ME. Environmental factors affecting self-management of chronic hepatitis B from the patients' perspective. J Clin Nurs 2019;28:4128-38. [PMID: 31240796 DOI: 10.1111/jocn.14973] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
722 Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data. Cells 2021;10:1263. [PMID: 34065305 DOI: 10.3390/cells10051263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
723 Yuen MF, Zhou X, Gane E, Schwabe C, Tanwandee T, Feng S, Jin Y, Triyatni M, Lemenuel-Diot A, Cosson V, Xue Z, Kazma R, Bo Q. Safety, pharmacokinet